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RESUMO 
 
A baixa solubilidade de fármacos apresenta-se como propriedade 
desafiadora no desenvolvimento de associações em dose fixa combinada. 
Visando contornar esta limitação em formulação composta pelos 
hipolipemiantes ezetimiba (EZE) e lovastatina (LOV), a obtenção de 
formulação incrementadora da solubilidade e taxa de dissolução foi 
investigada. Para tanto, sistemas coamorfos e formulações ternárias 
compostas por gelatina ou polímeros hidrofílicos foram testados para 
posteriormente compor uma forma farmacêutica final. Evitando a 
formação prematura do metabólito ativo de LOV, hidróxiácido de 
lovastatina (LOVh) em ambiente gástrico, uma formulação entericamente 
revestida preparada por leito fluidizado compôs o objetivo principal deste 
trabalho. Os sistemas coamorfos foram obtidos por fusão seguida de 
rápido resfriamento nas taxas molares de 1:1, 1:2, 2:1 e 1:4 (EZE:LOV), 
enquanto que formulações compostas por dois diferentes tipos de gelatina 
(com índices de bloom de 75 e 225), em presença ou não de polímeros 
hidrofílicos, foram preparadas por ativação mecânica em moinho de 
bolas. Para as dispersões sólidas ternárias, as mesmas foram nebulizadas 
em spray dryer variando-se as proporções fármaco:fármaco (1:1, 1:2 e 
1:4, m/m, EZE:LOV), o tipo de polímero (PVP K-30, PVP/VA-64, 
HPMC e Soluplus®), a quantidade de polímero (50, 75 e 90%) e a adição 
de surfactantes. As formulações foram caracterizadas através de técnicas 
em estado sólido e estudos  de dissolução in vitro. Sistemas coamorfos 
foram caracterizados como contendo uma única fase amorfa e ligações de 
hidrogênio entre os compostos foram detectadas. Entretanto, a taxa de 
dissolução destes fármacos não foi aumentada para nenhuma das 
formulações. Sistemas ternários com gelatina demonstraram pouco 
impacto no tipo da gelatina selecionada, especialmente para EZE, e um 
incremento discreto da taxa de dissolução, de 6 e 12 vezes para EZE e 
LOV, respectivamente, em comparação à sistema amorfo binário 
EZE:LOV. Por outro lado, a adição de polímeros demonstrou um 
aumento significativo na taxa de dissolução de ambos os fármacos, 
especialmente para as formulações compostas por Soluplus®. Para estas, 
os melhores resultados foram observados em presença de 90% de 
polímero, responsáveis pela liberação de 92 e 83% de EZE e LOV, 
respectivamente, em 5 minutos. Todas as formulações apresentaram-se 
amorfas com ligações de hidrogênio entre os componentes. Estudos de 
estabilidade demonstraram estabilidade físico-química a 4ºC/0% UR pelo 
período de 1 ano. Assim sendo, esta formulação foi selecionada para 
compor a formulação final em dose fixa combinada, preparada em leito 
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fluidizado. Estudos de formulação investigaram a influência do tipo de 
polímero entérico (Eudragit L100® e Eudragit L100-55®), do tamanho 
dos péletes de sacarose (300-415 μm e 710-850 μm) e do tempo de 
revestimento. Resultados mostraram que os péletes menores tendiam a 
aglomerar-se e a liberação dos fármacos foi prejudicada em condições 
ácidas, devido à formação de uma camada de revestimento irregular. O 
polímero Eudragit L100-55® necessitou de um tempo maior de 
processamento, mas camadas de revestimento mais finas levaram a uma 
menor liberação dos fármacos. Ambos os polímeros proporcionaram 
baixa liberação de EZE e LOV em ambiente gástrico e rápida dissolução 
em pH 6,8. Medidas off-line da espessura da camada de revestimento 
determinaram um tempo ideal de 15 e 30 min de revestimento entérico 
para formulações a base de Eudragit L100-55® e Eudragit L100®, 
respectivamente. Estudos de estabilidade conduzidos por 6 meses 
demonstraram propriedades físicas e liberação dos fármacos inalterados 
a temperatura ambiente e 0% UR. Desta forma, é possível concluir que 
este projeto foi capaz de desenvolver uma formulação final em dose fixa 
combinada, baseada em sistemas amorfos inovadores, como as dispersões 
sólidas ternárias, reportadas pela primeira vez em literatura, capazes de 
aumentar simultaneamente a taxa de dissolução dos fármacos pouco 
solúveis EZE e LOV. Embora aplicados a estes dois compostos 
especificamente, os resultados obtidos nesta tese podem servir como base 
para compor demais sistemas similares compostos por fármacos de baixa 
solubilidade aquosa.  
 
Palavras-chave: ezetimiba, lovastatina, dispersões sólidas ternárias, 
coamorfos, gelatina, dose fixa combinada 
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RESUMO EXPANDIDO 
Introdução 
O desenvolvimento de formulações em dose fixa combinada tem sido 
estimulada, inclusive por agências regulatórias internacionais, devido às 
suas vantagens frente à monoterapia. Aumento da adesão ao tratamento, 
redução de custos para pacientes e instituições, melhor abrangência 
terapêutica para pacientes com múltiplas enfermidades e a possibilidade 
de redução de doses e efeitos colaterais são algumas delas. É importante 
mencionar que a associação de dois ou mais fármacos em uma forma 
farmacêutica pode ser complexo, e aspectos farmacocinéticos e físico-
químicos devem ser levados em consideração. Neste contexto, a 
solubilidade dos compostos apresenta-se como um fator de elevada 
importância, principalmente no que concerne formas farmacêuticas 
sólidas de administração oral.  
Atualmente, o percentual de fármacos com baixa solubilidade é 
preocupante (em torno de 25 a 40% do total de fármacos desenvolvidos), 
de modo que muitos deles são rejeitados ou subutilizados pela indústria 
farmacêutica. Ainda, fármacos com baixa solubilidade geralmente 
requerem maiores doses para apresentar o efeito terapêutico desejado, o 
que também pode culminar em seu depósito em sítios específicos, 
formando agregados que aumentam seus efeitos tóxicos. 
Dentre as opções atualmente disponíveis visando ao aumento da 
solubilidade de fármacos, a conversão de sólidos cristalinos em amorfos 
apresenta-se como promissora e o seu sucesso encontra-se amplamente 
divulgado em literatura específica. Entretanto, estas estratégias tem sido 
aplicadas a fármacos administrados em monoterapia, e apenas mais 
recentemente, os sistemas coamorfos foram introduzidos com vistas à 
aplicação em associações de dose fixa. Por outro lado, as dispersões 
sólidas, vastamente investigadas quando compostas apenas por um 
fármaco lipofílico, nunca foram utilizadas com este propósito. Neste 
sentido, dispersões sólidas ternárias, compostas por dois fármacos 
lipofílicos e um polímero hidrofílico, constituem uma proposta inovadora 
e promissora. Ainda, o biopolímero gelatina, amplamente utilizada com 
outros propósitos na área farmacêutica é altamente solúvel em água, 
podendo constituir um promissor sistema carreador para aumentar a 
solubilidade de fármacos em estado amorfo. 
Os hipolipemiantes pouco solúveis ezetimiba (EZE) e lovastatina (LOV) 
pertencem à Classe II do Sistema de Classificação Biofarmacêutico e sua 
associação em prática clínica é considerada segura e eficaz. Muito 
embora, nenhuma formulação em dose fixa combinada composta por 
estes fármacos encontra-se disponível para comercialização. Ainda, é 
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importante ressaltar que a associação de EZE e LOV tem sido estimulada 
devido à ocorrência de importantes efeitos colaterais associados à classe 
das estatinas, além destas aumentarem o risco de desenvolvimento de 
diabetes do tipo II em pacientes hipercolesterolêmicos. 
 
Objetivos 
Neste contexto, este trabalho propõe a aplicação de estratégias amorfas 
inovadoras, como sistemas coamorfos, dispersões sólidas ternárias e 
formulações compostas por gelatina visando aumentar a solubilidade e 
taxa de dissolução dos fármacos EZE e LOV em uma forma farmacêutica 
de dose fixa combinada. Devido à instabilidade gástrica de LOV gerando 
precocemente seu metabólito ativo, este trabalho objetiva o 
desenvolvimento de uma forma farmacêutica final, baseada em dose fixa 
combinada e revestida entericamente. 
 
Metodologia 
Sistemas coamorfos de EZE e LOV nas proporções molares de 1:1, 1:2, 
1:4 e 2:1 (EZE:LOV) foram preparados através de fusão seguida de 
rápido resfriamento em equipamento de calorimetria exploratória 
diferencial modulada. Os sistemas ternários compostos por gelatina foram 
preparados através de moagem de alto impacto, otimizando-se parâmetros 
experimentais, em diferentes proporções de gelatina e fármaco-fármaco. 
No que se refere às dispersões sólidas ternárias, as mesmas foram 
nebulizadas em spray dryer, avaliando o impacto de diferentes polímeros 
hidrofílicos, proporção fármacos:polímero e presença de surfactantes.  
Para todos os casos, as proporções fármaco:fármaco foram selecionadas 
com base nas doses de administração disponíveis para comercialização 
(10 mg para EZE e 10, 20 e 40 mg para LOV). Todas as formulações 
foram caracterizadas através de técnicas de estado sólido e avaliadas por 
estudos de estabilidade e dissolução in vitro. 
A formulação com a melhor performance in vitro e com propriedades 
físico-químicas apropriadas foi selecionada para compor a forma 
farmacêutica final em dose fixa combinada, entericamente revestida e 
preparada em leito fludizada. Parâmetros de formulação e experimentais 
foram avaliados visando ao desenvolvimento de uma formulação 
gastroprotetora e capaz de promover uma liberação rápida e completa de 
ambos os princípios ativos em ambiente intestinal. 
 
Resultados e Discussão 
Os hipolipemiantes EZE e LOV foram escolhidos como fármacos modelo 
para desenvolvimento de forma farmacêutica em dose fixa combinada 
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capaz de aumentar a sua solubilidade e taxa de dissolução. Para tanto, 
estudos de pré-formulação foram realizados, promovendo uma 
caracterização em estado sólido de ambos os fármacos, a qual foi útil para 
monitorar as transformações ocorridas por conta do seu processamento. 
De maneira importante, estudos de solubilidade em equilíbrio 
demonstraram que EZE e LOV poderiam ser associados em uma forma 
farmacêutica sem efeitos deletérios à sua solubilidade.  
A partir de então, formulações foram desenvolvidas e os sistemas 
coamorfos foram as primeiras estratégias investigadas. Entretanto, 
embora completamente amorfos e apresentando ligações de hidrogênio, 
as quais poderiam beneficiar a sua estabilidade física, estes sistemas não 
foram capazes de aumentar a dissolução de EZE e LOV. Estes resultados 
podem ser provavelmente associados à baixa solubilidade em estado 
amorfo de EZE, a qual refletiu-se nas formulações. 
Optou-se então por investigar o potencial da gelatina como carreadora 
hidrofílica de sistemas ternários com EZE e LOV. Embora o sistema 
tenha sido otimizado a ponto de gerar sistemas completamente amorfos 
em muitos casos, o seu potencial in vitro não foi confirmado, 
demonstrando baixo percentual de liberação para a grande maioria dos 
sistemas desenvolvidos.  
Desta forma, a inserção de polímeros foi investigada, almejando aumentar 
a molhabilidade e área superficial através de seu processamento por meio 
de spray drying. Neste momento, o conceito de dispersões sólidas 
ternárias foi introduzida pela primeira vez. Diferentes polímeros 
hidrofílicos foram investigados e os melhores resultados foram 
observados para formulações constituídas de Soluplus®. Os resultados 
foram dependentes da concentração de polímero (numa relação 
diretamente proporcional), e não foram afetadas pelas diferentes 
proporções de fármaco:fármaco e pela presença de surfactante. A 
formulação composta por 90% de Soluplus® e numa proporção 
fármaco:fármaco de 1:1 (m/m) (ELS 1:1 90%) foi capaz de aumentar a 
eficiência de dissolução em 18 (EZE) e 6 (LOV) vezes em comparação 
às suas respectivas matérias-primas cristalinas. Ainda, esta mesma 
formulação foi capaz de liberar mais de 80% de ambos os fármacos em 
apenas 5 min. É importante mencionar que embora 90% de polímero seja 
considerada uma alta proporção, a baixa dose de administração de ambos 
os compostos (10 mg para EZE e 10 a 40 mg para LOV) permite o 
desenvolvimento de uma forma farmacêutica sólida de administração 
oral. Desta forma, ELS 1:1 90% foi selecionada como base para compor 
a forma farmacêutica final em dose fixa combinada. 
 
16 
 
Entretanto, a instabilidade em ambiente ácido de LOV, gerando 
precocemente o seu metabólito ativo (cuja concentração hepática deve ser 
maximizada) requereu o desenvolvimento de uma forma farmacêutica 
composta por revestimento entérico, a qual também seja capaz de 
promover rápida liberação de ambos os compostos em ambiente 
intestinal.  
Para tanto, optou-se pelo desenvolvimento de sistema multiparticulado 
por leito fluidizado utilizando péletes inertes de sucrose. Neste sentido, 
diferentes polímeros entéricos (Eudragit L100® e Eudragit L100-55®), 
péletes inertes com variados diâmetros externos (300-415 μm and 710-
850 μm) e tempo de revestimento foram investigados. Após extensa 
avaliação, verificou-se que a formulação composta por péletes de maior 
diâmetro apresentaram adequadas propriedades de fluidização sem 
aglomeração, gerando camadas de revestimento homogêneas. O polímero 
Eudragit L100-55® demonstrou-se mais adequado por permitir em um 
menor tempo de revestimento (15 min) e com uma camada entérica de 6,5 
µm, reduzida liberação em meio gástrico e rápida dissolução de ambos os 
fármacos em ambiente intestinal.  
 
Considerações finais 
Este trabalho reportou pela primeira vez o desenvolvimento de uma forma 
farmacêutica final em dose fixa combinada baseada em dispersões sólidas 
ternárias. O sistema utilizou técnicas de preparo de uso corriqueiro pela 
indústria farmacêutica, como o leito fluidizado, simplificando o seu 
escalonamento. Ainda, cabe mencionar que embora estes estudos tenham 
sido realizados com os fármacos EZE e LOV, seu potencial de aplicação 
extende-se a demais fármacos pouco solúveis e farmacocineticamente 
compatíveis a serem administrados em uma combinação de doses fixas. 
 
Palavras-chave: ezetimiba, lovastatina, dispersões sólidas ternárias, 
coamorfos, gelatina, dose fixa combinada 
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ABSTRACT 
 
Low solubility of drugs represents a challenging property on the 
development of fixed-dose combinations. Aiming to overcome this 
limitation in formulation composed by the hypolipidemic compounds 
ezetimibe (EZE) and lovastatin (LOV), the preparation of a system 
capable of enhancing their dissolution rate was investigated. For this 
purpose, co-amorphous systems and ternary formulations made up of 
gelatin or hydrophilic polymers were tested to further compose a final 
dosage form. In order to avoid the premature formation of the active 
metabolite of LOV, lovastatin hydroxyacid (LOVh), in gastric 
environment, an enteric coated formulation prepared by fluid bed coating 
represented the main goal of this research. Co-amorphous systems were 
prepared by quench cooling from the melt in molar ratios of 1:1, 1:2, 2:1 
and 1:4 (EZE:LOV), whilst formulations composed by two different types 
of gelatin (bloom 75 and 225), in presence or absence of hydrophilic 
polymers were obtained through ball milling. Regarding the ternary solid 
dispersions, they were prepared by spray drying, varying the drug:drug 
ratio (1:1, 1:2 and 1:4, w/w, EZE:LOV), the type of polymer employed 
(PVP K-30, PVP/VA-64, HPMC and Soluplus®), the amount of polymer 
(50, 75 and 90%) and the addition of surfactants. Formulations were 
characterized by means of solid-state techniques and in vitro dissolution 
studies. Co-amorphous systems were characterized as single amorphous 
phase and hydrogen bonding between the compounds was detected. 
However, the dissolution rate of the drugs was not enhanced through any 
of these co-amorphous systems. Gelatin-based formulations 
demonstrated low impact regarding the type of gelatin used, especially 
for EZE. Besides, a slight increase of dissolution rate, of about 6 and 12-
fold, for EZE and LOV, respectively, in comparison to a co-spray dried 
amorphous system of EZE:LOV, was observed. On the other hand, the 
addition of polymers demonstrated a significant enhancement of 
dissolution rate for both compounds, especially for Soluplus®-based 
formulations. For those, the best results were observed in presence of 90% 
of polymer, releasing 92% and 83% of EZE and LOV, respectively, 
within 5  minutes. All ternary solid dispersions were amorphous with 
hydrogen bonding among the components. Stability studies demonstrated 
physicochemical stability at 4°C/0% RH within 1 year. Based on that, this 
formulation was selected to compose the final dosage form based on a 
fixed-dose combination, prepared by fluid bed coating. Formulation 
studies investigated the influence of enteric polymer (Eudragit L100® and 
Eudragit L100-55®), sucrose beads size (300-415 μm and 710-850 μm) 
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and coating time. Results showed that smaller pellets tend to agglomerate 
and drug release was jeopardized in acidic conditions, due to the 
formation of an irregular coating layer. Eudragit L100-55® required a 
longer processing time, although thinner coating layers leaded to lower 
drug release. Both polymers provided low drug release in gastric 
environment and high dissolution in pH 6.8. Off-line measurements of 
coating thickness determined as 15 and 30 min appeared to be the ideal 
coating time for Eudragit L100-55® and Eudragit L100®-based 
formulations, respectively. Stability studies conducted during 6 months 
demonstrated unaltered physical and release properties of the drugs at 
room temperature and 0% RH. In this way, it is possible to conclude that 
this research project was able to develop a final fixed-dose combination, 
based on novel amorphous systems, such as spray dried ternary solid 
dispersions, never before reported in literature. This formulation was 
capable of enhancing simultaneously the dissolution rate of the poorly 
water-soluble compounds EZE and LOV. Although applied to these two 
compounds specifically, the results obtained in this thesis can be used as 
basis to compose other similar systems of poorly water-soluble 
compounds.  
 
Keywords: ezetimibe, lovastatin, ternary solid dispersions, co-
amorphous systems,gelatin,  fixed-dose combinations 
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1. GENERAL INTRODUCTION 
 
The development of fixed-dose combinations (FDCs) has been 
stimulated by international regulatory agencies, due to their advantages 
compared to the traditional monotherapy. Higher compliance to the 
treatment, cost reduction for both patients and institutions, better 
therapeutic approach for patients with multiple pathological conditions 
and the possibility of reducing dose and side effects, are some of them 
(SCHWEIN and SCHWEIN, 2014). However, few researches have been 
focusing on the development of FDCs based on modern formulation 
technologies  (BJERRUM, et al., 2013). 
It is important to mention that the association of two or more 
compounds in a dosage form can be complex, and pharmacokinetic and 
physicochemical aspects should be considered. In this context, the 
solubility of the compounds is highly relevant, especially regarding solid 
oral dosage forms.  
The poor aqueous solubility of an active pharmaceutical ingredient 
(API) is considered one of the most challenging properties regarding the 
development of successful solid dosage forms. Nowadays, an increasing 
number of APIs are poorly water-soluble and aiming to overcome this 
limitation, the conversion of a crystalline material into its amorphous state 
has been extensively explored (VO et al. 2013; LAITINEN et al., 2012). 
Different from crystalline materials, amorphous solids lack the three-
dimensional long-range order.  As  a  result  of  this random organization, 
amorphous materials exhibit high  internal  energy,  greater molecular  
mobility  and  enhanced  thermodynamic  properties  compared  to    
crystalline  solids. This leads to increased apparent solubility and 
dissolution rate, but also culminates in their thermodynamic instability. 
Amorphous solids tend to structurally relax and crystallize during 
manufacturing, storage or dissolution (JANSSENS and VAN DEN 
MOOTER, 2009). 
In an attempt to prepare more advanced FDCs, formulations based 
on hot melt co-extrusion (DIERICKX et al., 2014; VYNCKIER et al., 
2014), prilling (VERVAECK et al., 2014)  and co-amorphous systems 
(LAITINEN et al., 2013) have been recently reported. In most cases, 
systems composed of compounds with different solubility and/or 
intended for a combination of immediate/controlled release are described.  
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Considered as extremely challenging, the development of 
immediate-release FDCs composed exclusively of poorly water-soluble 
compounds has been scarcely investigated. Taupitz and coworkers 
developed FDCs of pioglitazone/glimepiride and simvastatin/ezetimibe, 
all BCS class II compounds. Different formulations were prepared and 
the best results were observed for ternary inclusion complexes composed 
of hydroxypropyl-β-cyclodextrin, Soluplus and one of the APIs. Fast and 
higher release in comparison to the commercial formulations was 
observed for both FDCs, prepared through a mixture of ternary complexes 
of each API (TAUPITZ et al., 2013). Our group recently published the 
first attempt to prepare spray dried ternary solid dispersions composed of 
the poorly water-soluble compounds ritonavir, darunavir and one 
hydrophilic polymer (hydroxypropyl methylcellulose, 
polyvinylpyrrolidone or polyvinylpyrrolidone-vinyl acetate 64). The 
main goal was to increase the solubility and dissolution rate of both APIs 
from a single spray dried formulation. However, the rate and extent of 
release of both ritonavir and darunavir from ternary spray dried powders 
were less than the release from binary spray dried formulations, 
independently of the polymer used. In addition, both APIs had a negative 
influence on the supersaturation level of each other. In this case, an 
increased dissolution rate of darunavir and ritonavir was only achieved 
through complexation with cyclodextrin and the best results were 
observed for spray dried particles composed of (2-hydroxypropyl)-β-
cyclodextrin, HPMC and Tween 80 (NGUYEN and VAN DEN 
MOOTER, 2014).  
Co-amorphous systems are recently developed formulations which 
allow the combination of two poorly water soluble APIs in a stable 
amorphous system. The major advantage towards well described solid 
dispersions is the absence of a carrier (polymer) in its composition. This 
basically means that usual problems in solid dispersions like large bulk 
volume, hygroscopicity and non-miscibility between the components can 
be avoided (LAITINEN et al., 2013). The combination of two poorly 
water-soluble compounds through co-amorphous systems was reported 
for naproxen:indomethacin (LÖBMANN et al., 2011), 
simvastatin:glipizide (LÖBMANN et al., 2012)  and 
ritonavir:indomethacin (DENGALE et al., 2014). For  
simvastatin:glipizide and ritonavir:indomethacin binary systems, no 
intermolecular interactions were observed between the compounds and 
only one of the APIs presented an increase in the dissolution rate 
(glipizide and ritonavir, respectively) (DENGALE et al., 2014; 
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LÖBMANN et al., 2012). However, for the naproxen:indomethacin co-
amorphous system, intermolecular interactions were assigned by FTIR 
and both compounds showed an increase of their dissolution rates 
(LÖBMANN et al., 2011).   
The hypolipidemic compounds ezetimibe (EZE) and lovastatin 
(LOV) belong to Class II of the Biopharmaceutics Classification System 
(BCS). Presenting synergistic activity on lowering the cholesterol levels, 
their association in clinical practice is considered safe and efficient 
(KERZNER et al., 2003). Besides, the use of EZE with statins presents 
benefits regarding the reduction of statins side effects and low risk on 
developing type 2 diabetes (CEDERBERG et al., 2015). However, 
although the promising aspects of this association, no FDC of EZE and 
LOV is currently marketed.  
Due to compatible pharmacokinetic parameters, similar doses and 
frequency of administration and low aqueous solubility, EZE and LOV 
were chosen as model compounds for this research. Aiming to overcome 
the physicochemical limitations of both compounds, as well as 
maintaining the benefits of their association, different technological 
approaches were targeted (e.g co-amorphous systems, ternary solid 
dispersions and gelatin-based formulations) to prepare a final dosage 
form with possible therapeutic and commercial applications.  
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1.1 OBJECTIVES 
 
1.1.1 Main objective 
 
To develop a fixed dose combination solid dosage form based on 
amorphous systems able to enhance the solubility and dissolution rate of 
the poorly water-soluble compounds ezetimibe and lovastatin.  
 
1.1.2 Specific objectives 
 
To perform the solid-state characterization of ezetimibe and 
lovastatin  through X-ray powder diffraction (XRPD), modulated 
differential scanning calorimetry (mDSC), infrared spectroscopy (IR) and 
intrinsic dissolution rate; 
 
To develop and validate a high performance liquid 
chromatography (HPLC) methodology aiming to quantify simultaneously 
ezetimibe and lovastatin in the developed formulations and dissolution 
studies; 
 
To prepare and evaluate, by means of solid-state techniques and in 
vitro dissolution studies, co-amorphous systems composed by ezetimibe 
and lovastatin, through quench cooling from the melt;  
 
To prepare and evaluate, by means of solid-state techniques and in 
vitro dissolution studies, the impact of adding gelatin or hydrophilic 
synthetic polymers (PVP K-30, PVP VA-64, HPMC and Soluplus®) to 
amorphous systems of ezetimibe and lovastatin, prepared by different 
techniques; 
 
To select the most promissing formulation and evaluate its 
physico-chemical stability during 12 months under different storage 
conditions (4°C/0% RH, 40°C/0% RH e 40°C/75% RH); 
 
To develop an enteric coated fixed dose combination by fluid bed 
coating able to avoid the hydrolytic formation of the hydroxyacid 
derivative of lovastatin in acidic conditions, as well as to promote a fast 
release of ezetimibe and lovastatin in simulated intestinal conditions.    
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1. FIXED DOSE COMBINATIONS 
 
Fixed-dose combinations (FDCs), defined as a combination of 
two or more active pharmaceutical ingredients (APIs) in a fixed ratio of 
doses, are becoming increasingly important from a public health 
perspective. Nowadays, FDCs have been commonly used for a wide range 
of conditions, including cardiovascular, metabolic and hormonal-related 
pathologies, infections, allergies and pain, and have been designed for 
different routes of administration (EMA, 2015; WHO, 2005).   
APIs in association can generate synergism or antagonism, both 
providing therapeutic benefits. Usually, combined APIs act through 
different mechanisms of action or target distinct physiological sites, 
which justifies the synergism. However, when combined, they should not 
present the same adverse reactions, in order to avoid exacerbation of 
undesired effects. Besides, their pharmacokinetic parameters should be 
compatible as to harmonize the route of administration, the interval 
between doses and the latency, the peak and duration of the therapeutic 
effect (WANNMACHER and HOEFLER, 2007).  
The potential advantages related to a FDC are: 
 additive or synergic effect of the associated APIs for 
each therapeutic indication or; 
 improved efficacy of the associated APIs, with no 
increased risks when compared to monotherapy or; 
 same therapeutic efficacy with reduced side effects, 
when compared to monotherapy or; 
 reduced incidence of microbial resistance or; 
 simplification of the therapeutic regimen (ANVISA, 
2010). 
Since the ‘polypharmacotherapy’ and the complexity of the 
therapeutic regimen have been pointed out as the main reasons for low 
compliance of patients to the treatment, efforts aiming the simplification 
of the drug therapy, especially in cases of chronic diseases, are necessary. 
Recent research has demonstrated that only around 35% of patients 
submitted to the ‘polypharmacotherapy’ are able to administer their 
medication correctly and regularly (SCHWEIM and SCHWEIM, 2014). 
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In this sense, FDCs have been playing an important role, since the risk of 
non-compliance to the treatment drops 24 to 26% in chronic patients 
using this kind of medication (BANGALORE et al., 2007).  
In Brazil, FDCs are regulated by the RDC (from Portuguese 
Resolução da Diretoria Colegiada) 210, from September 2nd, 2004, 
which requires the proof of the efficacy and safety of new associations. 
According to this legislation, clinical assays are required for each 
therapeutic indication, proving the advantage of using the combined drugs 
in comparison to the monotherapy. A technical report is also requested to 
justify the rational basis of the association (BRAZIL, 2004). In December 
2010, the Brazillian Health Regulatory Agency ANVISA has published 
two regulatory guidelines concerning the register of new associations 
(Guideline to Register New FDCs and the Guideline to Register New 
FDCs intended for Hypertension). These normatives complement the 
previous ones and have the purpose of enlightening the regulatory 
requirements of efficacy and safety necessary to register these medicines 
(ANVISA, 2010; 2010a). More recently, in 2014, ANVISA published the 
Technical Note NT 06/2014, that clarifies the relative bioavailability 
studies required to demonstrate the pharmacokinetic interaction in case of 
registering FDCs. According to this normative, these studies should be 
conducted with the reference medication administered isolated and 
simultaneously, in order to verify the occurrence or not of 
pharmacokinetic interactions between the compounds (ANVISA, 2014). 
Nowadays in Brazil, 40 FDCs are present in the National List of 
Essencial Medications (RENAME, from Portuguese Relação Nacional de 
Medicamentos Essenciais), updated and revised in June 2015, in different 
doses, dosage forms and designed to distinct routes of administration 
(BRAZILIAN HEALTH MINISTRY, 2014). Through the International 
agency Food and Drug Administration (FDA), more than 100 FDCs have 
been approved for commercialization. The importance of these 
associations have been highlighted by FDA through the normative intitled 
Guidance for industry: new chemical entity exclusivity determinations for 
certain fixed-combination drug products, which stimulates the 
development of new FDCs, allowing more formulations to be eligible for 
a longer period of market exclusivity (FDA, 2015).  
 Different chronic diseases of high socal impact are not 
satisfactorily covered by the currently available monotherapy treatments. 
Concerning dyslipidemia, although monotherapy with hypolipidemic 
drugs can provoke multiple changes in the lipidemic profile, the 
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association of drugs, especially between ezetimibe (EZE) and statins, has 
been indicated for a broader management of the phyisiological lipids (V 
BRAZILIAN GUIDELINE ON DYSLIPIDEMIA AND 
ATHEROSCLEROSIS, 2013). Besides, this association has been highly 
recommended due to increased risks of developing type 2 diabetes in 
hypercholesterolemic patients submitted to monotherapy with statins 
(CEDERBERG et al., 2015).  
The control of physiological lipids, such as triglycerides and 
cholesterol fractions, is of vital importance due to its relation with the 
development of atherosclerosis, the main cause of cardiovascular diseases 
(V BRAZILIAN GUIDELINE ON DYSLIPIDEMIA AND 
ATHEROSCLEROSIS, 2013). Nowadays, atherosclerosis represents the 
major cause of death in the world and the World Health Organization 
(WHO) affirms that levels of total cholesterol above 146 mg/dL (> 3.8 
mmol/L) are responsible for 18% of brain vascular diseases and for 56% 
of heart diseases in global scale (WHO, 2002). Besides, according to the 
Atlas of Heart Disease and Stroke, 17 million people die, every year, in 
the whole world, due to cardiovascular diseases (WHO, 2004).  
In Brazil, the cardiovascular diseases have also been the main 
cause of death (approximately 30%). They have been responsible for a 
high frequency of hospitalization, which impacts on high medical and 
social costs. In November 2009, 91970 hospitalizations occurred due to 
cardiovascular diseases, resulting in more than R$ 165 million expenses  
(VI BRAZILIAN GUIDELINES ON HYPERTENSION, 2010).  
 
2. EZETIMIBE AND LOVASTATIN 
 
Regarding the treatment of dylipidemia, the classes of drugs 
usually used are the statins (which can be administered in association with 
EZE), cholestiramine, fibrates and nicotinic acid (V BRAZILIAN 
GUIDELINE ON DYSLIPIDEMIA AND ATHEROSCLEROSIS, 
2013). 
Statins are considered the first choice drugs to reach the 
therapeutic target in hypercolesterolemic patients with risk or recurrent 
manifestation of coronary diseases (ARAÚJO; CASELLA FILHO and 
CHAGAS, 2005). These drugs inhibit the HMG-CoA reductase, leading 
to a reduced intracellular synthesis of cholesterol. In consequence, an 
increase in number of LDL-cholesterol receptors in the hepatocytes is 
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observed, which in turn, removes more VLDL-cholesterol and LDL-
cholesterol from the blood flow. Taken once a day, statins distribute 
selectively to the liver and are excreted mainly through feces (85%) and 
urine (10%). Their effect can be verified after 2 weeks of administration, 
becoming stable from the fourth week. Statins result in decreased levels 
of total cholesterol (around 30%), LDL-cholesterol (20 to 40%), 
triglycerides and VLDL-cholesterol (around 20%), associated with 
increased levels of HDL-cholesterol (up to 10%). Statins reduce 
cardiovascular mortality and the incidence of acute ischemic coronary 
events, as well as the need for myocardial revascularization and 
cerebrovascular accidents (BRAZILIAN CONSENSUS ON 
DYSLIPIDEMIA, 1996; V BRAZILIAN GUIDELINE ON 
DYSLIPIDEMIA AND ATHEROSCLEROSIS, 2013). 
Among the statins currently available, lovastatin (LOV, Figure 
1A), has been widely used in clinical practice, being one of the drugs 
which compose the RENAME. In Brazil, LOV is commercialized as 
tablets of 10, 20 and 40 mg (BRAZILIAN MINISTRY OF HEALTH, 
2014).  
 
Figure 1. Chemical structure of lovastatin (A) and its active β-hydroxy acid 
metabolite (B) 
 
 
 
 
LOV is a poorly water-soluble pro-drug (Class II in the 
Biopharmaceutics Classification System (BCS), refer to Topic 3), which 
is rapidly metabolized to its active β-hydroxy acid metabolite (LOVh, 
Figure 1B), mainly in the liver. In addition, LOVh can also be formed 
through chemical hydrolysis of LOV. Importantly, as both LOV and 
LOVh have the liver as their site of action, their concentration in this 
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organ should be maximized as much as possible. Studies in animals have 
demonstrated that LOV presents a better hepatic sequestration than 
LOVh, which in turn minimizes the systemic side effects (DUGGAN et 
al., 1988). As the author states that this provides a rational basis for the 
lactone to be the preferred API for the dosage form, the hydrolytic 
formation of the active metabolite in gastric conditions should be avoided.   
LOV shows high plasma protein binding (95%), fast 
biotransformation, t1/2 of 1-2 h, less than 5% absorption by oral route and 
tmax of 2 to 4 h (MARTINDALE, 2009). When administered in 10, 20 and 
40 mg, it is capable of reducing LDL-cholesterol levels in 21, 27 and 31%, 
respectively (HOU and GOLDBERG, 2009).  
Concerning its physicochemical properties, LOV (C24H36O5) has 
a molecular weight of 404.5 g/mol and melting point ranging from 174-
176°C. Its pKa is 14.9 and its logP value corresponds to 4.11 (BRITISH 
PHARMACOPOEIA, 2009). According to previous studies, LOV is 
considered stable under oxidative and thermal stress conditions, however, 
it is susceptible to photolysis and hydrolysis (acidic and alkaline). In this 
last case, its active metabolite LOVh can be generated (CHAUDHARI 
and UBALE, 2012). Polymorphic forms are not reported.   
EZE (Figure 2), is the first member of a new class of compounds, 
the 2-azetidinones, which selectively inhibit the absorption of biliary and 
dietary cholesterol from the small intestine by blocking the Niemann-Pick 
C1 like l protein. Its administration results in a reduction of cholesterol 
absorption from endogenous and exogenous sources (TIWARI and 
KHOKHAR, 2014).  
 
Figure 2. Chemical structure of ezetimibe 
 
Different from LOV, EZE shows pseudopolymorphism 
(PARTHASARADHI et al., 2003) and can be found as anhydrate 
(BRÜNING, ALIG and SCHMIDT, 2010)  and monohydrate 
(RAVIKUMAR and SRIDHAR, 2009). It has a melting point around 
F
N
OH
O
OH
49 
 
163°C, molecular weight of 409.4 g/mol (C24H21F2NO3), pKa of 9.5 and 
logP value of 4.56 (DE OLIVEIRA, 2007). As LOV, EZE is a poorly 
water-soluble drug which belongs to Class II in the BCS. EZE is 
chemically stable under thermal and oxidative stress conditions, although 
it is susceptible to neutral, acidic and alkaline hydrolysis (SINGH et al., 
2006).  
 EZE is rapidly captured by the intestinal cells after oral ingestion, 
and glucoronidized to its bioactive metabolite. In this form, it is absorbed 
and reaches the maxium plasma concentration after 1 h. Its half-life shows 
age-dependent variability, reaching longer plasma residence time in 
elderly patients. EZE and its active glucoronide are eliminated mainly 
through feces (80%) and a small percentage by urine (11%) (ARAÚJO; 
CASELLA FILHO and CHAGAS, 2005). 
EZE is administered once a day and commercialized as 10 mg 
tablets (ARAÚJO; CASELLA FILHO e CHAGAS, 2005). In 
monotherapy, it reduces LDL-cholesterol levels up to 20%. It has been 
more often employed in association with statins, due to a potencialized 
effect reducing the intracellular cholesterol levels. Reports declare that 
this association provides 20% extra reduction in LDL-cholesterol levels 
in comparison to statins in monotherapy (ARAÚJO; CASELLA FILHO 
and CHAGAS, 2005; SCHULZ, 2006; IV BRAZILIAN GUIDELINE 
ON DYSLIPIDEMIA AND ATHEROSCLEROSIS, 2007; HOU; 
GOLDBERG, 2009). Besides, this association promotes an additional 
reduction of triglycerides in a range of 7 to 13% and an increase of 1 to 
5% in HDL-cholesterol levels (HOU and GOLDBERG, 2009). Also, it is 
important to mention that the association of EZE with statins does not 
provoke any relevant pharmacokinetic alteration (SCHULZ, 2006). 
A clinical study conducted by Kerzner and coworkers in 2003 
evaluated the efficacy and safety of the coadministration of EZE (10 mg) 
and LOV (10, 20 or 40 mg) in 548 patients with primary 
hypercholesterolemia. Results indicated that the coadministration with 
EZE led to 10 and 14% reduction of trigycerides and LDL-cholesterol, 
respectively, besides promoting an increase of 5% of HDL-cholesterol, in 
comparison to LOV monotherapy. In this way, the therapeutics involving 
the combined administration of EZE + LOV resulted in an average 
reduction of 33 to 45%  of LDL-cholesterol levels and of 19 to 27% of 
triglycerides levels. In addition, an increase of 8 to 9% was observed for 
HDL-cholesterol. These results were dependent on LOV concentration. 
Besides, the combined administration of 10 mg EZE plus 10 mg LOV 
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(initial dose) demonstrated similar efficacy to the highest dose of LOV 
(40 mg) when administered in monotherapy. The coadministration was 
well tolerated and safe (KERZNER et al., 2003).  
In 2005, the coadministration of EZE + LOV was also evaluated 
by Tadiboyina and coworkers, in an adolescent patient with cholesterol 
ester storage disease. The administration of increasing doses of LOV 
during an approximate period of 80 months promoted an average 
reduction of 15% of LDL-cholesterol levels. However, with the addition 
of EZE (10 mg) to LOV (40 mg), an additional average decrease of 16% 
related to the LDL-cholesterol levels was observed. These data 
demonstrate the efficacy and tolerability of the combined administration 
of EZE and LOV in patients with this pathology (TADIBOYINA et al., 
2005). 
Although the association of EZE and LOV can be considered 
relevant and promising, the low solubility of both compounds makes the 
development of a FDC more challenging. EZE and LOV are Class II 
drugs in BCS (WU and BENET, 2005; TAKAGI et al., 2006), which 
means that they possess low solubility and high permeability. LOV is 
considered practically insoluble in water, although soluble in acetone and 
slightly soluble in anhydrous ethanol (BRITISH PHARMACOPOEIA, 
2009). Similar solubility is observed for EZE, which is practically 
insoluble in water, although very soluble in ethanol, methanol and acetone 
(DE OLIVEIRA, 2007).  
In this context, the development of formulations composed by 
these APIs should involve technological strategies capable of increasing 
its solubility and dissolution rate. Among the approaches available, such 
as micronization, solubilization in surfactant systems, formation of 
complexes soluble in water, utilization of salts, co-crystals and pro-drugs 
(BIKIARIS, 2011), the conversion of crystalline to amorphous solids is 
presented as a promising attempt.   
 
3. THE AMORPHOUS STATE AND ITS IMPACT ON THE 
SOLUBILITY OF DRUGS 
 
Solubility is a thermodynamic parameter defined as the 
maximum amount of a solid substance which can be dissolved in a certain 
volume of solvent or solution at constant and specified temperature and 
pressure (LACHMAN; LIEBERMAN and KANIG, 2001).  
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According to Florence and Atwood, various are the reasons 
which justify the vital importance of knowing how drugs dissolve to form 
a solution and the factors that maintain the solubility or that cause 
precipitation. Among them, it is well known that drugs should be 
molecularly dispersed, or in solution, to be absorbed, independent of the 
dosage form in which they are enclosed. In this sense, it is particularly 
important to have the knowledge about the solubility of a certain 
compound in biological fluids, so it can be able to cross the lipoprotein 
membranes (FLORENCE and ATWOOD, 2003).   
Nowadays, the percentage of APIs showing relevant therapeutic 
value and low aqueous solubility is estimated at 25 to 40% of the total of 
developed drugs (BIKIARIS, 2011). Due to their low bioavailability, this 
percentage of new APIs shows limited therapeutic application, being 
commonly rejected or subutilized by the pharmaceutical industry 
(SVENSON, 2009). Besides, drugs with low aqueous solubility can 
deposit in specific physiological sites, forming aggregates that increase 
their toxic effects (LIPINSKI, 2002).  
The influence of solubility, associated to permeability, on the ‘in 
vivo’ performance of a drug, instigated Amidon and coworkers to 
propose, in 1995, the BCS. In this classification system, drugs are 
qualified in four distinct classes according to the two parameters 
previously mentioned (AMIDON et al., 1995). 
In this context, the four classes are: 
 Class I: high solubility and high permeability; 
 Class II: low solubility and high permeability; 
 Class III: high solubility and low permeability; 
 Class IV: low solubility and low permeability. 
In order to be qualified in any of these classes, it is necessary to 
determine the solubility of the compound based on the dissolution of its 
highest dose in 250 mL of a buffer solution with pH ranging from 1.2 to 
6.8. The compound will be considered highly soluble if its highest dose 
dissolves in 250 mL of buffer, or less. On the other hand, a pharmaceutical 
compound is considered highly permeable if the fraction of absorbed dose 
is at least 85% (BRASIL, 2011) (Figure 3). 
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Figure 3. Correlation among solubility, permeability and dose 
 
 
 
Although showing high permeability, BCS Class II drugs present 
solubility problems in a way that dissolution becomes the limiting fator 
for its absorption. In this context, techonological approaches aiming the 
optimization of their physicochemical properties (e.g. solubility and 
dissolution rate) are considered as rational options to optimize 
therapeutics, as they can have a positive impact on the oral bioavailability 
of these compounds (AMIDON et al., 1995). To contemplate the interests 
of the pharmaceutical industry, these strategies should be linked to 
pharmaceutical formulations which present physicochemical stability, 
financial advantages, easy scale-up, and simple production (LIMA, 
2006).   
The amorphous materials compose an interesting strategy which 
aims enhanced solubility of drugs. These materials are considered a 
distinct class of solids, which do not present the three-dimensional 
molecular order, characteristic of crystalline solids. On the other hand, 
molecules in amorphous materials are randomly distributed and their 
interactions with other molecules, such as hydrogen bonding and 
electrostatic interaction, are not repeated with any regularity along the 
whole sample (HANCOCK, 2007). This arrangement provokes important 
differences in physicochemical properties of amorphous and crystalline 
solids, in a way that they can be easily differentiated, as described in 
Scheme 1.  
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Scheme 1. Characteristics of amorphous and crystalline solids. Adapted from 
Hancock (2007) 
 
Amorphous solids Crystalline solids  
True density of amorphous forms 
is 5 to 20% lower than the one 
presented by the crystalline form  
True density of pharmaceutical 
crystals ranges from 1 to 2.5 g/mL  
Amorphous particles are not 
refringent in polarized light 
microscopes  
Crystalline particles exhibit 
characteristic birefringent patterns 
when visualized in polarized light 
microscope  
X-rays are randomly diffracted in 
amorphous samples, resulting in a 
diffraction pattern composed of a 
broad halo 
X-rays are diffracted in a coherent 
and ordinated manner in crystalline 
powders, producing a diffraction 
pattern with characteristic and well-
defined peaks 
Amorphous materials usually 
exhibit a significant increase in 
water solubility and dissolution 
rate  when compared to crystalline 
materials  
Crytalline samples adsorb water in 
small quantities unless they form 
crystalline hydrates 
Amorphous materials exhibit a 
glass transition temperature (Tg) 
which in values, usually 
correspond to 2/3 of the crystalline 
melting point  
Crystalline materials exhibit defined 
melting points, which are associated 
to their enthalpy of fusion 
 
Amorphous solids are characterized by a glass transition 
temperature. From a thermodynamic point of view, when a crystal melts, 
it should crystallize when cooled below its melting point. However, at 
high cooling rates, crystallization is usually suppressed and the material 
is found in a super-cooled liquid state. As the temperature drops, 
molecular mobility is reduced and the super-cooled liquid escapes from 
the liquid state curve. At this point, molecular mobility is insufficient to 
allow the equilibrium of the system with the timeframe of the cooling 
process. In this sense, abrupt changes of entropy, enthalpy and volume of 
the material are observed, characterizing the glass transition. The region 
below the Tg is known as glassy state (Figure 4). Due to the high viscosity 
of this state, molecular mobility is reduced and relaxation processes 
become slow. In this way, the glassy state has rheological properties of a 
solid and molecular properties of a liquid (JANSSENS and VAN DEN 
MOOTER, 2009; BELLANTONE, 2014).  
54 
 
 
Figure 4. Schematic diagram showing changes in enthalpy (H), entropy (S) 
and volume (V) in liquid, crystalline and glassy state in function of 
temperature. Tg and Tf  represent the glass transition temperature and the 
temperature of fusion, respectively. Adapted from Janssens and Van den 
Mooter (2009).   
 
 
 
Besides the quench cooling from the melt method, amorphous 
solids can also be prepared by solvent evaporation methods (e.g. spray 
drying and freeze drying), precipitation from a solution, dehydration of 
hydrates and as consequence of mechanical stress induced by compaction, 
compression or intense crystal milling (HANCOCK, 2007; JANSSENS 
and VAN DEN MOOTER, 2009). 
To comprehend the relation between the amorphous state and the 
solubility of a compound, it is necessary to establish a relation between 
the dissolution process and the energy required for this event. At a certain 
temperature, the source of heat necessary for dissolution is known as 
solvation energy. Solvation is a phenomenum in which the solvent 
molecules “link” to undissolved drug molecules and the kinetic energy 
from solvent molecules is transferred to a complex drug-solvent. This 
energy transfer is a function of the attraction energy between drug and 
solvent and of the number of solvent molecules which effectively transfer 
energy to the undissolved drug. If this kinetic energy is sufficient to 
overcome the drug-drug interactions, the drug molecule leaves the 
undissolved environment and moves to the solvent, where it will be 
surrounded by more solvent molecules and will make part of the solution. 
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Once in solution, drug molecules are capable of getting dispersed in the 
solvent and will comprise the “dispersive region” (BELLANTONE, 
2014).  
In this context, any modification of the undissolved form that 
reduces the drug-drug attraction forces will be capable of reducing the 
energy necessary to make them dissolved. As a consequence of the 
disordered arrangement of the amorphous state, a larger separation 
between molecules is observed, as well as a reduction of the 
intermolecular attraction forces, in comparison to the crystalline state. In 
this way, the energy required to reach the melting point and the 
“dispersive region” is lower in amorphous materials than in the crystalline 
ones. This reduction of the necessary energy in case of amorphous 
materials culminates in a higher solubility and dissolution rate 
(BELLANTONE, 2014; HANCOCK, 2007).  
Another strategy to reduce the required energy to reach the 
“dispersive region” occurs through the addition of excipient molecules 
among drug molecules. In this case, the interactions between drug and 
excipient are weaker than the drug-drug interactions, and/or the 
interactions between excipient and water are stronger than the ones 
happening between drug and water. In the first case, there is a reduction 
of the necessary energy to displace the drug and reach the “dispersive 
region”. On the other hand, the second strategy comprehends an increase 
of the energy obtained from the excipient-water interactions to dissolve 
the drug molecules. This option is the base of solid dispersions and other 
polymer-based systems (BELLANTONE, 2014).     
However, it is important to mention that amorphous materials are 
thermodynamically unstable and there is a tendency to crystallize during 
processing, dissolution and storage (HE, 2009). In this context, the 
development of stable amorphous systems is a challenge for 
pharmaceutical researchers.  
The stabilization of amorphous drugs have been widely reported 
by means of solid dispersions and other polymer-based formulations 
(LEUNER and DRESSMAN, 2000; VASCONCELOS, SARMENTO 
and COSTA, 2007; VAN DEN MOOTER, 2012), and more recently, also 
through co-amorphous systems. In all these cases, the physical 
stabilization of these materials occurs via the increase of the overall Tg, 
by the miscibility between drug particles or drug-polymer particles, or 
through the establishment of intermolecular interactions such as hydrogen 
bonding (LAITINEN et al., 2013).  
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4. STRATEGIES IN AMORPHOUS STATE APPLIED TO 
IMPROVE SOLUBILITY AND DISSOLUTION RATE IN FIXED 
DOSE COMBINATIONS  
 
4.1 CO-AMORPHOUS SYSTEMS 
 
Co-amorphous systems have been recently introduced as 
potential systems involving poorly water-soluble drugs. These type of 
formulations aim to overcome the commonly reported problems faced 
with amorphous materials when composing the conventional 
combinations between drugs and hydrophilic polymers (LÖBMANN et 
al., 2012).   
Co-amorphous systems can be defined as systems which 
comprise the combination of two or more amorphous solids of low 
molecular weight, all in a single amorphous phase. These systems are 
capable of increasing the solubility and dissolution rate of poorly water-
soluble drugs, as well as their physical stability, mainly due to solid-state 
interactions (e.g. hydrogen bonding) among the components. Importantly, 
the co-amorphous systems show advantages even in comparison to the 
isolated amorphous drugs, demonstrating the efficiency of the 
combination. So far, co-amorphous systems described in literature have 
been obtained through solvent evaporation techniques (e.g. spray drying 
or under vaccum conditions), mechanical activation by milling and 
quench cooling from the melt (ALLESØ et al., 2009; CHIENG et al., 
2009; LAITINEN et al., 2012, LÖBMANN et al., 2012, 2012a; 
SHAYANFAR; JOUYBAN; HAMISHEHKAR, 2012; GAO et al., 2013; 
LÖBMANN et al., 2013, 2013a; SHIMADA et al., 2013).  
As mentioned previously, the major advantage of these systems 
refers to the replacement of hydrophilic polymers by drugs, since the 
commonly faced problems in solid dispersions such as their hygroscopic 
characteristic, miscibility problems and large total bulk volume, are 
overcome. In co-amorphous systems, the antiplastifying characteristic 
associated to the hydrophilic polymers in solid dispersions, becomes a 
property of one of the drugs or other component of the system, usually 
the one with the highest aqueous solubility (LAITINEN, et al., 2013). 
Besides, as in solid dispersions, a single and increased Tg is desired, which 
is intrinsically correlated to the miscibility of the system and corroborates 
to its physical stability (ALLESØ et al., 2009; LÖBMANN et al., 2013). 
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One of the first reports in literature about the combination of two 
drugs in amorphous state was described by Yamamura and coworkers, 
through the binary association between cimetidine and the nonsteroidal 
anti-inflammatory drugs (NSAIDs) naproxen (YAMAMURA et al., 
1996), indomethacin (YAMAMURA et al., 2000) and diflunisal 
(YAMAMURA et al., 2002). Initially, the researchers attributed the 
formation of the amorphous binary systems to the absence of 
intermolecular interactions between the imidazolic ring from cimetidine 
and the carbonyl group of the NSAIDs (YAMAMURA et al., 1996; 
2000). However, after a more detailed study with diflunisal, the 
obtainment of the amorphous systems was then attributed to a salt 
formation between the molecules, increasing the solubility of the poorly 
water-soluble drugs  (YAMAMURA et al., 2000; 2002). 
Later, these studies have been improved and the first co-
amorphous systems were reported. In 2009, Chieng and coworkers 
described the preparation of co-amorphous systems by milling of 
indomethacin and ranitidine hydrochloride, which comprised a single 
amorphous phase in 2:1, 1:1 and 1:2 (indomethacin:ranitidine 
hydrochloride) molar ratios (CHIENG et al., 2009). 
In the same year, Alleso and coworkers prepared co-amorphous 
systems, also by milling, with the BCS Class II compound naproxen and 
the BCS Class III drug, cimetidine, using the same molar ratios as 
previously reported. It was observed that the co-amorphous system was 
able to increase the intrinsic dissolution rate of naproxen and cimetidine 
up to 4 and 2 times, respectively. The 1:1 molar ratio provided the 
formation of intermolecular interactions between the compounds, besides 
being the proportion with the best physical stability (ALLESØ et al., 
2009). 
Similar reports have been described in 2011 by Löbmann and 
coworkers, with the preparation of co-amorphous systems of the BCS 
Class II compounds naproxen and indomethacin, by quench cooling. A 7-
fold increase in the dissolution of indomethacin was reported, besides a 
synchronized dissolution of the compounds, due to the formation of a 
heterodimer between the APIs (LÖBMANN et al., 2011).  
From these promising data, researchers have published the 
preparation of co-amorphous systems of simvastatin and glipizide 
(LÖBMANN et al., 2012), atorvastatin calcium and nicotinamide 
(SHAYANFAR; JOUYBAN; HAMISHEHKAR, 2012), repaglinide and 
saccharine (GAO et al., 2013), ritonavir and indomethacin (DENGALE 
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et al., 2014), salmeterol xinafoate and mometasone furoate (LIU et al., 
2015) and EZE and indapamide (KNAPIK et al., 2015). Recent papers 
have also demonstrated the potential of using aminoacids to prepare 
binary and ternary co-amorphous systems (LÖBMANN et al., 2013, 
2013a; LAITINEN et al., 2014; JENSEN et al., 2014; LENZ et al., 2015). 
In cases in which the solubility and/or the dissolution rate were evaluated, 
the reported co-amorphous systems demonstrated the improvement of 
both parameters, besides keeping or enhancing th physical stability of the 
system. In this way, these type of formulation has proven to be a 
promising alternative for FDCs composed of poorly water-soluble drugs 
(LÖBMANN et al., 2012a). 
 
4.2 SOLID DISPERSIONS  
 
 Solid dispersions can be defined as a system in which a drug, 
usually lipophillic, is dispersed in one or more hydrophillic and 
biologically inert carriers. The purpose of this type of formulation is 
generally to alter the cristallinity of the drug in order to enhance its 
dissolution rate and to disperse it in material with high solubility in 
aqueous environment (PADDEN et al., 2011).  
 The term solid dispersion has been more often associated to 
glassy solutions, which comprise the dispersion of a poorly water-soluble 
compound in amorphous carriers. In this case, a single amorphous phase 
is composed by molecules of drug well mixed with molecules of carrier, 
generating intimate miscibility which corroborates to the enhancement of 
the dissolution properties of the drug (VAN DEN MOOTER, 2012). In 
addition, solid dispersions can also have other different classifications, as 
depicted in Figure 5, according to their crystallinity degree and how the 
drug is distributed in the system (HE, 2009).   
The improvement of the dissolution rate of a drug by means of 
solid dispersions can be explained through the reduction of particle size 
and consequent increase of surface area, better drug wettability by the 
presence of a hydrophilic polymer, increased porosity of the whole 
system and especially due to drug amorphization and miscibility between 
drug and carrier(s) (BLOCK e SPEISER, 1987; CRAIG, 2002; 
VASCONCELOS; SARMENTO e COSTA, 2007).  
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Figure 5. Classification of solid dispersions according to the distribution of 
drug molecules in the carrier(s). From HE, 2009  
 
 
 
Despite of that, solid dispersions are widely investigated due to 
their capacity to stabilize amorphous drugs. This occurs mainly via the 
occurrence of intermolecular interactions among the components, such as 
hydrogen bonding, and an adequate miscibility of the compounds, usually 
increasing the overall Tg of the system. In this last case, the molecular 
mobility is reduced in conditions of temperature and relative humidity 
commonly occurent in storage, delaying the phase separation and crystal 
growing processes  (BHUGRA e PIKAL, 2008; VAN DEN MOOTER, 
2012). In general, relatively small amounts of polymer have demonstrated 
a significant inhibition of crystallization, both in solid-state before 
administration as well as after the introduction of the solid dispersion in 
a dissolution medium or gastrointestinal environment (ALONZO et al., 
2010).    
Sekiguchi and Obi (1961) proposed for the first time the 
formulation of a eutectic mixture aiming to increase the low solubility of 
a compound (SEKIGUCHI and OBI, 1961). These researchers have noted 
that the formation of these systems increased the dissolution rate and the 
bioavailability of hydrophobic compounds. In this context, many of these 
mixtures were synthesized with the same purpose, showing satisfactory 
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results. Many different pharmaceutical carriers were tested, such as urea 
and saccharose, which are higly water soluble, crystalline excipients.  
Nowadays, solid dispersions can be classified as first, second and 
third generations. Formulations similar to the ones developed by 
Sekiguchi and Obi are qualified as first generation systems. These ones 
refer to eutectic mixtures of drugs and highly soluble crystalline carriers 
(VASCONCELOS; SARMENTO and COSTA, 2007).  
Second generation solid dispersions comprise the formulations 
with amorphous polymers, which present more pronounced solubility and 
dissolution rate enhancements. The carriers most often employed in this 
kind of system are divided in two categories, the synthetic and non-
synthetic ones. The synthetic polymers include the polyvinyl pirrolidones 
(PVP), polyethylene glycol (PEG) and polymethacrylates. The semi-
synthetic polymers are mainly derived from cellulose, such as 
hydroxypropilmethyl cellulose (HPMC), ethyl celullose (EC), 
hydroxypropil cellulose (HPC) or derivatives from starch, like 
cyclodextrins (VASCONCELOS; SARMENTO and COSTA, 2007).  
On the other hand, the third generation of solid dispersions 
involves the utilization of surfactants, improving even more the low 
solubility of pharmaceutical compounds. Some examples of surfactants 
currently used are Soluplus®, Poloxamer 407® and Poloxamer 188® 
(SERAJUDDIN; SHEEN and AUGUSTINE, 1990; SHEEN et al., 1995). 
The choice of a carrier is a crucial point regarding the 
development of a successful solid dispersion, since it exherts a great 
influence on the dissolution properties and physical stability of the drug 
and formulation (BLOCK; SPEISER, 1987).  
In this sense, a carrier must accomplish with the following 
requisites: 
 Be highly water-soluble; 
 Be non-toxic and pharmacologically inert; 
 Be thermostable and present a low melting point, in 
cases in which the solid dispersions are prepared by 
melting methods; 
 Be soluble in a large variety of solvents, besides being 
capable of passing through the glassy state when applied 
to a solid dispersion obtained via a solvent evaporation 
method; 
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 Be chemically compatible with the drug, not forming too 
strong and complex chemical bonding with it, which 
could hamper its release and solubilization  (LEUNER e 
DRESSMAN, 2000; VADNERE, 2007). 
The carriers chosen to compose the solid dispersions in this 
research are shown in Scheme 2 and their main properties are described.  
According to their composition, solid dispersions can be 
classified as binary or ternary. Binary formulations are composed of the 
drug, usually lipophilic, and a hydophillic carrier. Ternary solid 
dispersions most often reported in literature correspond to a drug and a 
mixture of two carriers. For the first time, this research demonstrates the 
preparation and investigation of ternary solid dispersions composed of 
two poorly water-soluble compounds, in order to compose a FDC.  
Basically, solid dispersions can be prepared by a fusion method, 
solvent evaporation method or a combination of both (LEUNER e 
DRESSMAN, 2000; VAN DEN MOOTER, 2012; VO, PARK e LEE, 
2013). More recently, mechanical activation techniques, such as high 
energy milling, have been also used and have the advantage of being 
environmentally friendly and easy to scale-up, although more time 
consuming (RIEKES et al., 2014; NART et al., 2015). Melting methods, 
such as hot melt extrusion and quench cooling, are more adequate for 
drugs and carriers which mix in liquid state after the fusion of both. 
However, it can be more limiting due to the occurrence of sublimation, 
polymorphic transformation and thermal degradation (GOLDBERG; 
GIBALDI e KANIG, 1965; LEUNER e DRESSMAN, 2000). Solvent 
evaporation methods have the disadvantage of using organic solvents, but 
are especially indicated for thermolabile compounds. In this type of 
process, drug and carrier are dissolved in the same solvent or mixture of 
solvents, which are later removed by evaporation, under vaccum 
conditions, or by spray drying, freeze drying and supercritical fluid 
technology (BETAGERI and MAKARLA, 1995; LEUNER and 
DRESSMAN, 2000; SETHIA and SQUILLANTE, 2004; DURET et al., 
2012). 
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Scheme 2. Carriers used in solid dispersions and their main properties  
 
Chemical and 
comercial name 
Chemical structure Observations Reference 
Polyvinyl caprolactone 
(PVC) - polyvinyl 
acetate (PVA) – 
polyethylene glycol 
(PEG) copolymer 
 
Soluplus® 
 
Amphipillic properties and 
excelente capacity of forming 
solid solutions. Due to its wide 
solubility in organic solvents and 
low Tg ~ 70°C, it can be applied 
to the preparation of solid 
dispersions by solvent 
evaporation or melting methods. 
 
 
LINN et al., 
2012; 
HARDUNG, 
DJURIC and 
ALI, 2010.   
Hydroxypropilmethyl 
cellulose (HPMC) 
 
Methocel®, Metolose®, 
Pharmacoat®, 
Tylopur®, Tylose MO®  
 
 
Available in various grades, 
which vary according to its 
viscosity and substitution grade. 
Its molecular weight ranges from 
10,000 to 1,500,000 g/mol. It is 
soluble in cold water, forming a 
viscous colloidal solution, 
practically insoluble in hot water, 
chloroform, ethanol (95%) and 
ether, but soluble in mixtures of 
ethanol:dichloromethane, 
ROGERS, 
2009; WANG 
et al., 2015. 
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methanol:dichloromethane and 
water:ethanol. Presents a high  
Tg (~ 170-180°C). 
Polyvinyl pirrolidone 
(PVP) 
 
Plasdone®, Kollidon®, 
Povipharm® 
 
 
Synthetic linear polymer with 
different degrees of 
polymerization, resulting in 
materials with distinct molecular 
weights. It is characterized by its 
viscosity in aqueous solutions, 
which are expressed in K values, 
ranging from 10 to 120. It is 
easily soluble in acids, 
chloroform, ethanol (95%), 
ketones, methanol and water; 
practically insoluble in ether, 
hydrocarbonates and mineral oil. 
Presents a Tg value around 
150°C.   
KIBBE, 2009 
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Polyvinyl pyrrolidone-
polyvinyl acetate 
copolymer (PVP/VA) 
 
Kollidon VA 64®, 
Luviskol VA®, 
Plasdone S-630®   
 
 
 
Composed of a copolymer of 1-
vinyl-2-pyrrolidone and vinyl 
acetate, in a mass ratio of 3:2. 
The association of these two 
monomers implies to this 
polymer surfactant and stabilizer 
properties. It shows a K value 
varying from 25.4 to 34.2, which 
is associated to its viscosity in 
aqueous solutions. It shows 
solubility higher than 10% in 1,4 
butanediol, glycerol, butanol, 
chloroform, dichloromethane, 
ethanol (95%), methanol, 
polyethyleneglycol 400, 2-
propanol, propanol, 
propileneglycol and water. It is 
soluble in less than 1% of 
cyclohexane, diethylether, liquid 
parafine and pentane and has a  
Tg value of 106 °C. 
ABUBAKER, 
2009; 
GOUVEIA, 
2011  
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4.3 GELATIN-BASED FORMULATIONS 
 
 Gelatin is widely known as a natural, biocompatible, 
biodegradable and multifunctional highly water-soluble biopolymer. 
Obtained through partial hydrolysis of animal-source collagen, mainly 
from cattle bones, cattle hides, and porkskins, it can be qualified as Type 
A and Type B, if derived from acid or alkali-treated processes, 
respectively (GMIA, 2012; FOOX and ZILBERMAN, 2015).  
 Extraction processes applied to prepare Type A and Type B 
gelatin involve some important parameters such as pH, time, temperature 
and number of extractions, which vary according to the product needs, 
type of equipment employed, timing and costs. Usually, the number of 
extraction ranges from 3 to 6 and temperature varies from 50 to 60 ºC, at 
a first stage, being subsequently increased in steps from 5 to 10°C, close 
to the boiling point, in later stages. Initial extraction provides superior 
quality material, with higher molecular weights, viscosity, gel strength 
and lighter color, in comparison to later stages. Type A process usually 
applies hydrochloric acid or sulfuric acid, whilst alkali-treated process 
uses mainly lime (GMIA, 2012). 
  Composed by a heterogeneous mixture of water-soluble proteins 
of high average molecular weight (15,000 to 400,000 Da), the final 
composition of gelatin depends mainly on its source and extraction 
process, generating a wide variety of aminoacids, after hydrolysis. The 
three more aboundant aminoacids found in gelatin are glycine, proline 
and hydroxyproline. In terms of basic elements, gelatin is composed of  
50.5% carbon, 6.8% hydrogen, 17% nitrogen and 25.2% oxygen 
(KALLINTERI and ANTIMISIARIS, 2001; GMIA, 2012; FOOX and 
ZILBERMAN, 2015).  
 In comparison to other materials, gelatin offers the advantages of 
being cheap, readily available, biocompatible and biodegradable 
(ELZOGHBY,2013). Besides, although mainly derived from animal 
sources, the digestive process confers gelatin very low antigenicity, with 
the formation of harmless metabolic products upon degradation 
(SANTORO, TATARA and MIKOS, 2014). Being recognized as a 
Generally Regarded as Safe (GRAS) material by FDA, gelatin is widely 
employed due to its unique properties in food, pharmaceutical, cosmetic 
and medical applications (FOOX and ZILBERMAN, 2015).  
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 Having a long history of safe use in pharmaceuticals, especially 
in the composition of hard capsules, more recently, gelatin has been also 
used in the development of modern drug delivery systems. Its application 
has been reported in controlled drug delivery formulations, as an 
absorption enhancer or improving the dissolution of poorly water-soluble 
compounds (FOOX and ZILBERMAN, 2015). Regarding this last case, 
literature described gelatin-based formulations able to enhance the 
dissolution rate of nitrofurantoin, chlorothiazide, phenobarbital, 
prednisolone, griseofulvin, diazepam and piroxicam, as reported by 
Kallinteri and Antimisiaris (2001). These researchers stated that there is 
a tendency for larger gelatin-induced increases in solubility as drug 
lipophilicity increases. In the same context, gelatin-based systems were 
able to improve the dissolution rate of the poorly soluble drugs pranlukast 
(CHONO et al., 2008), ibuprofen (LI et al., 2008) and fenofibrate 
(YOUSAF et al., 2015).    
 However, although gelatin has a high ability to absorb water, 
leading usually to a very fast release profile, this biopolymer is also quite 
unstable in certain exposure conditions, which can have a negative impact 
on drug dissolution. Its exposure to environmental factors, such as 
humidity, heat and light, and/or chemical catalysts, results in the 
formation of a swollen, very thin, tough, rubbery,water-insoluble 
membrane, also known as pellicle. This membrane acts as a barrier and 
can restrict the release of a drug from a gelatin-based formulation. Not 
disrupted by gentle agitation, this membrane formation can be the reason 
of failure of some gelatin-based formulations or even of formulations 
comprised in gelatin capsules. Although some stabilizers have been 
identified and added in  formulation fills or films to avoid this matter, 
more effort has to be done to optimize the use of such promising 
biopolymer for pharmaceutical applications (SINGH and PAKHALE, 
2007).  
 
5. ENTERIC COATED MUTIPARTICULATE SYSTEMS  
 
 Basically, oral dosage forms are classified according to its release 
behavior in immediate and modified release systems. In the first case, the 
dosage form is developed to disintegrate and release its active compound 
without controlling the dissolution rate through polymeric coating, for 
example. On the other hand, modified release dosage forms can comprise 
the extended or delayed types. In extended release, the dosage form is 
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developed to release the active compound in a controlled way, under 
predetermined conditions of rate, duration and location, to reach and keep 
optimal therapeutic levels for a longer period of time (8-12 hours).  For 
delayed release dosage forms, the drug is not immediately released when 
administered, but after a certain period of time, as observed in enteric 
coated formulations (ANSEL, POPOVICH and ALLEN JR, 2011; 
COLLETT and MORETON, 2001).  
 Enteric coated dosage forms use polymers insoluble in gastric 
environment which avoid or delay the release of the drug in the stomach. 
These polymers are known to dissolve in a pH range from 4.8 to 7.2. The 
reasons which justify the enteric coating include: 
 Dosage forms composed by drugs unstable in gastric 
environment; 
 Dosage forms composed by drugs which irritate the gastric 
mucosa and cause undesired side effects, such as nausea and 
vomiting; 
 Dosage forms composed by drugs in which a delayed 
release with a lag time of 3 to 4 hours is indicated; 
 Dosage forms composed by drugs with a specific absorption 
site (absorption window) in the intestine (SINGH and KIM, 
2002; ANSEL, POPOVICH and ALLEN JR, 2011a).  
 Among the different enteric polymers available, the 
polymethacrylates Eudragit L100® and Eudragit L100-55® (Figure 6) 
have been often applied to protect APIs from the gastric environment 
(NGUYEN et al., 2016; TAYEL et al., 2016; BESENHARD et al., 2014; 
SAUER et al., 2009). Eudragit L100® is a pH dependent anionic polymer 
based on methacrylic acid and methyl methacrylate, in which the ratio of 
free carboxyl to ester groups is approximately 1:1. It starts to dissolve at 
pH 6.0. Eudragit L100-55® is also an anionic polymer, but it starts to 
dissolve at a slightly lower pH, 5.5. Its chemical structure consists of a 
copolymer of methacrylic acid and ethyl acrylate, and the ratio of free 
carboxyl to ester groups is approximately 1:1 (VAKA et al., 2014; 
NOLLENBERGER and ALBERS, 2013; CHANG et al., 2009).  
 The enteric coating can be applied to single unit dosage forms, 
such as tablets, or multiparticulate systems, like pellets.  Figure 7 depicts 
an enteric coated pellet and the release process of drugs (e.g. EZE and 
LOV) under gastrointestinal conditions. The figure shows the enteric 
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coating layer (e.g. Eudragit L100® or Eudragit L100-55®), the 
intermediate layer composed by a highly water-soluble solid dispersion 
and the inert core composed by sucrose. In gastric conditions, the enteric 
coating layer remains intact, avoiding drug release in stomach. At a 
certain pH (5.5 for Eudragit L100-55® and 6.0 for Eudragit L100®), the 
enteric coating layer starts to dissolve and the compounds are rapidly 
released due to the improved dissolution properties of the solid 
dispersion.  
 
Figure 6. Monomeric unit of Eudragit L100® (R1 = H3C; R2 = H3C) and 
Eudragit L100-55® (R1 = H; R2 = C2H5)    
 
 
 
Figure 7. Drug release from an enteric coated pellet. EC = enteric coating 
layer, SD = solid dispersion layer 
 
 Pellets are one of the main representatives of multiparticulate 
systems, along with granules and mini tablets. As the name suggests, 
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these systems comprise more than one dosage unit in a pharmaceutical 
dosage form. In case of pellets, they are conditioned inside of hard gelatin 
capsules, according to their doses of administration (COLLETT and 
MORETON, 2001).  
 Preparation of multiparticulate systems instead of the 
conventional single unit dosage forms, offers the advantage of presenting 
a more predictable gastric transit time, better distribution and absorption, 
facilitated disintegration, less frequent dose dumping issues and reduced 
risks of systemic toxicity and local irritation (ASGHAR and 
CHANDRAN, 2006). In theory, multiparticulate systems can also be an 
interesting choice to compose a FDC, since they allow the combination 
of more than one API, obtaining various release profiles from a single 
dosage form. 
 Fluid bed coating is one of the most used coating processes, and 
the term ‘fluidized bed’ is used because the powder bed or pellet bed acts 
as if it is a fluid (DIXIT and PUTHLI, 2009). Basically, every coating 
process consists of subjecting particles to continuous coating and drying 
cycles in order to accumulate coating layers. In a fluid bed coating 
operation, the three phases involved, solid (particles), liquid (coating 
solution) and gas (fluidizing air) are continuously interacting throughout 
the process. In a first step, the solid particles are loaded into the processor 
and submitted to the fluidizing air. Subsequently, the coating material is 
pumped through a nozzle and sprayed as droplets onto the particles, 
generating a homogeneous layering of the coating material. The non-stop 
drying, provided by the drying air set at a temperature able to promote 
solvent evaporation, allows the occurrence of the continuous layering. 
The success of the coating process depends on the ability of the droplet 
to be homogeneously spread on the particle surface, avoiding particle 
agglomeration (SAUER et al., 2013; DIXIT and PUTHLI, 2009).  
 Fluid bed coaters can be found in different settings as shown in 
Figure 8. The first type developed, known as top spray (Figure 8a), 
presents a nebulization system located at the superior part of the chamber. 
The efficiency, in terms of material deposited and coating quality, is low, 
generating materials with poor controlled release properties. From that,  a 
bottom spray fluid bed coater was developed (Figure 8b), in which the 
coating solution is nebulized from the inferior part of the equipment. This 
kind of system increases considerably the collision among particles and 
droplets of coating solution, resulting in a higher coating efficiency. 
However, due to the high concentration of humid particles, the 
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agglomeration risk is high. Despite of the different configurations of fluid 
bed coaters, the bottom spray mode with a Würster insert (Figure 8c) is 
especially interesting to coat small particles, as pellets, since it diminishes 
the risk of agglomeration, typical of the standard bottom spray mode. This 
type of fluid bed coater presents a higher drying rate and reduction of the 
potential of agglomeration, generating particles with a more 
homogeneous coating layer (FUKUMORI and ICHIKAWA, 2002; 
TEUNOU and PONCELET, 2002). 
 
Figure 8. Different fluid bed coater settings: (a) top spray, (b), bottom spray 
and (c) Wurster. Adapted from TEUNOU e PONCELET, 2002.   
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AMORPHOUS SYSTEMS OF EZETIMIBE AND LOVASTATIN 
MANUFACTURED THROUGH QUENCH COOLING FROM 
THE MELT 
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1. INTRODUCTION 
 
Co-amorphous systems have been recently introduced with the 
purpose of increasing the solubility and dissolution rate of drugs in 
therapeutic relevant combinations. These systems usually comprise 
amorphous binary mixtures of two small organic molecules, in a single 
phase, like drugs or amino acids (LAITINEN et al., 2013; LÖBMANN et 
al., 2013a, 2013b). More often, they are obtained in 1:1, 1:2 or 2:1 molar 
ratios through quench cooling from the melt, milling or solvent 
evaporation methods. The increase in the dissolution rate due to the 
conversion of the crystalline APIs to their amorphous state is reported in 
most cases (LAITINEN et al., 2013; DENGALE et al., 2014; LENZ et 
al., 2015).  
In addition, co-amorphous systems also stabilize the amorphous 
drug by the same mechanism described for the well-known solid 
dispersions. Increasing the overall glass transition temperature (Tg) of the 
system and ensuring the miscibility between APIs and the occurrence of 
intermolecular interactions like hydrogen bonding, are some possible 
ways to reach this purpose through co-amorphous systems (JANSSENS 
and VAN DEN MOOTER, 2009; LAITINEN et al., 2013). 
However, different from solid dispersions, co-amorphous 
systems are not composed by hydrophilic polymers. This basically means 
that usual problems in solid dispersions like large bulk volume, 
hygroscopicity and non-miscibility between the components can be 
avoided (LAITINEN et al., 2013).  
In order to enhance the solubility and dissolution rate of 
ezetimibe (EZE) and lovastatin (LOV), the preparation of co-amorphous 
systems was the first approach investigated. These compounds were 
chosen as model drugs as they both are poorly water-soluble compounds, 
qualified in Class 2 of the Biopharmaceutics Classification System 
(BCS), besides representing a relevant therapeutic combination to 
alternatively treat hypercholesterolemia. In addition, they present similar 
molecular weights (409,4 g/mol for EZE  and 404,54 g/mol for LOV), 
low and similar doses of administration (10 mg for EZE and 10, 20 or 40 
mg for LOV, once a day) and their chemical structures show specific 
groups which are potential sites of hydrogen bonding.  
87 
 
Based on that, the purpose of this chapter was to investigate co-
amorphous systems as an approach to improve the solubility and 
dissolution rate of EZE and LOV.  
 
2 EXPERIMENTAL 
 
2.1 MATERIALS 
 
EZE (anhydrous, 409.41 g/mol) and LOV (404.54 g/mol) were 
purchased from Pharma Nostra (Rio de Janeiro, Brazil) with batch 
numbers FM017H13 and 130312, respectively. In all experiments de-
ionized water (Maxima Ultra Pure Water, Elga Ltd., Wycombe, England) 
was used and the organic solvents were of pharmaceutical grade. 
  
2.2 DETERMINATION OF THE EQUILIBRIUM SOLUBILITY  
 
The equilibrium solubility of EZE, LOV, and the binary physical 
mixtures of EZE:LOV (1:1, w/w) were determined in acetate buffer pH 
4.5 + 0.025% of sodium lauryl sulfate (SLS). In glass test tubes, an 
excessive amount of pure EZE, LOV and the binary mixtures were added 
into 5 ml of the above media and the samples were kept for 48 hours in a 
rotary mixer (L26 Labinco BV, Breda, The Netherlands). After that, 1 ml 
of the supernatant was filtered through a Polytetrafluoroethylene (PTFE) 
membrane with 0.45 µm pore size (Grace Davison Discovery Science, 
Illinois, USA).  
The content of EZE and LOV dissolved in the filtrate was 
determined via isocratic HPLC analysis (Merk-Hitachi LaChrom 
system). The experiments were conducted on a reversed-phase 
Chromolith® Performance C18 column (100 x 4.6 mm i.d., 5 µm pore 
size). The mobile phase was composed of acetonitrile:water (50:50 v/v), 
with a flow rate of 1.0 ml/min, at room temperature. The UV detection 
was performed at 235 nm. 20 µl of samples was injected and the data 
acquisition was performed using Merck LaChrom D-7000 System 
Manager software. A standard calibration curve (peak area vs. known 
concentration) was developed by using standard solutions (0.0125–50 
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µg/ml) prepared by diluting the stock standard solution (200 µg/mL of 
EZE and LOV in acetonitrile) with the mobile phase. The statistical 
analysis of the data was conducted in GraphPad Prism 6 software through 
one-way ANOVA followed by Tukey test. Results were considered 
statistically significantly different if p < 0.05. 
 
2.3 PREPARATION OF CO-AMORPHOUS SYSTEMS BY QUENCH 
COOLING FROM THE MELT 
 
Co-amorphous systems of EZE and LOV in 1:1, 1:2, 1:4 and 2:1 
molar ratios (EZE:LOV) were prepared through quench cooling from the 
melt using a modulated differential scanning calorimetry (mDSC) 
equipment (Q2000 DSC, TA Instruments, Leatherhead, UK). The 
samples were placed in DSC sample holders, heated at 2°C/min to 180°C, 
kept isothermal for 5 min and quench cooled to -10°C. The experiments 
were performed in triplicate and the obtained samples were stored in a 
desiccator before analysis.  
The theoretical Tg of the binary systems was calculated through 
the Gordon Taylor equation (eq. 1): 
 
Tg mix= (W1*Tg1+K*W2*Tg2)/(W1+K*W2)   (Equation 1), 
 
where Tg mix is the theoretical Tg of the mixture, K is a constant, W1 and 
W2 correspond to the mass fraction of compounds 1 and 2, respectively 
and Tg1 and Tg2 refer to the experimental Tg of compounds 1 and 2, 
respectively. Tg 1 denotes the compound with the lowest Tg. The constant 
K is calculated as follows: 
 
K≅  (ρ1* Tg1)/(ρ2* Tg2)     (Equation 2), 
 
where ρ1 and ρ2 represent the amorphous density of compounds 1 and 2, 
respectively. Unit cell (crystalline) densities of 1.34 g cm−3 and 1.17 g 
cm−3 for EZE anhydrate and LOV, respectively, were obtained from the 
calculation of density (density = [1.66 x molecular weight x number of 
89 
 
molecules per assyimetrical unit]/unit cell volume), based on data 
reported in literature for the single crystal elucidation of these crystalline 
forms (SATO et al., 1984; BRÜNING, ALIG and SCHMIDT, 2010). 
Values corresponding to a decrease of 5% of the crystalline density were 
used as density values for the amorphous components. This 
approximation of densities is valid for small drug molecules such as those 
used in this study and has been already described for the estimation of the 
theoretical glass transition temperature of naproxen-cimetidine binary 
mixtures (ALLESO, et al., 2009). 
In order to obtain the pure amorphous APIs, EZE and LOV were 
submitted to the same experimental conditions described above and were 
denoted as EZEqc and LOVqc. 
 
2.4 X-RAY POWDER DIFFRACTION (XRPD) 
 
XRPD experiments were carried out at room temperature using 
an automated X’pert PRO diffractometer (PANalytical, Almelo, The 
Netherlands) with a Cu tube (Kα λ = 1.5418 Å) and the generator was set 
at 45 kV and 40 mA. EZE and LOV raw materials were applied on 
spinning zero background sample holders. Measurements were 
performed in a continuous scan mode from 4° to 40° with 0.0167° step 
size and 200 s per step counting time. 
Co-amorphous samples were analyzed in the same conditions but 
using regular sample holders. The samples were prepared and analyzed in 
DSC sample holders in a continuous scan mode from 4° to 35°. 
 
2.5 MODULATED DIFFERENTIAL SCANNING CALORIMETRY 
(mDSC) 
 
mDSC analyses were performed on a Q2000 DSC (TA 
instruments, Leatherhead, UK), equipped with a refrigerated cooling 
system (RCS90) accessory) under a dry nitrogen purge at a flow rate of 
50 ml/min. Indium standard was used for routine calibration (temperature, 
enthalpy), sapphire disks were used for heat capacity calibration. 
Approximately 5 mg samples were weighed using an analytical balance 
into aluminium pans with aluminium lids. The samples were scanned at 
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2°C/min from -10°C to 190°C (isothermal for 5 min) with an amplitude 
of 0.636°C and a period of 40 s. DSC thermograms were acquired and 
analyzed using Universal Analysis software (version 4.4, TA instruments, 
Leatherhead, UK). All samples were analyzed in duplicate. 
 
2.6 ATTENUATED TOTAL REFLECTANCE FOURIER 
TRANSFORM INFRARED (FTIR) SPECTROSCOPY 
 
FTIR spectra were acquired on a Vertex 70 spectrometer (Bruker, 
Billerica, USA), at room temperature, from 4000 to 400 cm−1, with the 
collection of 32 scans. Samples were analyzed as such. 
 
2.7 INTRINSIC DISSOLUTION RATE  
 
 For the determination of the intrinsic dissolution rate of co-
amorphous systems, a stationary disk apparatus was used and the paddles 
were rotated at 100 rpm. The dissolution medium was 900 ml of acetate 
buffer pH 4.5 with 0.5% of SLS, kept at 37°C. Samples were taken at 
different time intervals, filtered using a PTFE filter (pore size 0.45 µm) 
and immediately replaced with the same volume of fresh dissolution 
medium. Crystalline powders were firstly compressed using a hydraulic 
press at 460 kPa for 10 s, in a die of 6.5 mm diameter  (surface area of 
0.33 cm2). Co-amorphous samples were quench cooled from the melt in 
the same dies. The drug concentration was calculated using HPLC 
(section 2.2 of this chapter). 
The intrinsic dissolution profile was determined by plotting the 
cumulative amount of drug dissolved (mg) against time (min). The 
intrinsic dissolution rate  was expressed as the amount of API dissolved 
per unit of time and normalized for the area (mg.cm-2.min-1). After 3 hours 
of dissolution, the co-amorphous systems and quench cooled samples 
were immediately analyzed as such, by XRD, in order to verify the 
possibility of a solution-mediated crystallization. 
 Acetate buffer pH 4.5 was chosen as the dissolution medium due 
to the chemical stability of EZE and LOV in this solution. Preliminary 
tests performed in pH 1.2 and 7.0 indicated the instability of LOV under 
these conditions, demonstrated by the appearance of degradation peaks in 
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HPLC (see appendix). In addition, as both compounds are essentially non-
ionized over the physiological pH range, the dissolution profiles should 
be similar in solutions with different pH values. Besides, acetate buffer 
pH 4.5 is the recommended dissolution medium for EZE tablets according 
to Food and Drug Administration (FDA) (FDA, 2015). Also, as LOV 
must be administered with food, since its absorption can be decreased in 
fasted state (SWEETMAN, 2009), this pH is within the pH range of the 
gastric fed condition (JANTRATID et al., 2008).  
In vitro profiles were compared applying one-way ANOVA 
followed by Tukey test. Results were considered statistically significantly 
different if p < 0.05. 
 
3. RESULTS AND DISCUSSION 
 
3.1 DETERMINATION OF THE EQUILIBRIUM SOLUBILITY  
 
Firstly, in order to verify the feasibility of a fixed dose 
combination (FDC) based on EZE and LOV, equilibrium solubility 
experiments were carried out with pure APIs and a combination of both 
(1:1 w/w). After 48 hours, the solubility of EZE and LOV was 0.9 ± 0.1 
μg/ml and 3.8 ± 0.4 μg/ml, respectively, when isolated, and 0.8 ± 0.1 
μg/ml (EZE) and 4.3 ± 0.1 μg/ml (LOV) in combination. The equilibrium 
solubility values for both APIs separately and in combination were 
considered similar (p ≤ 0.05), indicating that their solubility in presence 
of each other is not influenced. Hence, EZE and LOV are promising 
candidates to be co-formulated in a FDC. 
 
3.2 SOLID-STATE CHARACTERIZATION OF CO-AMORPHOUS 
SYSTEMS 
 
As a first attempt to obtain a FDC, co-amorphous systems of EZE 
and LOV were prepared in different molar ratios. Different preparation 
techniques such as spray drying, cryomilling and quench cooling from the 
melt were attempted but only the latter was successful. Remaining 
crystallinity or more than one amorphous phase were observed in the 
other cases (data not shown).  
Based on that, co-amorphous systems were prepared through 
quench cooling from the melt and the corresponding XRD data are shown 
in Figure 9. Both raw materials are crystalline, as indicated by the 
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presence of characteristic Bragg peaks (Fig. 9A). According to literature, 
EZE can exist as an anhydrate or monohydrate form, which can be 
differentiated at low 2θ angles in XRD data. The peaks at 7.02, 8.36 and 
10.04° belong exclusively to the anhydrate, while the characteristic peaks 
of the monohydrate form are found at 7.98, 9.84 and 13.23° (BRÜNING, 
ALIG and SCHMIDT, 2010; RAVIKUMAR and SRIDHAR, 2005). It 
can be concluded that, the crystalline form of the EZE raw material used 
in this study corresponds to the anhydrate. No polymorphs are reported in 
literature for LOV and its main Bragg peaks are observed at 2θ 8.05°, 
9.54°, 11.03°, 15.83°, 16.86°, 17.68° and 19.07°, in agreement with 
previous reported data (YOSHIDA et al., 2011). After quench cooling 
from the melt, both APIs present an amorphous halo without crystalline 
peaks. Similar results are observed for all the co-amorphous samples, 
indicating  complete X-ray amorphization. 
 
Figure 9. XRPD of (A) crystalline raw materials EZE and LOV and (B) 
quench cooled samples: co-amorphous systems, EZEqc and LOVqc 
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The amorphous state of the quench cooled samples was 
confirmed through mDSC analysis. Regarding EZEqc, after the first 
heat/cooling cycle, the melting peak of EZE at 163°C disappears and a 
glass transition event is observed at 64°C. For LOVqc, the first heating 
cycle shows an endothermic event at 172°C and after cooling, at the 
second heating cycle, its amorphous state is confirmed by a glass 
transition temperature (Tg) at 25°C, followed by a heat-mediated 
crystallization around 80°C and a melting event at 171°C, in agreement 
with previous reports in literature. 
For the co-amorphous systems, single Tg values and the absence 
of melting events confirm the amorphous and single phase characteristics 
of these samples (Figure 10). Taking into account the Gordon Taylor 
equation (Equation 1) and the composition of the four different co-
amorphous systems, the theoretical Tg values were calculated. All the 
calculated values (41.6, 35.7, 31.5 and 28.8°C for 2:1, 1:1, 1:2 and 1:4, 
respectively) were lower in comparison to the experimental ones: 54.7°C 
(2:1), 48.9°C (1:1), 38.2°C (1:2) and 34.7°C (1:4).   
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Figure 10. Reverse heat flow curves, experimental glass transition 
temperatures and heat capacity of co-amorphous systems    
 
 
According to the Gordon-Taylor equation, deviations between 
these values indicate differences in the strengths of the intermolecular 
interactions between the components. If positive, it indicates that the 
amount and strength of bonding between the components of the mixture 
is stronger than the interactions occurring individually in each compound. 
On the other hand, if negative, this deviation can be attributed to an 
overall loss in the number and strength of hydrogen bonding in the 
mixture or to an increase in the free volume due to the mixing 
(LÖBMANN et al., 2011; 2012). Based on that, these results suggest a 
possible intermolecular interaction between EZE and LOV in all co-
amorphous systems. In addition, it is important to note that higher Tg 
values of the samples are directly related to an increased amount of EZE. 
This is due to the fact that EZE has a higher Tg value than LOV (64°C and 
25°C, respectively). 
FTIR analyses were performed to investigate potential 
interactions between the compounds in co-amorphous systems, as 
suggested by the deviations of the experimental Tg values. Both 
compounds present donor and acceptor H-bonding groups, which favour 
the occurrence of these interactions. Based on that, the most important 
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changes are observed concerning the broadening of the O-H band and 
shifts relative to O-H and C=O bands. 
EZE main bands appear at 3428 and 3252 cm-1 (O-H stretch), 
1725 cm-1 (C=O of lactam), 1508 cm-1 (ring C=C stretch), 1448 and 1429 
cm-1 (C-N stretch), 1214 cm-1 (C-F stretch), 1063 cm-1 (C-O stretch of 
secondary alcohol) and  821 cm-1 (ring vibration due to paradisubstituted 
benzene). EZEqc showed a similar spectrum, but with considerable 
changes regarding the broadening of the band at 3312 cm-1 and a shift of 
the C=O band from 1725 to 1717 cm-1. For LOV, characteristic bands are 
observed at 3538 cm-1 (O-H stretch), 2965, 2929 and 2868 cm-1 (methyl 
and methylene C-H stretch), 1722 and 1697 cm-1 (lactone and ester 
carbonyl stretch), 1459 cm-1 (C-C stretch in the aromatic ring), 1260, 
1214, 1073 and 1055 cm-1 (lactone and ester C-O-C bending vibration) 
and 969 cm-1 (C-OH stretch). Changes regarding the LOVqc spectrum are 
observed especially for the broader shifted band at 3443 cm-1, the 
inversion of the intensity between the bands at 1721 and 1701 cm-1, and 
the broadening and decreasing of the intensity respective to the band at 
1255 cm-1 (Figure 11).  
 
Figure 11. FTIR data of crystalline and quench cooled raw materials 
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The broadening of the O-H band for both EZEqc and LOVqc can 
be due to distinct chemical environments and establishment of different 
intramolecular interactions favoured by the high mobility and loss of 
order of amorphous materials (MARTÍNEZ et al., 2014). Shifts in the 
C=O bands result from the interaction of the lone pairs on the oxygen with 
a hydrogen donor group. This promotes an increase in the electronic 
polarization of the double bond, resulting in the weakening of the 
carbonyl bond. In an FTIR spectrum, this chemical arrangement is 
verified through shifts of the carbonyl stretch to lower wavenumbers 
(VOGT, ROBERTS-SKILTON and KENNEDY-GABB, 2013).  
The analysis of FTIR data of co-amorphous systems was done 
through the comparison between calculated and experimental spectra. 
The calculation was based on data of the pure amorphous APIs, taking 
into account the four different molar ratios used to prepare the co-
amorphous systems and assuming simple signal additivity of the 
compounds. 
FTIR spectra of the co-amorphous systems show that all the 
samples presented differences when compared to the calculated 
amorphous physical mixtures (Table 1 and Figure 12). Shifts are observed 
concerning the O-H and C=O bands, as well as the appearance of a small 
shoulder in the region of 1749 cm-1. These data confirm the occurrence of 
hydrogen bonding between EZE and LOV in co-amorphous systems. 
 
Table 1. Experimental and calculated FTIR data of co-amorphous systems 
Sample  O-H band (cm-1) C=O band (cm-1) 
Calculated Experimental Calculated Experimental 
EZE:LOV 1:1 3403 3350 1720 1715 
EZE:LOV 1:2 3430 3414 1721 1717 
EZE:LOV 1:4 3432 3404 1721 1717 
EZE:LOV 2:1 3383 3343 1719 1715 
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Figure 12. Calculated versus experimental FTIR data for 1:1, 1:2, 1:4 and 
2:1 EZE:LOV (m/m), demonstrating the broadening and shift of hydroxyl 
and carbonyl bands in all co-amorphous systems 
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Almost all co-amorphous systems reported present 
intermolecular interactions (LAITINEN et al., 2013), which favour their 
physical stability. However, binary systems composed of 
ritonavir:indomethacin (DENGALE et al., 2014) and 
simvastatin:glipizide (LÖBMANN et al., 2012) showed no interactions 
between the compounds and their physical stability was not affected, 
being justified by the molecular level miscibility between the APIs.   
 
3.3 IN VITRO DISSOLUTION OF CO-AMORPHOUS SYSTEMS 
 
Figure 13 shows the intrinsic dissolution profiles of the co-
amorphous systems and the quench cooled raw materials compared to 
those of the crystalline forms of EZE and LOV. The intrinsic dissolution 
data are presented in Table 2. 
 
Figure 13. Intrinsic dissolution profiles of crystalline (A) EZE and (B) LOV 
raw materials compared to the quench cooled samples and co-amorphous 
systems 
(to be continued)  
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Table 2. Intrinsic dissolution data  
Sample Equation 
(y = ax + b) 
Correlation 
coefficient 
(r) 
Intrinsic 
dissolution rate 
(mg.cm-2.min-1) ± 
SD 
EZE 
RM* y = 9 x 10-5x + 0,1304 0.98102 1.8 x 10-2 
EZEqc y = 4 x 10-5x + 0,0258 0.99378 7.2 x 10-3 
1:1 y = 3 x 10-5x + 0,0002 0.99970 4.8 x 10-3  
± 1.0 x 10-3 
1:2 y = 3 x 10-5x - 0,0116 0.99805 5.4 x 10-3 
1:4 y = 2 x 10-5x + 0,0004 0.99915 4.2 x 10-3 
± 1.0 x 10-3 
2:1 y = 4 x 10-5x - 0,0056 0.99865 8.4 x 10-3 
± 2.0 x 10-3 
LOV 
RM* y = 1 x 10-4x + 0,1041 0.99529 2.4 x 10-2 
 ± 3.4 x 10-3 
LOVqc y = 2 x 10-5x  - 0,0198 0.99564 4.2 x 10-2  
± 3.4 x 10-3 
1:1 y = 2 x 10-5x + 0,0014 0.99965 3.0 x 10-3 
± 3.5 x 10-4 
1:2 y = 3 x 10-5x - 0,002 0.99950 4.8 x 10-3 
± 3.5 x 10-4 
1:4 y = 6 x 10-5x + 0,0069 0.99965 1.0 x 10-2 
± 3.5 x 10-4 
2:1 y = 1 x 10-5x - 0,0014 0.99529 2.4 x 10-3 
± 3.7 x 10-4 
* RM: raw material 
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Linear dissolution profiles were observed for the samples along 
the assay. In case of LOV, LOVqc presented the highest dissolution rate 
(4.2 x 10-2 ± 3.4 x 10-3 mg.cm-2.min-1), although not significantly different 
(p ≤ 0.05) from the raw material (2.4 x 10-2 ± 3.4 x 10-3     mg.cm-2.min-
1). The dissolution profile of LOVqc showed a change in its slope after 
90 min, which was attributed to a solvent mediated crystallization (Figure 
14A). This data can be explained by the low Tg of the amorphous form of 
LOV (at 25°C), below the temperature of the dissolution medium (37 ± 
0.5°C).   
Unexpectedly, none of the co-amorphous systems increased the 
dissolution rate of the API and their dissolution rates are significantly 
different of LOVqc and raw material (p ≤ 0.05). The co-amorphous 
systems 1:1, 1:2 and 2:1 were considered similar, but significantly 
different from 1:4 (p ≤ 0.05). Solution-mediated crystallization was ruled 
out by XRD analyses for the samples 1:1, 1:2 and 2:1 (EZE:LOV m/m) 
(Figure 14D), indicating that EZE plays an important role on the 
stabilization of LOV, probably due to the increase in the Tg values. 
However, for 1:4 (EZE:LOV, m/m), which presents a Tg of 34.7 °C, a 
solution-mediated crystallization was observed and all the crystalline 
peaks were attributed to LOV (Figure 14C). 
For EZE, the crystalline raw material showed the highest 
dissolution rate (1.8 x 10-2 versus 7.2 x 10-3 mg.cm-2.min-1for EZEqc). In 
case of EZEqc, after 3 hours of dissolution, crystalline peaks 
corresponding to its anhydrate and monohydrate forms were observed (as 
well as crystalline peaks respective to the components of the dissolution 
medium), superimposed with the amorphous halo (Figure 14B). This 
partial transition to the monohydrate form has a negative effect on the 
dissolution of EZE, since its monohydrate form presents a lower aqueous 
solubility (8 µg ml-1) than its anhydrous form (12 µg ml-1). However, a 
complete crystallization of EZE did not occur until the end of the assay 
(evidenced by the amorphous halo observed by XRD), and its dissolution 
rate is still lower than the starting crystalline raw material.  
For all the co-amorphous samples, none of them were able to 
increase the dissolution rate of EZE. A solution-mediated crystallization 
was ruled out by XRD analyses after 3 hours of dissolution (Figure 14C 
and 14D), indicating that the amorphous form of EZE has a lower 
dissolution rate than its crystalline counterpart. Statistical analyses show 
that the raw material is significantly different from EZEqc and co-
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amorphous samples. All co-amorphous systems are considered similar (p 
≤ 0.05). 
 
Figure 14. Diffractograms of (A) LOV, (B) EZE, (C) 1:4 and (D) 1:1, 1:2 
and 2:1 EZE:LOV (m/m), compared to the diffractograms of SLS, sodium 
acetate and the XRD patterns of LOV, EZE anhydrate (EZE A) and EZE 
monohydrate (EZE M), obtained from the Cambridge Structural Database 
 
 
Amorphous materials generally increase the solubility and 
dissolution rate in comparison to the crystalline ones, but exceptions are 
reported. The example concerns the anti-HIV drug darunavir, where the 
crystalline darunavir ethanolate shows a higher dissolution than its 
amorphous form. This is due to the fact that darunavir ethanolate is a 
channel solvate that can exchange ethanol and water freely with one 
another, which facilitates wetting and dissolution, while its amorphous 
form shows only limited wettability (VAN GYSEGHEM et al., 2009). 
The amorphous form of carvedilol also presented a lower dissolution rate 
at 37°C, compared to its crystalline form. This finding was attributed to 
the formation of cohesive supercooled liquid state, supported by enthalpy 
relaxation studies, which indicated increase in enthalpy recovery and 
structural relaxation of amorphous form towards the supercooled liquid 
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region (POKHARKAR et al., 2006). However, for EZE, the reasons for a 
lower dissolution rate observed for its amorphous state remain unclear. 
 
4. CONCLUSIONS 
 
 Co-amorphous systems of EZE and LOV composing a single 
amorphous phase were successfully obtained by quench cooling from the 
melt. Occurrence of intermolecular hydrogen bonding was suggested 
through the comparison of theoretical and experimental Tg values and 
confirmed by FTIR. However, unexpectedly, amorphous EZE showed a 
lower dissolution rate in comparison to its crystalline form and this result 
was also observed for all co-amorphous formulations, which were also 
not able to increase the dissolution rate of LOV. As this type of 
formulation was not able to increase the dissolution rate of EZE and LOV, 
other strategies were further investigated, such as the addition of gelatin 
and hydrophilic polymers.  
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CHAPTER III 
 
DEVELOPMENT, CHARACTERIZATION AND IN VITRO 
DISSOLUTION STUDIES OF TERNARY AMORPHOUS 
SYSTEMS OF EZETIMIBE, LOVASTATIN AND GELATIN 
PREPARED BY HIGH IMPACT MILLING 
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1. INTRODUCTION 
 
 Gelatin is a water-soluble natural biopolymer derived from acidic 
or alkaline hydrolysis of collagen. Its composition varies according to the 
raw material used but it is mainly proteins (85-92%), mineral salts and 
water (DUCONSEILLE et al., 2015). In comparison to other materials, 
gelatin offers the advantages of being cheap, readily available, 
biocompatible and biodegradable (ELZOGHBY, 2013). Having a long 
history of safe use in pharmaceuticals, especially in the composition of 
hard capsules, more recently, gelatin has been also used in the 
development of modern drug delivery systems composed of poorly water-
soluble APIs.  
Kallinteri and Antimisiaris (2001) reported the increase of the 
solubility of seven drugs (nitrofurantoin, chlorothiazide, phenobarbital, 
prednisolone, griseofulvin, diazepam and piroxicam) in presence of 
gelatin and they stated that there is a tendency for larger gelatin-induced 
increases in solubility as drug lipophilicity increases. In the same context, 
gelatin-based systems were able to improve the dissolution rate of the 
poorly soluble APIs pranlukast (CHONO et al., 2008), ibuprofen (LI et 
al., 2008) and fenofibrate (YOUSAF et al., 2015). 
 The previous chapter has demonstrated that the obtainment of a 
binary co-amorphous system between ezetimibe (EZE) and lovastatin 
(LOV) was not enough to enhance their dissolution rate, in comparison to 
amorphous and crystalline raw materials. In this context, the addition of 
a ternary compound to this amorphous system seems like a promising 
approach. 
In this context, this chapter proposed the preparation of ternary 
amorphous systems composed of gelatin, EZE and LOV, in order to 
investigate the potential of this biopolymer to enhance the dissolution rate 
of the respective compounds. As an environmentally friendly, relatively 
simple process and of easy scaling up (BARZEGAR-JALALI et al., 
2010), the high impact milling was chosen as the preparation method. The 
obtained samples were characterized by means of X-ray powder 
diffraction and modulated scanning calorimetry and evaluated through in 
vitro dissolution studies. 
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2. EXPERIMENTAL 
2.1 MATERIALS 
 
Porcine gelatins type A bloom 75 (batch number 1408053) and 
bloom 225 (batch number 1386268), both mesh 100, were kindly supplied 
by Rousselot NV (Gent, Belgium). EZE and LOV were purchased from 
Pharma Nostra (Rio de Janeiro, Brazil), with batch numbers FM017H13 
and 130312, respectively. Soluplus® (batch number 23597787V0), 
Kollidon® VA64 (batch number 28569368E0) and Kollidon® 30 (batch 
number 72888756P0) were obtained from BASF® ChemTrade GmbH 
(Ludwigshafen, Germany) and HPMC E5 derived from Federa 
(Rotterdam, Netherlands). 
 
2.2 PREPARATION OF BALL-MILLED TERNARY SYSTEMS 
 
 Different ratios of APIs, gelatin and polymers (when applicable) 
were accurately weighed comprising a final mass of 30 mg. The ratios 
between the APIs varied from 1:1 to 1:4 (EZE:LOV w/w) according to 
their therapeutic doses and the percentages of gelatin ranged from 25 to 
75 %. The formulations were named as ELG (EZE:LOV:Gelatin) 75 or 
225 (according to the type of gelatin tested), followed by the percentage 
of each compound in the final composition. When polymers were added, 
they were identified as S, K30, VA64 and H for Soluplus®, Kollidon® 
30, Kollidon® VA64 and HPMC E5, respectively.  
Samples were kept in 2 mL eppendorf tubes and milled in a 
Retsch PM 400 MA ball mill (Haan, Germany) for 8 hours, at 400 rpm. 
High wear resistant zirconia beads (TOSOH Corporation, Tokyo, Japan) 
of 1, 3 and 5 mm external diameter were used as grinding media. Milling  
was  performed  at  room  temperature  and  no significant heating  of  the  
samples  was  noted  at  the  end  of  the  process. All samples were stored 
in desiccators containg P2O5 at room temperature prior to analysis. 
 
2.3 PREPARATION OF SPRAY DRIED SYSTEMS 
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Co-spray dried (coSD) samples composed of EZE:LOV 1:1 
(w/w) were prepared in order to compare with amorphous formulations 
in presence of gelatin. The spray drying method was chosen since it was 
not possible to obtain binary amorphous samples through milling. Spray 
dried powders were prepared using a Buchi mini spray dryer B191 
(Buchi, Flawil, Switzerland). Briefly, an accurate amount of the drugs 
was dissolved in dichloromethane and methanol in a volumetric ratio of 
50:50, comprising a final solid content of 2% (w/v). The operational 
conditions were: inlet temperature 65 °C, drying air flow rate 28 L/min, 
atomizing air flow 15 L/min and 6 mL/min feed rate using a peristaltic 
pump. The spray dried samples were prepared in duplicate and were kept 
in a vacuum oven at room temperature for 3 days to remove residual 
solvent. All samples were stored over phosphorous pentoxide in 
desiccators at room temperature prior to analysis. 
 
2.4 X-RAY POWDER DIFFRACTION (XRPD) 
 
 XRPD experiments were carried out at room temperature using 
an automated X’pert PRO diffractometer (PANalytical, Almelo, 
Netherlands) with a Cu tube (Kα λ = 1.5418 Å) and the generator set at 
45 kV and 40 mA. Ball milled samples were applied on spinning zero 
background sample holders. Measurements were performed in a 
continuous scan mode from 4° to 40° (2θ) with 0.0167° step size and 200 
s counting time. 
 
2.5 MODULATED DIFFERENTIAL SCANNING CALORIMETRY 
(mDSC) 
 
mDSC was performed  on  a  Q2000  DSC  (TA  Instruments,  
Leatherhead,  UK), equipped  with  the  refrigerated  cooling  system  
(RCS90)  accessory under  a  dry  nitrogen  purge  at  a  flow  rate  of  50  
ml/min.  Indium standard  was  used  for  routine  calibration  
(temperature,  enthalpy),  sapphire  disk  was  used  for  heat  capacity  
calibration. Approximately  5  mg  samples  were  weighed  using  an  
analytical  balance  into  aluminum  pans.  The  samples  were  then  
scanned  at  2 °C/min  from -10 to 230 °C with  the  following  modulation  
parameters: amplitude  of  0.636 °C  every  40  s.  DSC  thermograms  
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were  acquired and  analyzed  by  using  Universal  Analysis  software  
(version  4.4, TA  Instruments,  Leatherhead,  UK).   
 
2.6 IN VITRO DISSOLUTION STUDIES 
 
 Dissolution profiles of the crystalline EZE and LOV materials, 
as well as ball milled samples, were evaluated using USP II Dissolution 
Apparatus. In brief, accurately weighted samples equivalent to 10 mg 
EZE and 10 mg LOV were added into 500 mL acetate buffer pH 4.5 + 
0.025% SLS, in a dissolution vessel at 37 °C. The solution was stirred at 
a speed of 100 rpm for 120 minutes. Drug release was calculated from the 
drug concentration at different time intervals (5, 15, 30, 45, 60, 90 and 
120) and determined by HPLC (acetonitrile:water 50:50 v/v, 1 mL/min, 
λ = 235 nm, see appendix). 
 
3. RESULTS AND DISCUSSION 
 
3.1 CHARACTERIZATION OF RAW MATERIALS 
 
Prior to milling, drugs and gelatins were characterized by means 
of solid-state techniques in order to compare with the processed materials. 
X-ray diffractograms are shown in Figures 15. 
 As discussed in the previous chapter, LOV presents a crystalline 
diffractogram with main Bragg peaks at 2θ 8.05°, 9.54°, 11.03°, 15.83°, 
16.86°, 17.68° and 19.07°. These data are in agreement with literature, 
which also reports no polymorphism for this API (YOSHIDA et al., 
2011). On the other hand, EZE shows two crystalline forms,  being the 
anhydrous (BRÜNING, ALIG and SCHMIDT, 2010) and monohydrate 
(RAVIKUMAR and SRIDHAR, 2005). Based on the comparison of the 
X-ray diffraction patterns of the polymorphic forms of EZE and the 
diffractogram of the raw material, especially at low angles, it is possible 
to affirm that the raw material used for this research corresponds to the 
anhydrous form. For both gelatins, amorphous halos are observed. 
 
110 
 
Figure 15. X-ray diffractograms of EZE, LOV and gelatin 75 and 225 raw 
materials 
 
 
 
In order to check the miscibility among EZE, LOV and gelatin, a 
physical mixture composed of ELG75 25:25:50 was submitted to three 
heating cycles, following the conditions mentioned in topic 2.5 (Fig. 16). 
In the first heating it is possible to observe a solvent loss around 50°C 
followed by a melting event at 140°C. This event is a shift of EZE and 
LOV melting points. At 212°C the Tg of gelatin is observed. At the second 
and third heating cycles no melting peaks are observed indicating the 
amorphous state of the mixture. However, two Tg are shown in these 
heating cycles: 51°C and 204°C (2nd heating), 48°C and 198°C (3rd 
heating). The first one corresponds to the amorphous mixture between 
EZE and LOV and the second one is relative to pure gelatin. The shifts of 
the gelatin Tg indicate a possible miscibility among these components, 
which characterizes this system as promising. 
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Figure 16.  mDSC thermograms of ELG75 25:25:50 physical mixture. Black, 
blue and green represent the first, second and third heating cycles, 
respectively. The three curves up represent the heat flow and the three curves 
down the reversing heat flow. 
 
 
 
 
3.2 OPTIMIZATION OF THE MILLING PROCESS 
 
 In order to determine the optimal milling conditions, different 
rotation speeds, milling time, and amount of powder were tested. The 
samples submitted to these conditions were ELG75 25:25:50 and 
ELG225 25:25:50. The results are shown in Figures 17A-D. 
 First, a decrease in crystallinity was observed as the milling time 
and rotation speed increased, providing completely amorphous samples 
within 8 hours at 400 rpm (Figure 17A). After that, the number and 
combination of balls were also tested (Figures 17B,C). For the sample 
ELG75 25:25:50, amorphous samples were obtained with the 
combination of 1 ball of 5 mm with 8 balls of 3 mm. On the other hand, 
similar results were observed for ELG225 25:25:50 when 1 ball  of  5  
mm  and  8  balls  of  3  mm  were  combined  with  16 balls of 1 mm. 
These results demonstrate that there is a difference in the impact needed 
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to obtain amorphous samples composed of different types of gelatin. In 
addition, the combination of balls was also positive, since the bigger balls 
were probably responsible for increasing the impact and the smaller ones 
reduced the amount of powder adhered to the bottom of the eppendorfs. 
Finally, the amount of powder was also tested and better results were 
observed for 30 mg instead of 50 mg, for both formulations (Fig. 17D). 
This is also attributed to a higher impact, due to a higher ball to powder 
ratio. Based on these data, the selected milling conditions were: 400 rpm 
rotation speed, 8 hours of milling time, 1 ball of 5 mm plus 8 balls of 3 
mm plus 16 balls of 1 mm as grinding media and 30 mg of powder. 
 
Figure 17.  X-ray diffractograms regarding samples prepared with (A) 
different rotation speeds and milling times, (B, C) number and combination 
of balls and (D) amount of powder 
 
 
 
 
(to be continued) 
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3.3 X-RAY POWDER DIFFRACTION OF MILLED MATERIALS 
 
In order to verify the need of a hydrophilic carrier, pure raw 
materials and binary combinations of EZE:LOV in 1:1 and 1:4 were 
milled. The results are shown in Figure 18.  
 After 8 hours at 400 rpm, pure LOV presented a discrete 
broadening of its Bragg peaks as well as a small decrease of their intensity 
in comparison to the unprocessed raw material. On the other hand, pure 
EZE presented an amorphous halo with small Bragg peaks, which 
indicates a drastic change in its crystalline structure after milling, 
although presenting some remaining crystallinity. In addition, the peak at 
8.3°, characteristic of the anhydrous form, is still observed for this 
sample, demonstrating that no phase transition occurred during milling. 
Interestingly, when EZE and LOV are combined in different ratios, a 
drastic decrease of their crystallinity is observed, which indicates the 
beneficial effect of this combination. It is important to note that the 
remaining Bragg peaks for these samples are mostly attributed to LOV. 
However, no amorphous samples were obtained, indicating the need for 
a carrier. 
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Figure 18. Diffractograms relative to milled pure raw materials and binary 
combinations at different ratios 
 
 
In order to check the influence of gelatin on the degree of 
amorphization of the pure APIs, binary systems composed of 
EZE:Gelatin and LOV:Gelatin were obtained in different ratios (25:75, 
50:50 and 75:25, w/w) with the two types of gelatin (75 and 225) (Figures 
19A-D).  
Amorphous binary systems composed of EZE were prepared in 
presence of 75 and 50% of gelatin 75 and with 75% of gelatin 225. Small 
Bragg peaks overlapped to the amorphous halo are observed for the other 
combinations. These results demonstrate the importance of gelatin in the 
amorphization of EZE, since the pure API was not completely amorphous 
when milled as such. On the other hand, no amorphous samples were 
obtained for binary systems of LOV:Gelatin, although a drastic decrease 
of crystallinity was observed for the samples composed of 75% of gelatin.   
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Figure 19. X-ray diffractograms relative to binary systems composed of 
EZE:Gelatin and LOV:Gelatin in different ratios 
 
 
 
 
(to be continued) 
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The following step included the obtainment of the ternary milled 
systems. Initially, the ratios between the APIs was kept as 1:1 (w/w) and 
the amount of gelatin varied from 25 to 75% (Figures 20A-B). As it can 
be visualized, amorphous ternary systems were obtained with 50 and 75% 
of both types of gelatin. Small Bragg peaks that overlapped   with the 
amorphous halo for ELG75/225 37.5:37.5:25 were observed. These 
results demonstrate the success of this combination, especially regarding 
LOV, which was not completely amorphous even in binary mixtures with 
118 
 
EZE or gelatin, in different ratios. No differences were observed between 
the two types of gelatin. 
Figure 20. X-ray diffractograms relative to ternary systems composed of 
EZE:LOV:Gelatin in different ratios 
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In order to evaluate the influence of the ratio between the APIs, 
ternary systems composed of EZE:LOV in 1:4 (w/w) ratios were obtained 
in presence of 50 and 75% of gelatin (Figure 21). This ratio was selected 
since it represents the combination with the highest dose of LOV 
associated to EZE in clinical practice. Interestingly, as the amount of 
LOV increases it was not possible anymore to obtain amorphous systems 
with 50% of gelatin. However, when the amount of gelatin increases to 
75% and the ratio between the APIs is kept as 1:4 (EZE:LOV w/w) 
amorphous samples are obtained. These data demonstrate the deleterious 
effect of high amounts of LOV, prejudicing the obtainment of amorphous 
systems. In addition, it is important to mention the beneficial effect of 
gelatin, since binary systems composed purely of EZE:LOV in 1:4 ratios 
were semicrystalline. 
 
Figure 21. X-ray diffractograms relative to ternary systems composed of 
EZE:LOV in 1:4 ratios in presence of different amounts of gelatin 
 
 
 
As a final step, the influence of polymers typically used in the 
formulation of solid dispersions was investigated (Figure 22). For this 
purpose, the total amount of APIs was kept at 50% (1:1 EZE:LOV ratio). 
This condition was selected since amorphous samples are obtained with 
this composition in presence of gelatin. To minimize the number of 
experiments, these tests were performed with gelatin 75. The polymers 
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tested were Soluplus®, Kollidon® 30, Kollidon® VA64 and HPMC E5. 
The final composition of these samples was E:L:G:Polymer 25:25:25:25. 
 As it can be visualized, completely amorphous samples were 
obtained in presence of HPMC E5 and Kollidon® VA64. However, small 
Bragg peaks are observed for samples composed of Soluplus® and 
Kollidon® 30. These data demonstrate that these polymers prejudice the 
amorphization of the APIs in presence of gelatin. 
 
Figure 22. X-ray diffractograms regarding E:L:G:Polymer (25:25:25:25 
w/w/w/w) milled samples 
 
 
 
3.4 mDSC ANALYSIS 
 
 The ternary systems characterized as amorphous through XRPD 
were also analyzed by means of mDSC. The results regarding the samples 
ELG75/225 5:20:75, ELG75/225 25:25:50 and ELG75/225 12.5:12.5:75 
are shown in Figures 23A-C. 
 For samples ELG75/225 5:20:75 a solvent loss event is observed 
around 54°C that overlapped with a Tg at 47°C, which corresponds to the 
mixture of amorphous EZE and LOV. A small shifted melting event is 
observed at 134°C, probably attributed to small remaining crystals not 
detected by XRPD. At 213°C the Tg of gelatin is observed. No significant 
differences were observed between the two types of gelatin (Fig 23A). 
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The same tendency is observed for samples composed of 50% of gelatin. 
A first Tg at 50°C overlapped with the solvent loss, followed by a small 
melting event at 123°C and the gelatin Tg at 123°C (Fig.23B). On the 
other hand, the samples ELG 75/225 12.5:12.5:75 presented no melting 
event regarding EZE and LOV. Two Tg are observed; one at 63°C and 
the other at 211°C respective to phases composed of the APIs and gelatin, 
respectively. 
These results demonstrate that although amorphous halos were 
detected by XRPD some remaining crystallinity is still observed for some 
samples. In addition, all the ternary systems presented two different 
amorphous phases. 
 
Figure 23. mDSC thermograms of (A) ELG75/225 5:20:75, (B) ELG75/225 
25:25:50 and (C) ELG75/225 12.5:12.5:75. Black and blue curves represent 
samples prepared with gelatin 75 and 225, respectively. The two curves up 
represent the heat flow and the two curves down the reversing heat flow 
 
 
 
(to be continued) 
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3.5 IN VITRO DISSOLUTION STUDIES 
 
Samples submited to dissolution studies were chosen based on 
their amorphous state. In this regard, samples ELG75/225 12.5:12.5:75 
and ELG75/225 25:25:50 were evaluated by means of their in vitro 
performance and compared to the crystalline raw materials and coSD 
samples. Results are shown in Figure 24. 
B 
C 
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 Unexpectedly, for both APIs the amorphous coSD sample 
presented a lower dissolution rate in comparison to the crystalline raw 
material, achieving a maximum of 2% release after 120 minutes. 
However, all the ternary milled systems presented a higher dissolution 
rate for EZE compared to raw material. For these samples, the type of 
gelatin and the composition of the samples did not play an important role 
in the dissolution rate since all the formulations presented similar 
dissolution profiles. At the end of the assay, an increase was observed in 
the dissolution rate of EZE in ternary samples of 1.7 and 6.0 times in 
comparison to the crystalline and coSD samples, respectively.  
 For LOV, the only ternary system able to increase the dissolution 
rate in comparison to the crystalline raw material was ELG225 25:25:50. 
This result was also unexpected, since usually an increased amount of the 
hydrophilic carrier tends to increase the dissolution rate of the poorly 
water-soluble API. The enhancement of the dissolution rate of this sample 
within 2 hours in comparison to the crystalline raw material and the coSD 
sample was of 1.3 and 12.7 times, respectively. 
 
Figure 24. In vitro dissolution profiles of ternary ball milled systems ELG75 
12.5:12.5:75 (), ELG225 12.5:12.5:75 (), ELG75 25:25:50 (), ELG225 
25:25:50 (),compared to  co-spray dried materials () and crystalline raw 
materials ()  
 
 
(to be continued) 
0
2
4
6
8
10
12
14
0 20 40 60 80 100 120
E
Z
E
 r
e
le
a
se
 (
%
)
Time (min)
124 
 
 
 
4. CONCLUSIONS 
 
 Ternary systems composed by EZE, LOV and two different types 
of gelatin were successfully obtained through ball milling. The milling 
procedure was optimized and parameters like rotation speed, milling time, 
number and combination of balls and amount of powder demonstrated an 
important role on the obtainment of amorphous ternary systems. Gelatin 
was necessary to provide amorphous materials, since pure drugs and 
binary combinations of EZE and LOV showed remaining crystallinity. In 
addition, mDSC analyses revealed a tendency of mixing between gelatin 
and the APIs in physical mixtures as observed by a shift of its glass 
transition temperature. However, all ternary samples were composed of 
two different phases. When classical polymers were added to ternary 
gelatin systems, two of them (Soluplus® and Kollidon® 30) were not able 
to generate amorphous samples. Dissolution studies demonstrated an 
increase in the dissolution rate of LOV only through the formulation 
ELG225 25:25:50, which was able to increase the dissolution rate 1.3 and 
12.7 times in comparison to the crystalline raw material and co-spray 
dried sample, respectively. However, for EZE, all ternary systems 
enhanced its dissolution rate in comparison to the crystalline raw material 
and co-spray dried sample. These results emphasize the promising aspect 
of using gelatin in drug delivery systems composed of poorly water-
soluble APIs.  
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CHAPTER IV  
 
DEVELOPMENT, CHARACTERIZATION AND IN VITRO 
DISSOLUTION STUDIES OF TERNARY AMORPHOUS 
SYSTEMS OF EZETIMIBE, LOVASTATIN AND DIFFERENT 
HYDROPHILIC POLYMERS PREPARED BY SPRAY DRYING 
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1. INTRODUCTION 
 
 The application of solid dispersions as strategies to improve the 
solubility and dissolution rate of poory water-soluble compounds was 
firstly introduced in 1961 by Sekiguchi and Obi (SEKIGUCHI e OBI, 
1961). Since then, this type of formulation has been improved and widely 
investigated. Nowadays, solid dispersions can be classified according to 
their composition in binary and ternary systems, if composed by one 
lipophilic drug associated to one or two hydrophilic polymers, 
respectively. 
 Aiming to develop a formulation capable of increasing 
simultaneously the solubility and dissolution rate of ezetimibe (EZE) and 
lovastatin (LOV), co-amorphous systems were investigated as a first 
approach. However, as described in Chapter II, they were not able to reach 
the proposed goal and the obtained results proved that just the amorphous 
state is not enough to enhance the mentioned properties, especially for 
EZE.  
 In this way, the necessity to incorporate a third compound in the 
amorphous system of EZE and LOV was verified. Gelatin type 75 and 
225 have also been investigated, in absence and presence of synthetic 
polymers (Chapter III). Although a slight increase in dissolution rate was 
observed, these systems have still not reached 100 % release of EZE and 
LOV in in vitro dissolution studies. 
 Based on that, this chapter aims to investigate the effect of the 
addition of different hydrophilic polymers to the amorphous system 
between EZE and LOV. It is also aimed here that the preparation method 
can decrease the particle size, in order to have a positive impact on the 
dissolution rate of the compounds. Spray drying consists of a continuous 
one-step process, especially known for the fast solvent evaporation, 
which usually generates small amorphous particles. Besides, the physical 
chemical properties of the resulting product, as particle size and shape, 
humidity content and powder flow properties can be controlled by this 
process (PAUDEL et al., 2013).  
 In this context, this chapter introduced for the first time the 
concept of ternary solid dispersions prepared by spray drying two poorly 
water-soluble compounds and one hydrophilic polymer. The selected 
polymers were polyvinyl caprolactam-polyvinyl acetate-polyethylene 
glycol graft copolymer (Soluplus®), poly(vinylpyrrolidone-co-vinyl 
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acetate) (PVP VA64), polyvinylpyrrolidone (PVP K-30) and 
hydroxypropylmethyl cellulose (HPMC E5). The obtainment of single 
amorphous phase systems with intermolecular interactions (e.g hydrogen 
bonding) was targeted, in order to guarantee a better physical stability of 
the formulation. Variables such as type of polymer, drug:drug ratio, 
drugs:polymer ratio and addition of surfactants were investigated to reach 
the formulation with the desired properties.  
 
2. EXPERIMENTAL 
2.1 MATERIALS  
 
EZE (anhydrous, 409.41 g/mol) and LOV (404.54 g/mol) were 
purchased from Pharma Nostra (Rio de Janeiro, Brazil) with batch 
numbers FM017H13 and 130312, respectively. Polyvinyl caprolactam-
polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®), 
poly(vinylpyrrolidone-co-vinyl acetate) (PVP VA64) and 
polyvinylpyrrolidone (PVP K-30) were obtained from BASF® 
ChemTrade GmbH (Ludwigshafen, Germany), and hydroxypropylmethyl 
cellulose (HPMC E5) was obtained from Federa (Rotterdam, The 
Netherlands). Cremophor RH40® was obtained from BASF® 
(Ludwigshafen Rhine, Germany), Gelucire 44/14® from Gattefossé SAS 
(Saint Priest, France), Tween 80® from Fagron SAS (Waregem, 
Belgium),  Tween 20® from Applichem GmbH (Darmstadt, Germany) 
and  Vitamine E TPGS® from ISOchem (Gennevilliers, France). In all 
experiments de-ionized water (Maxima Ultra Pure Water, Elga Ltd., 
Wycombe, England) was used and the organic solvents were of 
pharmaceutical grade. 
 
2.2 PREPARATION OF SPRAY DRIED SAMPLES 
 
The spray-dried powders were obtained using a Buchi mini 
spray-dryer B191 (Buchi, Flawil, Switzerland). Briefly, an accurate 
amount of drugs and polymers, in which the total solid content was kept 
at 10% (w/v),  was dissolved in methanol (MeOH) for formulations 
composed of  Soluplus, PVP K30 and PVP VA64, and in a mixture of 
methanol:dichloromethane (DCM) (1:1, v/v) for HPMC E5. The co-spray 
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dried sample (EZE:LOVsd), composed exclusively of EZE:LOV (1:1, 
w/w), was prepared from a 2% solid content solution in MeOH:DCM 
(1:1, v/v) mixture and the pure APIs were dissolved in MeOH (EZEsd) 
and MeOH:DCM (1:1, v/v) (LOVsd), comprising a solution with 5% 
solid content.  The composition of all samples is shown in Table 3. The 
ratios between the APIs were chosen based on their doses of 
administration and the percentage of the surfactants Tween 20, Tween 80, 
Cremophor RH40, Gelucire 44/14 and Vitamin E TPGS (d-alpha 
tocopheryl polyethylene glycol 1000 succinate) (TPGS) was kept at 5%. 
By means of comparison, binary solid dispersions composed of one of the 
APIs and Soluplus were also prepared.  
 
Table 3. Composition of spray dried samples 
Formulation EZE:LOV 
(m/m) 
Polymer 
 (%) 
Surfactant  
(%) 
EZE:LOVsd 1:1 - - 
ELPVPK30 1:1 75 - 
ELPVPVA 1:1 75 - 
ELHPMC 1:1 75 - 
Ternary solid dispersions prepared with Soluplus® 
ELS 1:1 50% 1:1 50 - 
ELS 1:1 75% 1:1 75 - 
ELS 1:1 90% 1:1 90 - 
ELS 1:2 50% 1:2 50 - 
ELS 1:2 75% 1:2 75 - 
ELS 1:2 90% 1:2 90 - 
ELS 1:4 50% 1:4 50 - 
ELS 1:4 75% 1:4 75 - 
ELS 1:4 90% 1:4 90 - 
ELS Tween20 1:1 75 5 
ELS Tween80 1:1 75 5 
ELS Cremophor 1:1 75 5 
ELS Gelucire 1:1 75 5 
ELS TPGS 1:1 75 5 
Binary solid dispersions prepared with Soluplus® 
EZESol - 75 - 
LOVSol - 75 -  
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The solutions were spray dried using the following operational 
conditions: inlet temperature 65°C or 50°C for DCM:MeOH and MeOH, 
respectively, drying air flow rate 28 l/min, atomizing air flow 15 l/min 
and 5.5 to 7 ml/min feed rate. All spray dried samples were further post-
dried in a vacuum oven at room temperature for at least 3 days to remove 
the residual solvent prior to analysis. 
 
2.3 X-RAY POWDER DIFFRACTION (XRPD) 
 
XRD experiments were carried out at room temperature using an 
automated X’pert PRO diffractometer (PANalytical, Almelo, The 
Netherlands) with a Cu tube (Kα λ = 1.5418 Å) and the generator was set 
at 45 kV and 40 mA. EZE and LOV raw materials were applied on 
spinning zero background sample holders. Measurements were 
performed in a continuous scan mode from 4° to 40° with 0.0167° step 
size and 200 s per step counting time. 
Co-amorphous samples were analyzed under the same conditions 
but using regular sample holders. The samples were prepared and 
analyzed in DSC sample holders in a continuous scan mode from 4° to 
35°. 
 
2.4 MODULATED DIFFERENTIAL SCANNING CALORIMETRY 
(mDSC) 
 
mDSC analyses were performed on a Q2000 DSC (TA 
instruments, Leatherhead, UK), equipped with a refrigerated cooling 
system (RCS90) accessory) under a dry nitrogen purge at a flow rate of 
50 ml/min. Indium standard was used for routine calibration (temperature, 
enthalpy), sapphire disk was used for heat capacity calibration. 
Approximately 5 mg samples were weighed using an analytical balance 
into aluminium pans with aluminium lids. The samples were scanned at 
2°C/min from -10°C to 190°C (isothermal for 5 min) with an amplitude 
of 0.636°C and a period of 40 s. DSC thermograms were acquired and 
analyzed using Universal Analysis software (version 4.4, TA instruments, 
Leatherhead, UK). All samples were analyzed in duplicate. 
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2.5 ATTENUATED TOTAL REFLECTANCE FOURIER 
TRANSFORM INFRARED (FTIR) SPECTROSCOPY 
 
FTIR spectra were acquired on a Vertex 70 spectrometer (Bruker, 
Billerica, USA), at room temperature, from 4000 to 400 cm−1, with the 
collection of 32 scans. Samples were analyzed as such. 
 
2.6 SCANNING ELECTRON MICROSCOPY (SEM) 
 
SEM pictures were recorded using a Phillips XL30 SEM-FEG 
(Philips, Eindhoven, The Netherlands) equipped with a Schottky field-
emission electron gun. A beam of 15 kV was used and detection was 
performed using a conventional Everhart-Thornley secondary electron 
detector. The samples were affixed onto an aluminum stub with a double-
sided adhesive carbon tape, and then coated with platinum under vacuum 
using a sputtering device (Balzers Union, Liechtenstein) before imaging.   
 
2.7 PARTICLE SIZE MEASUREMENT 
 
 The particle size distribution of the spray dried formulations was 
measured by laser diffraction using a Mastersizer 2000 equipment 
(Malvern Instruments Ltd, Malvern, UK) coupled to the dry sample 
dispersion unit Scirocco 2000. The dried powder samples were placed at 
the dispersion unit, fed to the equipment with a vibration feed rate of 35% 
and dispersed with an air pressure of 4 bar. 
 
2.8 EQUILIBRIUM SOLUBILITY MEASUREMENTS 
 
The equilibrium solubility of EZE, LOV, and the binary physical 
mixtures of EZE:LOV (1:1, w/w) were determined in acetate buffer pH 
4.5 + 0.025% of sodium lauryl sulfate (SLS), as well as in pre-dissolved 
Soluplus solutions (n = 3). In glass test tubes, an excessive amount of pure 
EZE, LOV and the binary mixtures were added into 5 ml of the above 
media and the samples were kept for 48 hours in a rotary mixer (L26 
133 
 
Labinco BV, Breda, The Netherlands). After that, 1 ml of the supernatant 
was filtered through a PTFE membrane with 0.45 µm pore size (Grace 
Davison Discovery Science, Illinois, USA).  
The content of EZE and LOV dissolved in the filtrate was 
determined by using isocratic HPLC analysis (Merk-Hitachi LaChrom 
system). The experiments were conducted on a reversed-phase 
Chromolith® Performance C18 column (100 x 4.6 mm i.d., 5 µm pore 
size). The mobile phase was made up of acetonitrile:water (50:50 v/v), 
with a flow rate of 1.0 ml/min, at room temperature. The UV detection 
was performed at 235 nm. 20 µl of samples was injected and the data 
acquisition was performed using Merck LaChrom D-7000 System 
Manager software (see Appendix).  
The statistical analysis of the data was conducted in GraphPad 
Prism 6 software through one-way ANOVA followed by Tukey test, in 
which significant results present a probability lower than 5% (p < 0.05 
with a 95% confidence interval). 
 
2.9 IN VITRO DISSOLUTION STUDIES 
 
Dissolution profiles were obtained under non-sink conditions 
using a SR8PLUS dissolution station (SpectraLab Scientific Inc., 
Markham, Canada). For solid dispersions, an accurate amount of spray 
dried sample, equivalent to 10 mg EZE and/or 10 mg LOV, was evaluated 
in 500 ml of acetate buffer solution pH 4.5 with 0.025% of SLS, at 37°C. 
The solution was stirred with paddle apparatus II at a speed of 100 rpm. 
Samples were taken at different time intervals, filtered using a PTFE filter 
(pore size 0.45 µm) and immediately replaced with the same volume of 
fresh dissolution medium. The obtained dissolution profiles were 
evaluated by means of their dissolution efficiency (DE, Equation 5). For 
this purpose, the area under the dissolution curve (AUC) at time t was 
calculated and expressed as the percentage of the rectangular area 
described by 100% of dissolution within the same period. The area under 
the curve was determined using the software Graph Pad Prism 6.  
 
DE (%) = AUC0-60 min X 100  Equation 5 
            AUCTOTAL 
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The content of EZE and LOV dissolved in the filtrate was 
determined as described in topic 2.8. 
The ‘in vitro’ profiles were compared applying one-way 
ANOVA followed by Tukey test Results were considered statistically 
significantly different if p < 0.05. The data were processed in Graph Pad 
Prism 6 software. 
 
2.10 STABILITY STUDIES 
 
The sample ELS 1:1 75% was stored in desiccators and exposed 
to different conditions (40°C/0% RH, 40°C/75% RH and 4°C/0% RH) 
during 1 year. The conditions regarding 0% and 75% RH were achieved 
with phosphorous pentoxide and NaCl saturated solution, respectively. 
The stability of the samples was evaluated by means of XRD and ‘in vitro’ 
dissolution studies.  
 
3. RESULTS AND DISCUSSION 
 
 Initially, by means of comparison, both APIs were spray dried 
separately (EZEsd, LOVsd) and in combination (EZE:LOVsd). As it can 
be seen in the Figure 25A, EZEsd was completely amorphous after the 
spray drying process, as well as EZE:LOVsd. On the other hand, LOVsd 
was still highly crystalline. Dissolution testing of EZEsd, LOVsd and 
EZE:LOVsd were performed in acetate buffer pH 4.5 + 0.025% of SLS. 
Very low percentages of release were observed for EZE from EZEsd 
(1.3% ± 0.9) and EZE:LOVsd (2.0% ± 0.2) after 120 min. Similar results 
were observed for LOV with 16.0% ± 0.5 and 2.4% ± 0.2  of release for 
LOVsd and EZE:LOVsd, respectively.  
Based on these poor dissolution characteristics, different 
hydrophilic polymers (HPMC, PVP K-30, PVP VA-64 and Soluplus) 
were combined to EZE and LOV, comprising the novel spray dried 
ternary solid dispersions. Solid-state characterization through XRD 
showed that all formulations were completely x-ray amorphous (Figure 
25B). mDSC analysis revealed  single phase systems for samples 
composed of PVP K-30 and PVP VA-64 with Tg values at 131.5 and 96.3 
°C, respectively. Formulations prepared with Soluplus and HPMC E5 
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showed two amorphous phases with Tg values at 59.9/92.4°C and 
91.4/150.5°C, respectively (Figure 26). 
 
Figure 25. XRPD data regarding spray dried (A) raw materials isolated 
(EZEsd;LOVsd) and in combination (EZE:LOVsd), and (B) ternary solid 
dispersions with different hydrophilic polymers 
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Figure 26. mDSC data for ternary solid dispersions composed of different 
hydrophilic polymers. Blue and black curves correspond to the reversing heat 
flow and its derivative, respectively. The peak temperatures of each glass 
transition event is shown in °C 
 
 
 The dissolution profiles of the ternary solid dispersions were 
compared to those of the crystalline raw materials as depicted in Figure 
27. For EZE, all the solid dispersions were able to increase the dissolution 
rate of the API, which dissolved to ca. 2.6% in 120 min, versus 12.5% 
(ELPVPK30), 12.3% (ELHPMC), 22.2% (ELPVPVA) and 42.4% 
(ELSoluplus). On the other hand, for LOV, ELPVPK30 showed a slightly 
lower release (8.6%) when compared to the crystalline raw material 
(12.3%). Other ternary solid dispersions showed higher percentages of 
release of 18.9% (ELHPMC), 20.1% (ELPVPVA) and 61.4% (ELS 1:1 
75%).    
For both APIs, Soluplus showed the best dissolution 
characteristics. This polymer is known for providing solubility 
enhancement by its amphiphilic structure, but also offers the feasibility of 
forming solid solutions with poorly soluble drugs (LINN et al., 2012). 
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Figure 27. (A) EZE and (B) LOV release profiles from ternary solid 
dispersions compared to their respective crystalline raw materials 
 
First of all, in order to prove the need for ternary solid 
dispersions, instead of a physical mixture of two binary formulations, 
binary solid dispersions composed of EZE or LOV with 75% of Soluplus 
were prepared. Firstly, the equilibrium solubility of both APIs from these 
formulations was determined and compared to that from the ternary 
systems. After 48 hours, EZE achieved 1.6 ± 0.1 µg/ml in ES 75%, whilst 
in the ternary formulation with the same amount of polymer (ELS 1:1 
75%) the equilibrium solubility reached 3.1 ± 0.1 µg/ml. For LOV, these 
values were 1.9 ± 0.2 and 2.7 ± 0.1 µg/ml for binary and ternary systems, 
respectively. Equilibrium solubility data for all the ternary solid 
dispersions are shown in Table 4. For EZE, the solubility tends to be 
higher as the amount of polymer and LOV increases. ELS 1:4 90% 
reaches a solubility up to 26.1 ± 0.9 µg/ml, which corresponds to an 
increase of more than 27 times when compared to the crystalline raw 
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material. On the other hand, the equilibrium solubility of LOV was not 
influenced by the amount of polymer.    
 
Table 4. Equilibrium solubility data in acetate buffer pH 4.5 + 0.025% SLS 
after 48 h 
 
Sample EZE LOV 
µg/mL ± SD 
ES 50% 
LS 50% 
1.0 ± 0.1  
- 
- 
2.0 ± 0.3 
ES 75% 1.6 ± 0.1 - 
LS 75% - 1.9 ± 0.2 
ES 90% 4.7 ± 0.1 - 
LS 90% - 2.2 ± 0.2 
ELS 1:1 50% 1.3 ± 0.1  2.4 ± 0.2 
ELS 1:1 75% 3.1 ± 0.1 2.7 ± 0.1 
ELS 1:1 90% 9.7 ± 0.1 3.9 ± 0.2 
ELS 1:2 50% 1.9 ± 0.1 2.0 ± 0.1 
ELS 1:2 75% 3.7 ± 0.1 2.2 ± 0.1 
ELS 1:2 90% 15.9 ± 0.2 2.8 ± 0.2 
ELS 1:4 50% 3.0 ± 0.1 1.7 ± 0.1 
ELS 1:4 75% 7.4 ± 0.1 2.1 ± 0.1 
ELS 1:4 90% 26.1 ± 0.9 3.3 ± 0.2 
 
 Dissolution studies were, in combination with equilibrium 
solubility, also useful to compare binary and ternary solid dispersions 
(Figure 28). Although the dissolution profiles of the binary solid 
dispersions seem to be slightly higher in comparison to the ternary one 
(ELS 1:1 75%), no significant difference was observed among the three 
formulations (p ≤ 0.05). This is another proof that the APIs do not 
influence their mutual dissolution rate. In addition, this can be considered 
advantageous for ternary systems, since the same release is achieved with 
a single step process, instead of a two-step process and a further powder 
blending step, if compared to a physical mixture of binary solid 
dispersions composing a FDC. These data clearly show the advantage of 
a ternary solid dispersion compared to a binary system. Soluplus was 
selected for more detailed investigation by applying different API:API 
ratios (1:1 to 1:4, related to the dose of EZE and LOV; 10 and 10, 20 and 
40 mg, respectively), APIs:polymer ratios (from 50:50 to 10:90), and 
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adding surfactants, in an attempt to increase the wettability and the 
dissolution rate of the APIs. 
 
Figure 28. Dissolution profiles of binary (LS 75% and ES 75%) versus the 
ternary solid dispersion ELS 1:1 75% 
 
Firstly, as can be seen in Figure 29, spray drying is a successful 
technique to obtain x-ray amorphous ternary solid dispersions, 
independent on their composition.  
 
Figure 29. XRD data relative to ternary solid dispersions composed of 
Soluplus with (A) 1:1, (B) 1:2 and (C) 1:4 EZE:LOV ratios, and (D) in 
presence of surfactants 
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However, the number of amorphous phases varied among the 
formulations (Table 5). Single phase amorphous systems were observed 
with lower ratios of polymer, indicating a better miscibility among the 
three components. In addition, similar Tg values were observed among 
these samples, which ranged from 55.8 to 57.9°C. As the amount of 
Soluplus increases to 75 and 90%, a second Tg is observed at higher 
temperatures, ranging from 70.4 to 100.5°C. 
 
Table 5. mDSC data of ternary solid dispersions 
 
Sample Melting 
Point 
Glass Transition Temperature (Tg)  
Number Onset 
(°C)  
Peak 
(°C) 
Endset  
(°C) 
ELS 1:1 50% No 1 51.6 56.9 74.3 
ELS 1:1 75% No 2 50.1 59.9 64.0 
78.8 92.4 93.9 
ELS 1:1 90% No 2 55.8 
90.4 
62.3 
100.5 
70.4 
108.2 
ELS 1:2 50% No 1 51.1 57.9 73.1 
ELS 1:2 75% No 2 52.2 
83.3 
57.2 
84.2 
63.0 
91.4 
ELS 1:2 90% No 2 54.6 
86.4 
65.5 
89.8 
71.4 
99.8 
ELS 1:4 50% No 1 47.5 55.8 70.1 
ELS 1:4 75% No 2 52.6 
80.5 
57.5 
83.0 
64.7 
94.1 
ELS 1:4 90% No 2 57.3 
95.6 
72.0 
96.8 
73.6 
103.5 
ELSTween20 No 2 49.6 
72.5 
53.6 
73.7 
56.2 
83.4 
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ELSTween80 No 2 51.8 
70.2 
58.0 
70.4 
59.0 
85.0 
ELSCremophor®  No 2 51.1 
76.2 
58.0 
77.0 
59.0 
88.1 
ELSGelucire®  No 1 55.1 69.6 84.3 
ELSTPGS No 2 48.6 
74.2 
56.0 
75.9 
62.2 
88.1 
 
  
 FTIR analysis was carried out to investigate possible 
intermolecular interactions between the APIs and the polymer. Table 6 
summarizes the FTIR data for the ternary solid dispersions. Spectra 
corresponding to ternary solid dispersions with 1:1 API:API ratios are 
found in Figure 30. 
 
Table 6. Experimental and calculated FTIR data of ternary solid dispersions 
with Soluplus 
Sample O-H band (cm-1) C=O band (cm-1) 
Calculated Experimental Calculated Experimental 
1:1 50% 3433 3338 1727/1633 1733/1635 
1:2 50% 3441 3341 1726/1630 1730/1637 
1:4 50% 3446 3350 1726/1631 1728/1635 
1:1 75% 3449 3356 1730/1631 1734/1634 
1:2 75% 3451 3351 1729/1630 1733/1634 
1:4 75% 3447 3355 1730/1631 1732/1633 
1:1 90% 3450 3444 1731/1630 1733/1634 
1:2 90% 3449 3441 1731/1631 1733/1633 
1:4 90% 3448 3442 1730/1630 1732/1635 
Cremophor 3450 3360 1729/1631 1732/1634 
Gelucire 3446 3355 1729/1631 1733/1634 
TPGS 3449 3345 1730/1631 1732/1633 
Tween20 3447 3348 1730/1631 1732/1634 
Tween80 3446 3367 1730/1631 1733/1633 
 
 
As discussed previously, EZE and LOV present potential sites 
for hydrogen bonding. The Soluplus spectrum shows intermolecularly 
hydrogen bonded O-H stretching at 3448 cm-1, vinyl acetate monomer 
ester stretching at 1733 cm-1 and vinyl caprolactam monomer C=O 
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stretching at 1633 cm-1 (data not shown), in agreement with previously 
reported data (LIN et al., 2015). As both bands of interest are present in 
the spectra of the two APIs and Soluplus, the FTIR data of the 
formulations were compared to the amorphous physical mixtures of the 
three components, in order to facilitate the data analysis (Figure 30). 
Bands indicative of interactions among drugs and the polymer, which 
include the hydrogen bonding acceptor C=O stretching and the hydrogen 
bond donor O–H stretching, presented significant shifts in all 
formulations. In addition, a broadening of the O-H band was also noted. 
Based on that, it can be concluded that intermolecular hydrogen bonds 
were established. Samples presenting different API:API ratios but the 
same amount of polymer showed similar FTIR spectra, as well as samples 
with surfactants and ELS 1:1 75%.  
 
Figure 30. Experimental and calculated ATR data for ternary solid 
dispersions with Soluplus composed of 1:1 API:API ratio and different 
polymer concentrations (50, 75 and 90%) 
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SEM micrographs of the ternary solid dispersions were compared 
with EZE:LOVsd to evaluate the influence of the polymer on the 
morphology of the particles. As can be seen in Figure 31, the spray dried 
particles are spherical and show a heterogeneous particle size distribution. 
EZE:LOVsd present a smooth surface on which some needle shape-like 
crystals can be observed. This can most likely be  associated with the low 
solubility of the compounds in the solvents chosen. Although both EZE 
and LOV are poorly water-soluble compounds, their solubility in organic 
solvents is distinct and finding a suitable solvent mixture combined to an 
adequate feed concentration was challenging. The average particle size 
for this sample is 3.16 µm (D[4,3]). When in presence of polymer, the 
crystals disappear and the surface of the particles shows indentations 
which tend to increase in presence of higher amounts of Soluplus. 
Basically, the ternary solid dispersions showed bigger, but  similar mean 
particle sizes which ranged from 5.4 µm (ELS 1:4 90%)  to 7.7 µm 
(D[4,3]) (ELS 1:1 90%). These results can be explained by the different 
feed concentrations between EZE:LOVsd (2%) and the ternary solid 
dispersions (10%). It is well known that the feed concentration is directly 
proportional to the mean diameter of spray dried particles (MEEUS et al., 
2015). In addition, more concentrated feed solutions tend to generate 
hollow particles with rough surface, higher porosity and lower bulk 
density (VAN GYSEGHEM et al., 2009; LITTRINGER et al., 2012). 
Besides, the wrinkled morphology of the ternary solid dispersions can 
also be attributed to the high solubility of the polymer in methanol. 
Further evaporation of the solvent from the core of the droplets leads to 
shell folding and wrinkled morphology. Also, as methanol requires low 
quantities of thermal energy for vaporization, due to its low boiling point, 
the solidification point will be reached faster, resulting in an increase in 
void volume and porosity (POKHARKAR et al., 2006; RIZI et al., 2011). 
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Formulations prepared with surfactants led to bigger mean particle sizes 
ranging from 9.47 µm (ELSTween80) to 17.43 µm (D[4,3]) 
(ELSCremophor). 
 
Figure 31. SEM micrographs of (A) EZE:LOVsd (3500x), (B) EZE:LOVsd 
(10000x), (C) ELS 1:2 50% (5000x) and (D) ELS 1:2 90% (5000x). The 
arrows in B indicate the presence of crystalline needles on the surface of the 
spherical EZE:LOVsd particles  
 
 
‘In vitro’ dissolution studies demonstrate that for the first time 
reported a spray dried ternary solid dispersion is able to increase the 
dissolution rate of two poorly water-soluble APIs simultaneously. 
Ternary solid dispersions composed of  Soluplus  demonstrated enhanced 
dissolution properties as the amount of polymer increased (Table 7). Very 
low release profiles were observed in presence of 50% of polymer for 
both APIs. As the amount of Soluplus increased to 75%, ELS 1:4 75% for 
example, achieved 88.7% ± 2.0 and 70.0% ± 5.2 for EZE and LOV, 
respectively, at 120 min. The fastest dissolution rate for both APIs was 
observed for ELS (1:1) 90%, in which 92.5 % ± 6.2 of EZE and 83.7% ± 
7.6 of LOV were released in 5 min (Figure 32). This formulation 
presented an increase in the dissolution efficiency of almost 18 and 6 
times for EZE and LOV, respectively, when compared to the crystalline 
A
C D
B
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raw materials. Although 90% can be considered a high amount of 
polymer, the low doses of both compounds still make the development of 
a formulation feasible. In addition, this ternary solid dispersion is 
advantageous compared to the ones with 1:2 and 1:4 EZE:LOV (w/w) 
ratios. In this case, the dose of the statin can be decreased, which is ideal 
concerning its side effects and influence on the development of type 2 
diabetes in hypercholesterolemic patients (CEDERBERG et al., 2015).  
Importantly, Soluplus was able to maintain the supersaturation of both 
APIs during the dissolution test for all formulations. The ratios between 
the APIs did not have a clear influence on the release profiles. For the 
samples composed of surfactants, no significant increase in the 
dissolution rate of EZE and LOV was observed when they were compared 
to ELS (1:1) 75% (Figure 33). A similar finding was reported for solid 
dispersions of EZE, hydroxypropylcellulose and Tween 80. The polymer 
had an important influence of the solubility and dissolution rate of the 
API, while no significant difference was observed with the addition of the 
surfactant (RASHID et al., 2015).  
 
Table 7. Percentage of dissolution (% D) at 120 min and dissolution 
efficiency (DE) data 
Sample EZE LOV 
%D ±SD DE (%) %D ±SD DE (%) 
Raw material 2.6 ±0.2 5.5 12.3 ±0.6 14.5 
ELS 1:1 50% 18.4 ±5.7 16.4 28.3 ±5.8 22.3 
ELS 1:1 75% 42.4 ±1.8 40.2 61.4 ±6.8 57.2 
ELS 1:1 90% 97.5 ±0.6 98.9 85.2 ±2.7  84.9 
ELS 1:2 50% 15.3 ±3.8 10.7 15.3 ±3.2 11.3 
ELS 1:2 75% 44.5 ±1.5 46.8 45.7 ±1.9 39.8 
ELS 1:2 90% 98.6 ±5.0 90.7 59.4 ±2.7 56.3 
ELS 1:4 50% 17.1 ±1.3 12.2 13.3 ±2.6 10.0 
ELS 1:4 75% 88.7 ±2.0 82.3 70.0 ±5.2  69.0 
ELS 1:4 90% 103.8 ±0.9 101.0 73.2 ± 1.8 71.4 
ELS Tween 20 36.5 ±0.4 43.9 55.6 ±3.6  53.6 
ELS Tween 80 37.0 ±0.4 42.3 59.4 ± 1.6 58.8 
ELSCremophor®  54.7 ±4.0 47.0 67.1 ±3.8 64.1 
ELSGelucire® 41.5 ±5.0 39.8 57.1 ± 4.4 53.0 
ELS TPGS 41.5 ±0.3 40.6 64.2 ± 0.9 62.9 
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Figure 32. Dissolution profiles of EZE and LOV in the ternary solid 
dispersion ELS 1:1 90% compared to their respective crystalline raw 
materials 
 
Figure 33. ‘In vitro’ dissolution data for (A) EZE and (B) LOV regarding 
ternary solid dispersions composed of surfactants 
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Stability assays conducted during 1 year in different storage 
conditions were studied through XRD and ‘in vitro’ dissolution analyses 
(Figures 34 and 35). ELS 1:1 75% was selected for stability investigation 
due to its intermediate dissolution performance. Hence, changes (positive 
or negative) during the study could be more easily visualized. After 6 
months, it was noted that temperature did not have an influence on the 
stability of samples in dry conditions. Samples kept at these conditions 
remained amorphous. On the other hand, at high relative humidity (75%), 
a drastic decrease in the dissolution performance was found for EZE and 
LOV, although this sample remained x-ray amorphous. In this case, a 
possible phase demixing between the APIs and the polymer could have 
happened, jeopardizing drug release.  
After 1 year storage, EZE and LOV could not be detected in 
dissolution studies at 40°C/75% RH. In addition, within the same 
timeframe, a significant decrease in dissolution percentage was also 
observed for samples kept at 40°C/0% RH. These results demonstrate that 
for these samples drastic temperature conditions must be avoided. On the 
other hand, samples kept at 4ºC/0% RH remained amorphous and showed 
no statistical difference regarding their dissolution profile compared to 
time zero. 
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Figure 34. XRD data for ELS 1:1 75% at time zero (T0) and after 1 year 
exposed to different stability conditions 
 
 
Figure 35. ‘In vitro’ dissolution profiles of ELS 1:1 75% at time zero (T0), 
after 180 days (180d) and after 1 year (1y) exposed to different stability 
conditions 
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Lower dissolution rates observed for samples kept at 40°C/75% 
RH were also observed for solid dispersions composed of cinarizine and 
Soluplus. Samples under stress conditions showed a reduced dissolution 
and a crystallization of the drug with an increased crystallinity in the order 
of 40°C/75% RH, >60°C/0% RH, >25°C/94% RH, >40°C/0% RH, 
>25°C/75% RH. In addition, although still amorphous, samples stored at 
25°C showed a decrease in their dissolution rate. According to the 
authors, the change in Tg values could be pointed as a possible 
explanation for this behavior (TIAN et al., 2014). Decreased dissolution 
during stability studies at high temperature and humidity were also 
described for solid dispersions of piroxicam and Soluplus. The samples 
remained amorphous under dry conditions (0% RH/6°C and 0% 
RH/25°C) and crystallization was observed at 40% RH/25°C and 75% 
RH/25°C. A decrease in the dissolution profile was noted already after 
the first week for the sample at 75% RH/25°C and increased over time up 
to 6 months (LUST et al., 2015). 
 
4. CONCLUSIONS 
 
 This chapter describes for the first time enhanced dissolution 
characteristics of two poorly water-soluble compounds from a single 
spray dried ternary solid dispersion. Due to their physical chemical 
properties and therapeutically relevant association, EZE and LOV were 
selected as model compounds in a fixed dose combination. Equilibrium 
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solubility data proved the feasibility of this combination, since the APIs 
did not influence their mutual solubility. Based on the failure of co-
amorphous systems and gelatin to improve the dissolution rate of EZE 
and LOV, different hydrophilic polymers were investigated to compose 
the novel ternary solid dispersions. Among them, Soluplus showed the 
best performance and all the spray dried ternary solid dispersions 
prepared with this polymer enhanced the dissolution rate of the APIs. The 
advantages of these formulations were also proved versus binary solid 
dispersions composed of the same amount of Soluplus. All the 
formulations were X-ray amorphous and hydrogen bonding interactions 
between the compounds were detected by FTIR analysis.  An increase of 
18 (EZE) and 6 (LOV) times regarding the dissolution efficiency was 
observed for ELS 1:1 90%, when compared to the crystalline raw 
materials. This formulation was able to release ca. 92 and 83% of EZE 
and LOV, respectively, in 5 min. Stability studies conducted at 40°C/75% 
RH demonstrated a decrease in the dissolution rate for both APIs, 
although the samples remained X-ray amorphous. However, in dry 
storage conditions and low temperature, the ternary solid dispersion 
showed a similar dissolution profile compared to the sample at time zero 
and  unaltered physical stability. These promising data open new 
perspectives regarding the development of fixed dose combinations 
composed of poorly water-soluble APIs. 
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CHAPTER V 
 
DEVELOPMENT, CHARACTERIZATION AND IN VITRO 
DISSOLUTION STUDIES OF AN ENTERIC-COATED FIXED-
DOSE COMBINATION COMPOSED OF TERNARY SOLID 
DISPERSIONS OF EZETIMIBE AND LOVASTATIN 
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1. INTRODUCTION  
 
 Fixed-dose combinations (FDCs), defined as a combination of 
two or more active pharmaceutical ingredients (APIs) in a fixed ratio of 
doses, are becoming increasingly important from a public health 
perspective. Nowadays, FDCs have been commonly used for a wide range 
of conditions, including cardiovascular, metabolic and hormonal-related 
pathologies, infections, allergies and pain, and have been designed for 
different routes of administration (EMA, 2015; WHO, 2005).     
Regarding the use of FDCs for hypercholesterolemia, recent 
studies have proven that the combination of statins, the so-called first 
choice lipid lowering agents, with other drugs, such as ezetimibe (EZE), 
is highly recommended. Besides the frequent and severe side effects, such 
as myopathy, which can result in rhabdomyolysis leading to renal failure, 
the use of statins has also been associated with an increase of 46% in the 
development of diabetes type 2 (CEDERBERG et al., 2015). 
The successful development of a ternary solid dispersion with 
Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol 
graft copolymer) by spray drying was demonstrated in the previous 
chapter. The dissolution enhancement of both compounds was directly 
proportional to the amount of polymer, reaching its best performance with 
the formulation composed of EZE:LOV:Soluplus®, in a mass ratio of 
5:5:90 (ELS 1:1 90%) (RIEKES et al., 2016). However, dissolution 
studies performed in simulated gastric fluid (0.1 M HCl) provoked the 
hydrolysis of LOV (data not shown), causing the premature formation of 
its hydroxyacid derivative (LOVh). Importantly, as both LOV and LOVh 
have the liver as their site of action, their concentration in this organ 
should be maximized as much as possible. Studies in animals have 
demonstrated that LOV shows a better hepatic sequestration than LOVh, 
which in turn minimizes the systemic side effects (DUGGAN et al., 
1988). As the author states that this provides a rational basis for the 
lactone to be the preferred API for the dosage form, the hydrolytic 
formation of the active metabolite in gastric conditions should be avoided. 
For this purpose, the development of an enteric-coated formulation is 
ideal, to safely prevent the premature formation of LOVh. 
Fluid bed coating is one of the most used coating processes. 
Despite of the different configurations of fluid bed coaters, the bottom 
spray mode with a Würster insert is especially interesting to coat small 
particles, as pellets, since it diminishes the risk of agglomeration, typical 
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of the standard bottom spray mode (DIXIT and PUTHLI, 2009). 
Preparation of multiparticulate systems, such as pellets, granules and 
mini-tablets, instead of the conventional single unit dosage forms, offers 
the advantage of presenting a more predictable gastric transit time, better 
distribution and absorption, facilitated disintegration, less frequent dose 
dumping issues and reduced risks of systemic toxicity and local irritation 
(ASGHAR and CHANDRAN, 2006). In theory, multiparticulate systems 
can also be an interesting choice to compose a FDC, since they allow the 
combination of more than one API, obtaining various release profiles 
from a single dosage form. However, more scientific investigation is 
necessary to understand it more deeply and optimize the critical 
manufacturing parameters. In the case of EZE and LOV, as the coating 
process involves the obtainment of a two-layered formulation, the 
manufacturing becomes more complex. The developed formulation 
should be able to protect especially LOV from the gastric environment, 
avoiding the formation of LOVh, and later rapidly release both APIs in 
the upper intestine.  
In this context, this chapter aims to investigate the preparation of 
enteric-coated FDC solid dispersions composed of EZE and LOV, 
manufactured by fluid bed coating. Formulation and process parameters 
were tested and the obtained formulations were characterized by solid-
state techniques and in vitro dissolution studies. 
  
 
2. EXPERIMENTAL 
 
2.1 MATERIALS 
 
 EZE and LOV were purchased from Pharma Nostra® (Rio de 
Janeiro, Brazil) with batch numbers FM017H13 and 130312, 
respectively. LOVh  was prepared according to Bogman and coworkers 
(2001), by hydrolyzing LOV in 0.05 M NaOH, resulting in a theoretical 
concentration of 1 mg/ml. The solution was stirred at room temperature 
during 30 min, followed by pH adjustment to 7.4 with 0.2 M HCl. The 
solution was stored at 4ºC prior to use (BOGMAN et al., 2001).  
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Soluplus® was obtained from BASF® ChemTrade GmbH 
(Ludwigshafen, Germany), while Eudragit L100® (poly(methacrylic 
acid-co-methyl methacrylate) 1:1) and Eudragit L100-55® 
(poly(methacrylic acid-co-ethyl acrylate) 1:1) were kindly donated by 
Evonik Industries AG® (Darmstadt, Germany). Sucrose beads (mean 
diameter of 300-415 µm and 710-850 µm) were provided by Hanns G. 
Werner GmbH (Tornesch, Germany). 
 
2.2 PREPARATION OF THE FLUID BED COATED BEADS  
 
Based on the previous chapter, a system composed of 
EZE:LOV:Soluplus® (5:5:90, w/w/w) was selected to make up the glass 
solution layer. For this purpose, EZE, LOV and Soluplus®, dissolved in 
2.5 l of a 10% (w/v) ethanolic solution, were coated onto 500 g of  sucrose 
beads, using a bottom-spray fluid bed system with a Würster insert 
(Aeromatic MP 1 Multiprocessor, GEA Pharma System AG, Bubendorf, 
Switzerland). Prior to coating, the beads were pre-heated for 30 min in 
the coating chamber. The operational conditions were: drying air volume 
of 1566.3 l/min, inlet temperature of 50°C, atomizing air pressure of 1.5 
bar and feed rate of 12 ml/min for beads of 710-850 µm mean diameter. 
For the smaller ones (300-415 µm), the parameters were kept the same, 
except the atomizing air pressure and the feed rate, changed to 1 bar and 
9 ml/min, respectively. 
The enteric coating process was started immediately after the 
glass solution layer was applied. In this step, 1 l of a 10% (w/v) ethanolic 
solution containing either Eudragit L100® or Eudragit L100-55®, and 20 
g of triethyl citrate (TEC) was sprayed onto the sucrose beads coated with 
the ternary solid dispersion layer. Regarding the beads of 710-850 µm 
mean diameter, the operational conditions used for the glass solution 
remained the same for Eudragit L100®, whilst for Eudragit L100-55® the 
feed rate was lowered to 6 ml/min, due to the higher viscosity of this 
solution, leading to aggregation of the beads. The smaller beads (300-415 
µm) adopted the same experimental parameters described for Eudragit 
L100-55®, except that in this case the solid content of the enteric coating 
solution was decreased to 5% (w/v), to avoid agglomeration of the pellets.  
In all cases, during the enteric coating step, approximately 5 g of 
samples were withdrawn periodically until the end of the process, to 
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verify the effect of coating time and the thickness of the enteric layer on 
drug release.  
The coated beads were unloaded, weighed and kept in a 
desiccator, at 0% RH (using phosphorous pentoxide), at room 
temperature. Stability of the formulations was investigated by X-ray 
powder diffraction (XRPD) and drug release studies (section 2.3 and 2.6, 
respectively) after 6 months of storage under the mentioned conditions. 
 
2.3 X-RAY POWDER DIFFRACTION (XRPD) 
 
XRPD experiments were carried out using an automated X’pert 
PRO diffractometer (PANalytical, Almelo, The Netherlands) with a Cu 
tube (Kα λ = 1.5418 Å), and a generator set at 45 kV and 40 mA. The 
measurements were performed at room temperature on whole beads, in 
transmission mode. The selected experimental settings included a 
continuous scan mode from 4° to 40° 2θ with 0.0167° step size and 200 s 
per step counting time. 
 
2.4 SCANNING ELECTRON MICROSCOPY (SEM) 
 
SEM pictures were recorded using a Phillips XL30 SEM-FEG 
(Philips, Eindhoven, The Netherlands) equipped with a Schottky field-
emission electron gun. A beam of 15 kV was used and detection was 
performed using a conventional Everhart-Thornley secondary electron 
detector. Cross-sectioned and entire beads were affixed onto an aluminum 
stub with a double-sided adhesive carbon tape, and then coated with 
platinum under vacuum using a sputtering device (Balzers Union, 
Liechtenstein) before imaging.  
 
2.5 PARTICLE SIZE MEASUREMENT 
 
The mean particle size distribution of the coated beads was 
measured by laser diffraction using a Mastersizer 2000 equipment 
(Malvern Instruments Ltd, Malvern, UK) coupled to the dry sample 
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dispersion unit Scirocco 2000. The samples were placed in the dispersion 
unit, fed to the equipment with a vibration feed rate of 30% and dispersed 
with an air pressure of 2 bar. All samples were measured in triplicate. 
 
2.6 IN VITRO RELEASE STUDIES 
 
 Release profiles were obtained under non-sink conditions using 
a SR8PLUS dissolution station (SpectraLab Scientific Inc., Markham, 
Canada). An accurate amount of beads, equivalent to 10 mg of EZE and 
10 mg of LOV, was evaluated in 900 ml of 0.1 M HCl containing 0.025 
% (m/v) of sodium lauryl sulfate (SLS) and in 900 ml of 10 mM 
phosphate buffer pH 6.8 + 0.01% (m/v) SLS, at 37°C, in order to mimic 
the gastric and intestinal conditions, respectively. The solution was stirred 
with paddle apparatus II at a speed of 120 rpm, in order to avoid the 
agglomeration of the beads at the bottom of the dissolution vessels. 
Samples were taken at different time intervals, filtered using a PTFE filter 
(pore size 0.45 µm) and immediately replaced with the same volume of 
fresh dissolution medium. Dissolution profiles were compared by means 
of one-way ANOVA followed by Tukey’s test. Results were considered 
to be statistically significantly different if p < 0.05. The statistical analysis 
was performed by the GraphPad Prism 6 software. 
The amount of EZE and LOV dissolved was determined using an 
isocratic HPLC method (see Appendix). The experiments were conducted 
on a reversed-phase Thermo® BDS Hypersil C18 column (250 x 4.6 mm 
i.d., 5 µm pore size). The mobile phase was composed of 
acetonitrile:water (60:40 v/v), and used at  a flow rate of 1.0 ml/min, at 
room temperature. The UV detection was performed at 235 nm. 20 µl of 
samples was injected and the data acquisition was performed using Merck 
LaChrom D-7000 System Manager software. 
 
3. RESULTS AND DISCUSSION 
3.1 PREPARATION AND CHARACTERIZATION OF THE 
ENTERIC-COATED FDC 
 
 In order to achieve efficient drug delivery, pharmaceutical 
formulations must be able to deliver a sufficient concentration of 
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unchanged API at its intended site of action. The development of ternary 
solid dispersions with EZE, LOV and Soluplus® by our group provided 
enhanced dissolution rate of both APIs in acetate buffer pH 4.5, but also 
showed the formation of the active metabolite, LOVh, in gastric 
environment (see Appendix, Figure 45). In this case, the undesired and 
premature formation of LOVh in the stomach jeopardizes the efficiency 
of the dosage form, since the parent drug presents a higher hepatic 
sequestration than LOVh. The high pre-hepatic concentration of the 
metabolite increases the systemic burden, instead of maximizing the 
concentration of LOV in the liver, its site of action (DUGGAN, et al., 
1988).  
Based on these findings, the development of an enteric-coated 
formulation was considered. For this purpose, fluid bed coating was 
selected. Consisting of a one-step process, it does not require separate 
drying steps, addition of excipients and further manufacturing stages, 
such as milling or compression, which can induce phase separation or 
crystallization (SINGH et al., 2016; AYENEW et al., 2012). However, 
although this technique has been successfully applied to the development 
of solid dispersions (YAN et al., 2016; DEREYMAKER and VAN DEN 
MOOTER, 2015; LI et al., 2012; SUN et al., 2008), the preparation of 
more complex formulations still remains relatively unexplored.  
We investigated the influence of bead size, type of enteric 
polymer and coating time (which is related to the coating thickness), on 
the release performance of the two APIs. The other processing parameters 
were selected based on a previous study (DEREYMAKER and VAN 
DEN MOOTER, 2015) and were optimized for each formulation. The 
inlet temperature (50°C) was selected since it provides adequate solvent 
evaporation and it is below the glass transition temperature of Soluplus® 
(ca. 70°C) (BASF, 2010). An atomizing air pressure of 1.5 bar was ideal 
to fluidize the beads without inducing particle entrainment.   
 
3.2 IMPACT OF BEAD SIZE 
 
 The size of inert sucrose beads is an important parameter, which 
should be taken into consideration in fluid bed coating. Especially in this 
type of processing, particles must present adequate cohesive and density 
properties, in order to allow fluidization and avoid agglomeration. 
Moreover, the change in bead size can have a direct impact on the 
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thickness of the coating layer, interfering with the in vitro drug release 
(WESDYK et al., 1990).  
For this reason, inert sucrose beads with mean diameters ranging 
from 300 to 415 µm and 710 to 850 µm have been tested and their impact 
has been analyzed through in vitro studies in acidic conditions. This 
criterion was selected based on the importance of the coating layer to 
avoid the premature formation of LOVh in the stomach. At this stage of 
investigation, the type of enteric polymer remained constant and Eudragit 
L100-55® was selected. 
 
Figure 36. SEM micrographs of enteric-coated smaller beads (300-415 µm)  
before (A-C) and after (D-F) process optimization. Agglomeration is 
indicated in A by the arrows. Polymeric nets are shown in B and C after 
enteric coating. The coating layers relative to the solid dispersion (SD) and 
enteric coating (EC) are shown in F and their borders are indicated by the 
arrow 
 
 
Different bead sizes required distinct processing parameters. 
Particle agglomeration was a common problem faced by the smaller 
beads, mainly during the enteric coating step, and lowering the feeding 
rate at this stage from 12 to 6 ml/min was necessary. A similar approach 
was attempted with the glass solution layer; 9 ml/min feeding rate was 
adopted instead of 12 ml/min. In addition, the solid content of the enteric 
solution was decreased by half (5% w/v), increasing the total coating 
volume.  Based on SEM images (Figure 36), it was possible to observe 
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that the adhesion between the beads was attributed to the presence of 
polymeric nets, probably formed by inadequate solvent evaporation of the  
highly viscous solution. After process optimization, coating layers were 
clearly formed and agglomeration was less frequently observed. 
However, as an important disadvantage, the enteric coating process took 
much longer with the smaller beads (349 min), compared to the bigger 
ones (175 min). 
 
Figure 37. Influence of coating time on in vitro dissolution  of EZE and LOV 
in acidic conditions (presented as % release), from small (300-415 µm) and 
large (710-850 µm) beads 
 
 
 
When compared by in vitro dissolution studies in acidic 
conditions, beads with distinct size ranges yielded different results 
(Figure 37). According to official compendia, less than 10% release in 
HCl 0.1 M meets the criteria of gastro protection for enteric-coated 
formulations. Both EZE and LOV showed less than 10% drug release for 
all coating times in case of the larger beads, as well as more consistent 
data and lower drug release as the coating time increased, especially for 
LOV. On the other hand, large variability was observed for drug release 
from the smaller beads, which reached values higher than 10% in some 
cases (up to 8.7 ± 4.5% for EZE and 9.2 ± 3.7% for LOV). In addition, 
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there was no logical trend with respect to the coating time. This data 
demonstrates that the coating of these samples was probably not 
homogeneous, suggesting the occurrence of agglomeration, even after the 
process optimization. In this case, the use of small inert beads, with sizes 
ranging from 300 to 415 µm is not ideal. Based on these data, further tests 
(varying the type of enteric polymer and coating time) have been 
performed with inert beads ranging from 710 to 850 µm. 
 
3.3 IMPACT OF POLYMER TYPE AND COATING TIME 
 
 Enteric coating layers composed of Eudragit L100® and Eudragit 
L100-55® were tested with inert sucrose beads (particle size 710-850 
µm), in order to verify the impact of the type of polymer. Although more 
viscous solutions were obtained with Eudragit L100-55®, thus requiring 
the optimization of process parameters, both formulations have been 
successfully obtained. The yield was  93.8% and 88.4% for the final 
formulations composed of Eudragit L100® and Eudragit L100-55®, 
respectively.   
SEM micrographs (Figure 38) show spherical particles with 
different morphological aspects regarding the coating process and the 
polymer used. The surface of the pellets is rough with indentations after 
coating with the first layer (solid dispersion). However, after coating with 
the enteric polymers, the surface becomes smoother with homogeneous 
distribution of the enteric layer. Concave pores, which were probably 
generated during the volatilization of the spray solution from the surface 
of the pellets, are observed on the surface of the formulations composed 
of Eudragit L100®. These apertures are more scarce in samples composed 
of Eudragit L100-55®. The spherical morphology remains after the enteric 
coating process, indicating adequate drying and rigidity of the particles. 
The cross-section views indicate that the inner core has a rough structure, 
tightly coated by the solid dispersion layer, which is compact and smooth. 
A delimited border can be easily distinguished between this layer and the 
enteric coating layers. The concave pores observed on the surface of the 
formulations composed of Eudragit L100-55® remain in the inner enteric 
layer. Their presence on the surface increases the pellet surface area and 
facilitates water penetration and eventual release of the drugs.   
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Figure 38. SEM micrographs of pellets coated with the solid dispersion layer 
(A and D) and enteric-coated with Eudragit L100® (B and E) and Eudragit 
L100-55® (C and F). Panel B shows an enlarged surface view to provide a 
better visualization of the pores. The cross-sectioned pellets (D-F) show the 
core, the solid dispersion (SD) and the enteric coating (EC) layers. Arrows 
indicate the borders between the SD and the EC layers   
 
 
Particle size measurements by laser diffraction were performed 
to follow the coating thickness along the processing. Application of the 
solid dispersion coating layer increased the mean particle size to 919.7 ± 
11.6 µm, and a coating ratio of 0.48 µm/min was determined based on the 
coating time (208 min). The mean particle size reached 1006.4 ± 35.6 µm 
and  963.1 ± 15.9 µm at the end of the enteric coating process, for samples 
composed of Eudragit L100® and Eudragit L100-55®, respectively.  Both 
formulations displayed a linear relation between the enteric coating time 
and the increase of their particle size (Figure 39). The coating rate could 
be determined by the slope of their linear equation as 1.03 µm/min and 
0.43 µm/min for beads with Eudragit L-100® and Eudragit L100-55®, 
respectively. The concern about monitoring the film thickness during the 
coating process is of high importance due to its relation to the release 
profile and drug stability. Too tick coating layers can prejudice the release 
of immediate release dosage forms, resulting in delayed release. On the 
other hand, if too thin, the coating layer can expose the dosage form to 
premature release and provoke degradation or crystallization (KNOP and 
KLEINEBUDDE, 2013). Although continuous and in-line monitoring 
methods are more appropriate, e.g. visual imaging (KADUNC et al., 
2014), and spectroscopic methods like near infreared (NIR) and Raman 
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spectroscopy (KNOP and KLEINEBUDDE, 2013), the off-line 
monitoring by particle size measurement is also feasible, since it 
generates simple, fast and reliable measurements to determine the end 
point of coating. For this purpose, they need to be related to the 
dissolution performance of the withdrawn samples. 
 
Figure 39. Linear relation between the particle size, in µm, and the coating 
time of the enteric coating layers composed of Eudragit L100® () and 
Eudragit L100-55® () 
 
As the degree of crystallinity of LOV and EZE is an important 
parameter related to drug release, the samples were analyzed with XRD. 
The diffractograms shown in Figure 6 demonstrate that the starting raw 
materials are crystalline. LOV has main Bragg peaks at 2θ 8.05°, 9.54°, 
11.03°, 15.83°, 16.86°, 17.68° and 19.07°, in agreement with previous 
reports (YOSHIDA et al., 2011). EZE can be found in anhydrate or 
monohydrate forms, which are differentiated at low 2θ angles in XRD 
data; the peaks at 7.02, 8.36 and 10.04° belong exclusively to the 
anhydrate, while the ones found at 7.98, 9.84 and 13.23° correspond to 
the monohydrate (BRÜNING et al., 2010; RAVIKUMAR and 
SRIDHAR, 2005). The raw material used in this study has main 
crystalline peaks at 7.01, 8.34, 10.04, 16.54, 20.30, 23.71 and 25.73°, 
indicating that it corresponds to the anhydrate form. However, after the 
coating process, from both solid dispersion and enteric layers, all 
formulations only show Bragg peaks characteristic of the sucrose beads, 
indicating amorphization of the APIs (Figure 40). These results indicate 
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that the coating process did not lead to a deleterious effect to the 
formulation, since the spray dried formulation ELS 1:1 90% (composed 
of EZE, LOV and Soluplus® in 5:5:90 mass ratio, respectively) was 
completely amorphous (RIEKES et al., 2016).   
 
Figure 40. Diffractograms of (A) crystalline raw materials, (B) formulations 
with Eudragit L100® and (C) formulations with Eudragit L100-55®, 
compared to the inert sucrose beads 
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(to be continued) 
 
In order to investigate the impact of the different enteric 
polymers on the dissolution performance of the enteric-coated 
formulations, the pellets were evaluated in gastric conditions (in order to 
assess its gastro resistance) and in phosphate buffer pH 6.8, aiming to 
verify if a fast release of both APIs could be achieved in this condition. 
Figure 41 shows the percentage release of EZE and LOV in 
gastric conditions (HCl 0.1 M + 0.025% (m/v) of SLS). If the desired 
release in this condition is considered (less than 10% release in HCl 0.1 
M), it can be observed that only the formulation coated for 15 min with 
Eudragit L100® does not comply with this rule. This formulation released 
16.8 ± 0.3% of EZE and 9.1 ± 3.5% of LOV. If this data is associated to 
the thickness of the enteric coating layer, it is possible to conclude that 
for this polymer, at least 30.9 µm is necessary to sufficiently reduce drug 
release in acidic condition. On the other hand, for Eudragit L100-55®, 
acceptable release was already obtained after 15 min of coating (6.9 ± 
1.2% for EZE and 3.8 ± 1.7% for LOV), although the coating thickness 
of this layer is much thinner (6.45 µm) than the one obtained with 
Eudragit L100®. This indicates that Eudragit L100-55® provides a more 
efficient gastro protection. In addition, it is important to mention that even 
after 15 min, the presence of LOVh was negligible.  The different release 
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behavior between the two polymers can be at least partially explained by 
the morphological aspects observed by SEM analysis. Samples composed 
of Eudragit L100® showed concave pores on the surface, which could 
ease water penetration and drug release. For both polymers, almost no 
release of LOV was observed after 45 min of coating regarding the 
systems with Eudragit L100® and after 75 min for the samples composed 
of Eudragit L100-55®. This can be translated into 46.4 µm (Eudragit 
L100®) and 32.3 µm (Eudragit L100-55®) of enteric layer thickness. 
 
Figure 41. Percentage release of EZE and LOV from formulations prepared 
with (A) Eudragit L100® and (B) Eudragit L100-55®, after 90 min of 
dissolution studies in HCl 0.1 M + 0.025% of SLS 
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 After the gastric stage, samples were submitted to release studies 
in phosphate buffer pH 6.8, as shown in Figure 42. As the sample coated 
for 15 min with Eudragit L100® did not meet the acceptance criteria in 
gastric environment, it was not selected for further studies. Results show 
a fast release for all formulations, which were considered statistically 
similar, despite of the different coating times. Approximately 100% of 
release was achieved after 30 min for EZE with samples composed of 
Eudragit L100®, while formulations with Eudragit L100-55® released 
approximately 92%. LOV, on the other hand, showed lower dissolution 
percentages in general, as compared to EZE, releasing approximately 
80%. This trend was also observed with the ternary solid dispersions of 
EZE, LOV and Soluplus® previously reported (RIEKES et al., 2016), 
indicating that the coating process did not provoke deleterious effects on 
the release profiles of the APIs. In addition, both systems were able to 
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enhance the dissolution rate of the two compounds compared to the 
respective crystalline raw materials, which released 5.9 ± 0.5% (EZE) and 
4.6 ± 0.1% (LOV) within the same timeframe. Based on the in vitro 
dissolution studies, it is possible to conclude that both polymers were 
successful. However, Eudragit L100-55® was more efficient, requiring 
less coating time and consequently, thinner coating layer, to provide 
lower drug release and conversion to LOVh. In addition, a short coating 
time, 15 min, was considered adequate for this polymer, since gastro 
protection and fast release in pH 6.8 was observed. In case of Eudragit 
L100®-based formulations, 30 min were necessary to obtain the gastro 
protective effect. 
 
Figure 42. In vitro dissolution profiles of enteric-coated formulations 
composed of (A) Eudragit L100® and (B) Eudragit L100-55®, in phosphate 
buffer pH 6.8 containing 0.01% of SLS 
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3.4 STABILITY STUDIES 
 
As Eudragit L100-55®-based formulations prepared with large 
sucrose beads (710-850 µm particle size) were considered the most 
appropriate ones for enteric-coated EZE/LOV pellets, the stability of 
these samples was verified.  
Stability studies were conducted after 6 months storage at 0% RH 
and room temperature. The XRD data (Figure 43) show the 
diffractograms at the start and end of the coating process, in comparison 
with a fresh sample. No additional Bragg peaks are observed, besides 
those from the sucrose beads, indicating that the samples remain stable 
and the APIs amorphous, during  storage. 
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Figure 43. Diffractograms relative to formulations with Eudragit L100-55®, 
at time zero (T0) and after 6 months of storage 
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For the in vitro dissolution studies, samples were selected from 
the initial stages of the coating process since they are more prone to 
crystallization and surface defects. Data obtained in acidic condition 
demonstrate similar percentage release for both APIs from both enteric-
coated formulations, reflecting the integrity of the coating layer. EZE 
release in acidic medium was 6.89 ± 1.22% from a freshly prepared 
sample, compared to 6.92 ± 1.04% after 6 months storage. For LOV, 3.81 
± 1.69% and 4.16 ± 2.17% were released from samples at T0 and 6 
months storage, respectively. Dissolution data were considered 
statistically similar for EZE and LOV (p > 0.05). 
Similar trends were observed regarding the dissolution profiles 
obtained in phosphate buffer pH 6.8 (Figure 44). Although a slight 
decrease in EZE’s release was observed, formulations from T0 and stored 
after for 6 months were statistically similar (p > 0.05). 
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Figure 44. Dissolution profiles of EZE and LOV from Eudragit L100-55®-
based formulation, with 15 min of enteric coating time, at time zero (T0) and 
after 6 months 
 
4. CONCLUSIONS 
In order to avoid the premature formation of LOVh in gastric 
environment, enteric-coated FDCs of EZE and LOV were developed. We 
demonstrate for the first time the feasibility of an enteric-coated FDC 
based on ternary solid dispersions, prepared by fluid bed coating. In order 
to develop an adequate formulation, process parameters such as inert bead 
size, type of enteric polymer and coating time have been investigated. 
Inert sucrose beads were firstly coated with a glass solution layer 
composed of EZE, LOV and Soluplus®, in a 5:5:90 mass ratio, according 
to previous results reported by our group. The use of smaller beads (300-
415 µm mean diameter) revealed difficulties with processing, leading to 
frequent pellet agglomeration. This in turn, reflected on highly variable 
drug release in acidic conditions, even after process optimization. In 
addition, the lower feeding rate (6 ml/min) and solid content of the enteric 
polymer solution (5% w/v) implied in a longer time processing, compared 
to the beads with larger mean diameter. When Eudragit L100® and 
Eudragit L100-55®-based formulations were compared, different 
morphological features were noticed.  Microscopy analysis revealed 
spherical particles with concave pores on the surface of pellets coated 
with Eudragit L100®, which possibly contributed to a higher drug release 
from this polymer, despite of presenting a thicker coating layer. Absence 
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of crystals in SEM micrographs suggested the amorphicity of the 
compounds, which was confirmed by XRD for Eudragit L100® and 
Eudragit L100-55®-based formulations. Importantly, laser diffraction 
analysis allowed the off-line particle size measurements providing fast 
and reliable values of coating thickness. From these data, it was possible 
to determine the minimum coating thickness to assess an adequate release 
in gastric and intestinal conditions. Values of  30.9 µm and 6.5 µm were 
obtained for samples coated with Eudragit L100® and Eudragit L100-55®, 
respectively, demonstrating better performance of the latter. Regarding 
the coating time, although faster and higher percentages of release were 
observed with shorter coating times, samples selected at the beginning 
and end of the coating process were considered similar.  Finally, after 6 
months of storage, samples showed unaltered physical properties and 
dissolution behavior. Based on these findings, these formulations 
comprise an interesting alternative to administer EZE and LOV in a FDC.  
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APPENDIX 
 
DEVELOPMENT AND VALIDATION OF A HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY METHOD 
FOR SIMULTANEOUS DETECTION OF EZETIMIBE AND 
LOVASTATIN 
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1. INTRODUCTION 
 
The analysis of drugs is required both during the development 
and quality control of dosage forms. In this way, it is necessary that the 
methods applied to detect and quantify the drugs be adequate and 
compliant to the analytical requirements. To assure that, analytical 
methods should be validated according to international regulations and 
the parameters usually evaluated are linearity and range, limits of 
detection and quantification, specificity, precision, accuracy and 
robustness (ICH, 2005; USP 30, 2007). 
Regarding dosage forms composed of fixed dose combinatons, 
the development of an analytical method capable of detecting 
simultaneously all drugs can be complex, especially if the compounds 
present very distinct physico chemical properties.  
The combination of ezetimibe (EZE) and lovastatin (LOV) in 
clinical practice aiming to treat hypercholesterolemic patients is 
considered safe and efficient (KERZNER et al., 2003), especially if the 
severe side effects associated to the monotherapy with LOV are taken into 
account (e.g. myopathy and rhabdomyolysis). Besides, recent report has 
demonstrated that statins are responsible for an increase of 50% of the 
risk of developing type II diabetes in patients with hypercholesterolemia 
(CEDERBERG et al., 2015).  
In this sense, the coadministration with EZE is advised to 
promote a dose reduction of statins. However, no commercial fixed dose 
combination of EZE and LOV is currently available. 
In this context, as this thesis comprehend the development of a 
fixed dose combination dosage form of EZE and LOV, the existence of 
an analytical method to simultaneously detect both compounds is 
mandatory. Literature presents two reports of high performance liquid 
chromatography (HPLC) methods for EZE and LOV. Nevertheless, both 
require the use of buffer solutions or pH adjustment of the mobile phase 
(KHAN et al., 2010; RAJ et al., 2013), making the method less attractive 
to the quality control routine.  
Based on that, this section aims for the development and 
validation of a robust, simple and fast analytical HPLC method, capable 
to detect simultaneously EZE and LOV.  
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2. EXPERIMENTAL 
 
2.1 MATERIALS 
 
EZE and LOV were purchased from Pharma Nostra (batches 
FM017H13 – India and 130312 – China, respectively). HPLC-grade 
acetonitrile was obtained from JT Baker (Phillipsburg, NJ, EUA). All 
other chemicals used were pharmaceutical-grade. During the analysis, 
ultrapure water was obtained using a Milli-Q Gradient System (Millipore, 
Bedford, MA). 
 
2.2 METHODS 
 
2.2.1 Instrumentation and chromatographic conditions 
 
The isocratic LC analysis was performed on a Merk-Hitachi 
LaChrom system using a reversed-phase Chromolith® Performance C18 
column (100 x 4.6 mm i.d., 5 μm). The mobile phase was made up from 
acetonitrile:water (50:50 v/v), with a flow rate of 1.0 mL.min-1, at 25.0 
ºC. Detection was performed at 235 nm. Samples were filtered through a 
0.45 μm membrane filter and a volume of 20 μL was injected. Data 
acquisition was performed using Merck LaChrom D-7000 System 
Manager software to measure the detected peaks.   
 
2.2.2 Preparation of standard solutions 
 
An amount of 10.0 mg of EZE and 10.0 mg of LOV were 
accurately weighed and transferred to an individual 20.0 mL volumetric 
flask, then diluted to volume with acetonitrile to obtain a concentration of 
500.0 μg.mL-1. The stock solutions (n=3) were stored at room temperature 
and protected from light. Working standard solutions were prepared daily 
by diluting the stock solution to a concentration of 20 μg.mL-1 with 
acetonitrile:water (50:50 v/v). The solution was filtered through a 0.45 
µm PTFE filter prior to injection.  
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2.2.3 Method validation 
 
Validation was based on the requirements of the ICH guideline 
for validation of analytical procedures (ICH, 2005). The parameters 
analyzed were specificity, linearity, range, limits of quantification and 
detection, accuracy, precision and robustness. 
 
2.2.3.1 Specificity 
 
 In order to determine the specificity of the method, both 
compounds (10 mg each) were added to 500 mL of 0.01 M HCl pH 1.2 
and kept at 100 rpm during 90 min. At the end of the assay, 5 mL-aliquot 
was withdrawn, filtered with a 0.45 µm PTFE membrane filter and 
injected in triplicate. 
 This condition was selected to mimick the acidic stage of an in 
vitro dissolution test. It is known that a hydrolytic conversion of LOV to 
its active metabolite lovastatin hydroxyacid (LOVh) occurs in acidic 
conditions and should be avoided. For this reason, an enteric-coated 
formulation is recommended for this compound.  
 
2.2.3.2 Linearity, limits of detection (LOD) and quantification (LOQ) 
 
The calibration curves were obtained from seven concentration 
levels ranging from 0.4 to 50.0 μg.mL-1. Analyses were performed in 
triplicate and the regression lines were calculated by the method of the 
least square of peak area versus drug concentrations. 
The limits of detection (LOD) and quantification (LOQ) were 
estimated based on the standard deviation of the y-intercepts of regression 
analysis (σ) and the slope (S), by the Equation 1 and Equation 2. The 
values of concentration obtained were further evaluated experimentally. 
 
LQ = (10 σ) / S    Equation 1 
 
LD = (3,3 σ) / S   Equation 2 
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2.2.3.3 Accuracy 
 
The accuracy was determined by comparison of the drug content 
results obtained with  the proposed method with that of a second well-
characterized analytical procedure (KHAN et al., 2010). A concentration 
of 10.0 μg.mL-1, which corresponds to 100.0 % of the label claim, was 
analyzed, in triplicate, through both HPLC methods. The statistical 
analysis of the data was carried out through Student’s t-test, where 
significant results present a probability lower than 5% (p ≤ 0.05 with a 
95% confidence interval) by MS Excel® software. 
 
2.2.3.4 Precision 
 
The precision of the method was determined by repeatability 
(intra-day) and intermediate precision (inter-day). The repeatability was 
evaluated by assaying six samples of the 100.0 % standard concentration 
(50.0 μg.mL-1) during the same day and under the same experimental 
conditions. The intermediate precision was evaluated by assaying 
solutions on three different days. The analyses were performed in 
triplicate and expressed as % RSD. 
  
2.2.3.5 Robustness 
 
The robustness of the method was evaluated against variations in 
wavelengh (234, 235 and 236 nm), flow rate (0.9, 1.0 and 1.1 mL/min) 
and ratio of the mobile phase constituints (ACN:H2O 48:52, 50:50 and 
52:48 v/v). Samples in these conditions were analyzed in triplicate and 
results were expressed as % RSD.  
  
2.2.3.6 Statistical analysis 
 
 The statistical analysis of the data was carried out through one 
way analysis of variance (ANOVA) where significant results present a 
probability lower than 5% (p ≤ 0.05 with a 95% confidence interval). The 
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statistical evaluation of the results was performed in MS Excel® software.
 For the accuracy parameter, statistical analysis was performed 
trough Student’s t-test, following the same specifications as described 
above.  
 
3. RESULTS 
 
3.1 DEVELOPMENT OF THE ANALYTICAL METHOD BY HPLC 
 
 Aiming to achieve a fast method with good resolution between 
the peaks of EZE and LOV, as well as with LOVh, different mobile phase 
ratios and compositions, flow rate and oven temperatures were tested and 
adjusted. Besides, the need to develop a simple method that could be 
easily applied to the quality control routine of a lab was also taken into 
account, since the reported methods require the use of buffer solutions or 
pH adjustment (KHAN et al., 2010; RAJ et al., 2013). 
 In this way, mobile phase compositions were evaluated, varying 
the ratios of methanol, acetonitrile and water. Acetonitrile decreased the 
retention time and enhanced the peak shape and symmetry, however, a 
good resolution of peaks was only achieved when water was added, 
especially at 50:50 v/v ratio. 1.0 mL/min flow rate was chosen to allow 
an adequate separation of the peaks, besides being the usual flow rate 
adopted for most methods. To select the proper wavelength, 50 µg/mL 
solution of EZE and LOV was scanned in UV spectrophotometer (Varian 
UV/Vis CARY) from 200 to 400 nm. High absorption was detected at 
235 nm for both compounds. The oven temperature was kept at 25.0 ºC, 
since changes in this parameter did not seem to have an impact on the 
resolution between peaks. 
 At the end, a simple and fast method was developed, with 
retention times of 3.09 nm and 8.11 min for EZE and LOV, respectively, 
with total run time of 11 min.   
  
3.2 ANALYTICAL VALIDATION 
 
3.2.1 Specificity 
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 Figure 45 depicts the chromatogram containing peaks related to 
EZE, LOV and LOVh.  The peak at approximately 1.7 min refers to 0.01 
M HCl and mobile phase. As it is possible to observe, the method is 
capable of eluting all compounds with adequate resolution, without 
overlapping, verifying the specificity of the developed method.  
 
Figure 45. Representative chromatogram obtained with the following 
conditions: ACN:H2O (50:50, v/v), 1 mL/min, 25°C, 235 nm, showing peaks 
of EZE (3.1 min), LOVh (4.2 min) and LOV (8.1 min) 
 
 
 
3.2.2 Linearity 
 
 The evaluation of the linearity demonstrates that EZE and LOV 
showed a linear correlation in the range of 0.4 to 50.0 μg.mL-1, with a 
determination coefficient (R2) of > 0,999, for both compounds (Figure 
46). The representative linear equation for EZE was y = 43533x – 222.37, 
and y = 51163x – 3407.6 for LOV, where x is concentration in µg.mL-1 
and y is the peak area. The data were validated by means of the analysis 
of variance (ANOVA), which demonstrated linearity significant linear 
regression (p < 0.05) and no significant deviation from linearity (p > 
0.05).  
LOQ and LOD values were 60.0 ng/mL and 20.0 ng/mL, 
respectively, for both compounds. As these values are lower than the 
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lowest concentration of the calibration curve, it is possible to affirm that 
the method is sensitive. 
 
Figure 46. Mean calibration curves of EZE () and LOV (), obtained as a 
function of the peak areas versus concentration, in µg/mL. Their respective 
linear equations and determination coefficients are also depicted   
 
 
3.2.3 Accuracy 
 
 Results related to accuracy (Table 8) are expressed as percentage 
of recovery of EZE and LOV from both methods. Significant differences 
(p > 0,05) between the results obtained by the preposed method and the 
one reported in literature (KHAN et al., 2010) were not observed. 
Besides, RSD values are within the acceptable range (100 ± 2 %). 
 
Table 8. Data referring to the accuracy of the method 
 
Proposed method Comparison method 
Concentration 
(%) 
RSD 
(%) 
Concentration (%) RSD 
(%) 
EZE 95.8 0.4 100.1 1.9 
LOV 94.6 0.2 94.4 0.5 
 
 
3.2.4 Precision 
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 Data referring to the precision of the method, expressed as RSD 
(%) comply with the acceptance criterium of 5% (ICH, 2005). Results of 
0.4 e 1.3 % for intra and inter-day analyses, respectively for EZE, and 0.7 
and 1.1 % for intra and inter-day analyses, respectively for LOV, have 
been found. Samples quantified in three different days were considered 
statistically similar (p > 0,05), for both EZE and LOV.  
 
3.2.5 Robustness 
Table 9. Data referring to the robustness of the method, compared to the 
parameters of the developed method (ACN:H2O (50:50, v/v), 1 mL/min, 
25°C, 235 nm) 
Parameter evaluated EZE (%) LOV (%) 
234 nm 97.3 101.6 
236 nm 97.0 101.9 
0.9 mL/min 113.2 107.8 
1.1 mL/min 93.2 86.4 
ACN:H2O 48:52 (v/v) 102.9 94.4 
ACN:H2O 52:48 (v/v) 102.3 93.3 
 
 As can be observed in Table 9, robust quantification against 
changes related to the wavelength and mobile phase ratio was obtained. 
However, for EZE and LOV, variations of flow rate show significant 
differences in their quantification, and their content varied from 86.4 to 
113.2%.  
 Based on these data, it is possible to affirm that the method is 
robust against slight and deliberated changes regarding the wavelength 
and mobile phase ratios, however, the flow rate must remain unaltered for 
both compounds. 
  
4. CONCLUSIONS 
 
 The HPLC method developed demonstrated to be adequate for 
the simultaneous detection and resolution of EZE, LOV and LOV active 
metabolite, LOVh, obtained through hydrolytic conditions. This method 
was validated in accordance to the regulatory agencies and was 
188 
 
considered specific, sensitive, linear, accurate, precise and robust against 
variations of wavelength and mobile phase ratios. 
 In this way, it becomes an important tool to simultaneously detect 
EZE and LOV in fixed dose combination dosage forms, as well as 
dissolution and stability studies.  
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FDCs have proven to be an adequate choice to treat patients 
suffering from multiple pathologies, and lately, regulatory agencies such 
as FDA, have estimuated the registration of new formulations. However, 
the development of a FDC can be challenging, since the formulation steps 
require a deep understanding of particular characteristics of more than 
one compound. In addition, if the drugs present inadequate 
physicochemical properties, such as poor solubility, the formulation 
should be able to overcome this limitation.   
Nevertheless, although much effort has been put on developing 
more efficient formulations based on a single poorly water-soluble 
compound, by solid dispersions, salt formation, cocrystallization, lipid-
based formulations, complexation with cylodextrins, and other 
approaches, for example, a different perspective is seen for FDCs. Scarce 
innovation in this field is urging for the investigation and development of 
more modern tools. 
Due to the synergistic hypolipidemic properties of EZE and LOV, 
with proven safe and efficient combination in clinical practice, besides 
their limiting physicochemical properties, these compounds have been 
chosen as model drugs to develop novel FDCs based on amorphous 
systems. 
In this context, a relatively recent technological approach has been 
developed known as co-amorphous systems. Proposed to overcome the 
deficiencies inherent to solid dispersions, these systems comprise a 
binary, and more recently also ternary amorphous combinations, 
composed only of the APIs and/or small active molecules, such as 
aminoacids. Most of the reports regarding this topic have shown 
promissing data, which show enhanced solubility and dissolution rate of 
the involved compounds, besides improving their amorphous physical 
stability. 
As a quite classic and well-known excipient used in a great number 
of pharmaceutical formulations, besides its use in other fields, gelatin has 
also shown its potential when combined to a drug molecule to either 
influence its immediate or modified release. As a safe and vastly explored 
molecule, the generation of FDCs based on gelatin formulations could 
also be an interesting approach. However, although presenting important 
benefits, such as being water-soluble, biocompatible, biodegradable, 
cheap and readily available, it has never been explored as a possible 
carrier for FDCs composed of poorly soluble compounds. 
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Solid dispersions are widely known, explored and investigated, 
composing nowadays a few number of commercialized formulations. 
Focused on enhancing the solubility and dissolution rate of poorly soluble 
compounds, they have not been explored, by now, as a possible approach 
for FDCs.  
In this context, this research project aimed to develop a FDC based 
on two poorly water-soluble compounds, EZE and LOV. Amorphous 
formulations were developed and investigated, being comprised by the 
three strategies mentioned previously. Co-amorphous systems, gelatin-
based formulations and ternary solid dispersions were selected since their 
principles and basic knowledge have already been target of many 
investigations, facilitating their understanding in a more complex system. 
Besides, they present scarcely explored potential to compose a FDC.   
Importantly, developing a single formulation composed of both 
compounds in amorphous state present some important advantages 
compared to physical mixtures of binary amorphous systems comprised 
by each API and its carrier. To be mentioned, the time and cost savings 
of a single step process, instead of a two-step process and a powder 
blending step, required for the preparation of two binary solid dispersions, 
is an interesting example.   
A case of approach in this sense was reported by Taupitz and 
coworkers in 2013 (TAUPITZ, DRESSMAN and KLEIN, 2013). These 
authors focused on verifying the potential of cyclodextrins and solid 
dispersions to improve the dissolution rate of ezetimibe/simvastatin and 
pioglitazone/glimepiride in FDCs. Although the results were promising, 
especially concerning the ternary complex consisting of hydroxypropyl-
β-cyclodextrin (HP-β-CD) and Soluplus®, in this research, each 
compound was formulated separately. This basically means that besides 
the formulation steps required for each compound, generating a two-step 
process, an additional blending step of physical mixtures would be further 
required. Furthermore, the total bulk volume of the final formulation 
could hamper the development of the dosage form. For this reason, we 
focused on developing a co-formulation with an adequate balance 
between number of processing steps and performance. 
However, although much more interesting, especially concerning 
the scale-up perspective, co-formulating a FDC is not always a straight 
forward process. An example of this was reported by our group, testing 
the behavior of ritonavir and darunavir, both poorly water-soluble 
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compounds, in a FDC in the form of dispersible powders. Ternary spray 
dried systems composed either by HPMC, PVP K-30, and PVP/VA 64 
and the two drugs were investigated. Basically, the authors verified that 
the presence of darunavir always decreased the supersaturation level of 
ritonavir and vice versa no matter which polymers were used. Moreover, 
the performance of the ternary systems was always inferior to the 
respective binary ones. Also, in this case, in order to restrict the mutual 
negative influence between darunavir and ritonavir, a complex of both 
ritonavir and darunavir with HP-β-CD was prepared and improved the 
dissolution rate of both compounds (NGUYEN and VAN DEN 
MOOTER, 2014).  
The investigation of the supersaturation behavior of one drug in 
presence of another in a FDC was also target of research by Trasi and 
Taylor (2015). These authors used ritonavir, lopinavir, paclitaxel, 
felodipine, and diclofenac as poorly water-soluble model compounds and 
verified that the amorphous solubility of each component in aqueous 
solution drops significantly by the second component, as long as the two 
drugs are miscible in the amorphous state. This data reinforces previous 
results reported by Nguyen and Van den Mooter (2014), demonstrating 
the difficulty in co-formulating with two poorly water-soluble 
compounds. 
More recently, a novel FDC was developed by Liu and coworkers 
(2015). These authors prepared a novel FDC composed by salmeterol 
xinafoate and mometasone furoate in a composite particle formulation as 
brittle matrix powder and investigated its suitability as an inhaled 
combination product. FDCs with and without stabilizers, such as lactose, 
mannitol, glycine and trehalose, were investigated and the authors 
observed that the formulations exhibited improved aerodynamic 
properties when delivered by dry powder inhalation as compared to the 
micronized blends of the same substances. In addition, the proposed FDC 
resulted in delivered dose uniformity, which corroborated to a 
significantly higher lung concentration of drugs than for the crystalline 
physical blend. Although the results are promising for this type of 
formulation, the manufacturing process is relatively unexplored by the 
pharmaceutical industry.  
Therefore, aiming to develop an easy and single-step processing 
formulation, composed of EZE and LOV, in a FDC with enhanced 
physicochemical properties of both compounds, co-amorphous systems 
prepared by quench cooling from the melt were investigated. Although 
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single amorphous systems were obtained, the dissolution rate of both 
compounds was not enhanced. Interestingly, in this case, the dissolution 
rate of amorphous EZE was not increased in comparison to its crystalline 
counterpart. Although contact angle measurements were performed to 
investigate the possible causes (data not shown), the explanation for this 
matter remains unclear. Similar reports have been found for other 
compounds, such as darunavir ethanolate (VAN GYSEGHEM et al., 
2009) and carvedilol (POKHARKAR et al., 2006). Certainly, this 
behavior had a negative impact on the combined systems, since all 
formulations with LOV had a low dissolution rate, for both compounds. 
Co-amorphous systems of EZE and indapamide are described in 
literature, but the paper does not investigate the dissolution properties of 
both compounds. The focus of their research is molecular dynamics and 
physical stability of the co-amorphous systems and the authors conclude 
that the presence of indapamide reduces the molecular mobility of EZE, 
providing long term stability to the formulation (KNAPIK et al., 2015).  
Successful reports of co-amorphous systems available in literature 
usually combine one poorly water-soluble compound, with a hydrophilic 
one, which facilitates the wettability of the system. When EZE and LOV 
were combined, the amorphous state of both was apparently not sufficient 
to improve their solubility and dissolution rate. A similar report was found 
in literature for a co-amorphous system composed by two poorly water-
soluble compounds, simvastatin and glipizide. Also in this case, the 
amorphous state of both APIs was not sufficient to improve their 
solubility simultaneously. Although enhanced dissolution rate was 
noticed for glipizide in ball milled co-amorphous systems, no 
improvement was achieved for simvastatin (LÖBMANN et al., 2012). 
However, when in presence of small hydrophilic molecules, such as 
aminoacids, the dissolution rate of simvastatin was substantially 
improved (CRAYE et al., 2015; HEIKKINEN et al., 2015). This data 
reinforces the fact that for higly lipophilic substances, the amorphization 
in some cases needs to be combined to other parameters, such as 
improved wettability and particle size reduction, for example, to 
overcome the limiting solubility.   
In this context, the disappointing results with the co-amorphous 
systems of EZE and LOV also led to the conclusion that the addition of a 
highly water-soluble compound was necessary to improve the solubility 
of EZE and LOV in a FDC.  
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As a second attempt, the incorporation of gelatin to the system, 
through an environmentally friendly process, the high energy milling, was 
exhaustively explored. Different API:API and APIs:gelatin ratios, as well 
as milling time, number of balls, rotation speed and addition of 
hydrophilic polymers were tested. However, although gelatin seemed to 
have an influence on the dissolution rate of the compounds, its impact 
was not sufficiently expressive, even in presence of high content of the 
biopolymer. Although a report in literature states that there is a tendency 
for larger gelatin-induced increases in solubility as drug lipophilicity 
increases (KALLINTERI and ANTIMISIARIs, 2001), and improved 
dissolution rates were observed for pranlukast (CHONO et al., 2008), 
ibuprofen (LI et al., 2008) and fenofibrate (YOUSAF et al., 2015) in 
gelatin-based systems, this fact could not be exactly transposed to EZE 
and LOV, based on the not too expressive enhancement on their 
dissolution rate in presence of the biopolymer.  
It is known that gelatin can be quite unstable when exposed to 
humidity, heat and light, resulting in the formation of a swollen, very thin, 
tough, rubbery,water-insoluble membrane, known as pellicle. This 
membrane can act like a barrier during dissolution and restrict the release 
of drugs from this type of systems. This could be a possible explanation 
for the not so significant release profiles of EZE and LOV in gelatin-based 
systems. Besides, although hydrophilic polymers could be combined to 
gelatin to overcome this problem, the total bulk volume would increase 
and limit the compounding step.  
Thus, the next step comprised the investigation of  highly 
hydrophilic and synthetic polymers to compose the unexplored ternary 
solid dispersion concept. Until to date, the potential of solid dispersions 
to prepare a FDC has been scarcely explored. Nowadays, Kaletra® is the 
only marketed FDC based on a ternary solid dispersion system (VAN 
DEN MOOTER, 2011). Composed by the polymer PVP/VA, this 
formulation is prepared by hot melt extrusion and opens many 
possibilities for other novel amorphous FDCs. 
The ternary solid dispersion system developed in this research 
investigates for the first time the use of spray drying as the manufacturing 
process of this type of ternary system. Extremely efficient on 
amorphization of compounds, spray drying is one of the most used and 
explored processing techniques in the pharmaceutical industry, which 
eases its scale up and represents a major advantage towards other 
manufacturing processes.  
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Preliminary studies were conducted with four different polymers 
(HPMC, PVP K-30, PVP/VA -64 and Soluplus®), which were chosen 
based on their common and successful use in binary solid dispersions. 
From all the options, Soluplus® provided significant solubility and 
dissolution rate enhancement, demonstrating to be an adequate choice to 
comprise the system. The formulation containing 90% of this polymer 
was able to reach around 90% release of both compounds within 15 
minutes, showing a significant dissolution efficiency enhancement 
compared to the respective pure crystalline compounds. These data 
demonstrate that the addition of the hydrophilic polymer, combined to a 
processing technique able to promote significant particle reduction, was 
the solution to the limited dissolution rate of both compounds. The 
amorphization by itself was not enough to reach the desired release 
properties of EZE and LOV. 
Prepared in a single step process, both compounds remained in 
amorphous state with adequate dissolution performance for 1 year, in low 
temperature and humidity conditions. In comparison to other 
formulations found in literature, this one does not require a blending step, 
and the chemical interactions between the compounds, which would not 
exist in a physical mixture of two binary systems, auxiliate on maintaining 
the physical stability of the formulation.  
 However, due to the instability of LOV in acidic consitions, which 
leads to the premature formation of its active metabolite, lovastatin 
hydroxyl acid, an enteric coated formulation was a necessary requisite to 
proceed with the development of a dosage form. In order to prepare a final 
formulation, the spray dried ternary solid dispersion with the best ‘in 
vitro’ performance (ELS 1:1 90%) was selected. But, due to the need for 
an enteric coating layer, the spray drying process was transformed up to 
a fluid bed coater. 
The coating process is an important and complex step which 
demands the investigation of different formulation and process 
parameters. It is well known that the coating time, the polymer type, the 
type of equipment, the size of the coated particles, the compostion of the 
coating solution, the drying and curing steps, besides the operational 
parameters, such as air flow, drying temperature, atomization air and flow 
rate of the coating solution play an important role on the preparation of 
successful formulations (DEREYMAKER and VAN DEN MOOTER, 
2017; KNOP and KLEINEBUDDE, 2013; WESDYK et al, 1990).  
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For this reason, the type of polymer, the composition of the coating 
layer, the size of the inert sucrose beads and the coating time were tested 
and optimized to develop the desired final dosage form based on a FDC.  
Fluid bed coating has already been applied to prepare binary solid 
dispersions, as described by Yan and coworkers (2016), in wax-based 
floating solid dispersion pellets, by Sun and coworkers (2008), who could 
enhance the dissolution rate of Silybum marianum extract in solid 
dispersion pellets, and by Li and coworkers (2012), showing improved 
dissolution rate of a novel compound Tanshione II, which composed a 
ternary solid dispersion with PVP K-30 and Poloxamer 188®. More 
recently, fluid bed coated solid dispersions have also shown its 
importance on controlling the release of indomethacin from glass 
solutions layered with a rate controlling membrane (DEREYMAKER and 
VAN DEN MOOTER, 2017; 2017a). However, to the best of our 
knowledge, this type of processing has never been applied before on 
preparing FDCs based on ternary solid dispersions.  
In comparison to other manufacturing techniques, fluid bed 
coating shows the advantage of consisting of a one-step process, which 
does not require separate drying steps, addition of excipients and further 
manufacturing stages, such as milling or compression, which can induce 
phase separation or crystallization. In addition, multiparticulate systems 
such as pellets, can also be an interesting choice to compose a FDC, since 
they allow the combination of more than one API, obtaining flexible 
release profiles from a single dosage form. From a pharmacokinetic point 
of view, multiparticulate systems offer the advantage of presenting a more 
predictable gastric transit time, better distribution and absorption, 
facilitated disintegration, less frequent dose dumping issues and reduced 
risks of systemic toxicity and local irritation (ASGHAR and 
CHANDRAN, 2006) 
Based on this background, fluid bed coating of the ternary solid 
dispersions of EZE and LOV was processed by fluid bed coating, varying 
the processing and formulation parameters. In comparison to Eudragit L-
100, the system with Eudragit L100-55®  proved to be more indicated, 
since it did not require a long coating time and presented a homogeneous 
layer which avoided the release in acidic conditions. In addition, in 
neutral conditions, which mimicks the intestinal environment, the APIs 
were fastly released. Regarding the size of the coated particles, bigger 
beads were better, avoiding particle agglomeration and showing a more 
homogeneous coating layer. Similar findings were reported by Wesdyk 
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and coworkers (1990), for another fluid bed coated system. Importantly, 
from the off-line measurement of the coating layer thickness by laser 
diffraction,  it was possible to determine the minimum coating thickness 
to assess an adequate release in gastric and intestinal conditions. Values 
of 30.9 µm and 6.5 µm were obtained for samples coated with Eudragit 
L-100® and Eudragit L100-55®, respectively, demonstrating better 
performance of the latter.The results and the investigation performed in 
this thesis have shown that is possible to obtain a FDC made up of two 
poorly water-soluble compounds, prepared by quite simple approaches. 
From all the options tested, the ternay solid dispersions, coated by 
Eudragit L100-55® through fluid bed coating, showed the most adequate 
performance. This represents an interesting disclosure, since, both the 
process and the formulation steps (e.g. solid dispersion preparation and 
enteric coating) are widely used and relatively easy to scale up. 
Although promising, this formulation still has to comply with some 
important steps in order to be a possible candidate for marketing. Clinical 
studies present different stages, starting from the pre-clinical tests, 
performed in animals, by means of bioavailability studies. This important 
step comprises the future perspective of this research. In order to perform 
a reliable study, the first step should comprise the development of a 
bioanalytical method, which detects the main compounds and their 
metabolites in blood. Although contemplated in the initial plan of this 
thesis, bioavailability studies in Beagle dogs was not possible to be 
carried out due to lack of operational conditions at the main institution of 
this thesis. As a complementary study, pharmacodynamic tests verifying 
the lipid lowering capacity of the developed FDC in hyperlipidemic rats 
could also be an interesting investigation. 
To conclude, it is important to highlight that although this research 
was carried out with EZE and LOV, the knowledge obtained with these 
compounds can be extended to other poorly water-soluble APIs. FDCs 
are very beneficial to patients, and the hope is that in the near future, more 
modern formulations, like the one developed in this thesis, could be 
applied to marketable dosage forms and reach different therapeutical 
targets. 
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